SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES

Chapter Twenty-Five of the Medical Services Manual

MEDICATO OF LOUISIANA
DEPARTMENT OF HEALTH AND HOSPITALS
BUREAU OF HEALTH SERVICES FINANCING

PREFACE

PREFACE

Medicaid of Louisiana (Title XIX), formerly known as the Louisiana Medical Assistance Program, is designed to assist eligible Medicaid recipients in obtaining medical care within the applicable federal and state rules and regulations. Medicaid of Louisiana is administered by the Department of Health and Hospitals (DHH), Bureau of Health Services Financing (BHSF). Reimbursement may be made for substance abuse and mental health services when these services are provided to eligible Medicaid recipients by qualified, enrolled providers.

This manual is one of a series published for the use of medical services providers enrolled in Medicaid of Louisiana. It is not a legal description of all aspects of Medicaid of Louisiana or Title XIX rules and regulations, but it does set forth the conditions and requirements substance abuse and mental health services providers must meet to qualify for reimbursement. In addition, the manual provides the procedural information providers will need to file claims for services promptly and accurately.

This manual is applicable to providers who file claims with the fiscal intermediary, Paramax, for recipients of Medicaid services. We suggest that you study the material and maintain it in a special file for future reference.

From time to time, policies governing substance abuse and mental health services may change. Providers will be notified via written memorandums and revised manual pages regarding revisions and updates to policies in this manual. All revisions received should be placed in the appropriate section of the manual. Should there be a conflict between manual material and pertinent laws or regulations governing Medicaid of Louisiana, the latter take precedence.

Providers may obtain copies of this manual by contacting the Provider Relations Unit at Paramax at (504) 924-5040.

TABLE OF CONTENTS

TABLE OF CONTENTS

SECTION NAME	PAGE NUMBER
GENERAL MEDICAID INFORMATION	1-1
MEDICAID MANAGEMENT INFORMATION SYSTEM (MMIS)	2-1
UNDERSTANDING MEDICAID OF LOUISIANA	3-1
What Is Medicaid?	3-1
How Does Medicaid Work?	3-1
Administration of the Program	3-2
Standards for Participation	3-3
Picking and Choosing Services	3-3
Indication of Agreement	3-4
Out-of-State Medical Care	3-5
RECIPIENT ELIGIBILITY	4-1
Classifications of Eligible Recipients	4-1
Categorically Needy	4-1
Medically Needy	4-1
Regular Medically Needy	4-1
Spend-Down Medically Needy	4-1
Identification of Eligible Recipients	4-4
Lock-In Program	4-9
Third-Party Liability	4-14
PROVIDER ENROLLMENT	5-1
Change of Address/Enrollment Status	5-2
DESCRIPTION OF SUBSTANCE ABUSE SERVICES	6-1
Covered Services	6-1
Service Limits	6-1
Medicare/Medicaid Recipients	6-2
Medicaid Recipients Only	6-2
Substance Abuse Procedure Codes	6-3
Diagnosis Codes	6-4

ISSUED MARCH 1, 1993

TABLE OF CONTENTS

DESCRIPTION OF MENTAL HEALTH SERVICES	7-1
Covered Services	7-1
Evaluation and Assessment Services	7-2
Treatment and Counseling Services	7-3
Rehabilitation or Rehabilitation Services	7-4
Service Limits	7-5
Mental Health Services Procedure Codes	7-6
DESCRIPTION OF MENTAL HEALTH REHABILITATION SERVICES	8-1
TIMELY FILING GUIDELINES	9-1
HCFA-1500 (12/90) BILLING INSTRUCTIONS	10-1
General Reminders	10-1
Specific Billing Instructions	10-3
THE REMITTANCE ADVICE	11-1
The Purpose of the Remittance Advice	11-1
What Happens to Your Invoice?	11-1
Returned Claims	11-1
What Happens to a Processed Claim?	11-2
Approved Claims	11-2
Denied Claims	11-2
Pended Claims	11-3
How to Check the Status of a Claim - Control Number	11-3
Remittance Advice Copy Requests	11-4
ADJUSTING/VOIDING CLAIMS	12-1
General Reminders	12-1
Specific Instructions for Completion of the 213	12-3
FRAUD AND ABUSE	13-1
General	13-1
Fraud	13-1
Provider Fraud	13-2
Recipient Fraud	13-3
Abuse	13-4
Provider Abuse	13-4
Recipient Abuse	13-4
Fraud and Abuse Detection	13-5
Referrals	13-5

MEDICAL SERVICES MANUAL	TABLE OF CONTENTS
Recipient Verification Notices (REOMBs)	13-5
Computer Profiling	13-7
Administrative Sanctions	13-8
Levels of Administrative Sanctions	13-8
Grounds for Sanctioning Providers	13-10
Appeals	13-14
RETURN/REFUND CHECKS	14-1
Return Checks	14-1
Refund Checks	14-1
THE PRIOR AUTHORIZATION UNIT	15-1
PARAMAX PROVIDER RELATIONS	16-1
Recipient Eligibility Verification System	16-2

ISSUED MARCH 1, 1993

GENERAL MEDICAID INFORMATION

GENERAL MEDICAID INFORMATION

The Louisiana Medical Assistance Program, now referred to as Medicaid of Louisiana, became effective on July 1, 1966, under provisions of Title XIX of the 1965 Amendments to the *Federal Social Security Act* and Article 18, Section 7, Subsection 1, of the *Louisiana Constitution*, as amended. The Louisiana Department of Health and Hospitals (DHH), Bureau of Health Services Financing (BHSF), is the designated state agency responsible for administering the program. Medicaid of Louisiana is designed to provide certain healthcare benefits for those *categorically needy* and *medically needy* recipients who are in need of medical services.

The BHSF is responsible for the overall management of Medicaid of Louisiana, including the following functions:

- Determining all necessary regulations and guidelines for Medicaid of Louisiana program policy;
- Administering the program;
- Determining the services covered by the program and setting the reimbursement rates within federal guidelines;
- Determining eligibility of recipients, maintaining the recipient eligibility file, and issuing identification cards to certain categories of recipients; and
- Enrolling providers who wish to participate in the program.

In addition, the DHH, BHSF, has contracted with Paramax to implement and operate a Medicaid Management Information System (MMIS) for Medicaid of Louisiana. The contract provides that the fiscal intermediary, Paramax, be reimbursed a fixed price for each claim which is paid.

The second secon

GENERAL MEDICAID INFORMATION

Paramax is also responsible for performing portions of the work associated with the administration of the program. Duties include providing the following:

- Clerical staff to process claims,
- Computer systems designed to DHH standards for federal funding for administrative control,
- Computer equipment and program support,
- Management information tools to improve control of the program,
- Provider Relations personnel,
- Louisiana Drug Utilization Review (LADUR),
- A Surveillance and Utilization Review Subsystem (SURS) and SURS personnel,
- Prior Authorization personnel, and
- Pharmacy and nursing home audit profiles.

			.)
	,		

MMIS

MEDICAID MANAGEMENT INFORMATION SYSTEM (MMIS)

As fiscal intermediary, Paramax is required to operate an approved Medicaid Management Information System (MMIS), consistent with guidelines established by the DHH.

MMIS is a claims processing and information retrieval system designed to improve the management and control of Title XIX expenditures. The system is designed to reduce program costs through effective claims processing and utilization control. The major objectives of the system are as follows:

- Improve services to recipients,
- Reduce payment time to providers,
- Provide faster responses to inquiries,
- Improve claims processing efficiency,
- Increase use of computer capabilities,
- Provide greater utilization of the information database,
- Improve control and audit trails,
- Improve ability to handle increased claims volume, and
- Improve ability to handle federal reporting requirements.

Automation serves as the foundation for the system. Data entry of claims is performed through the use of batch key-entry and online teleprocessing technology. The capability exists for online data entry and update of the informational files which support claims processing. Data security is provided through the employment of batch controls and audit trails. Backup and recovery procedures exist that support the security efforts. Manual operations provide a smooth interface with the automated aspects of the system.

UNDERSTANDING MEDICAID OF LOUISIANA

UNDERSTANDING MEDICAID OF LOUISIANA

WHAT IS MEDICAID?

Medicaid is a means of delivering medical care to eligible needy individuals. The term *Medicaid* is derived from the words *medical* and *aid*, and it indicates the financial, as well as the medical assistance, that many patients require.

The state's Medicaid plan is formally included within Medicaid of Louisiana. The legal basis for the plan is contained in Title XIX of the Social Security Act; and, therefore, the term Title XIX is also used to refer to the program. Thus, Medicaid of Louisiana may be referred to as The Medical Assistance Program or Title XIX.

The Medicaid system provides government funds for health professionals who perform and/or deliver medically necessary services and/or supplies for eligible Medicaid recipients.

HOW DOES MEDICAID WORK?

The Provider's Role: The Provider's role is to render health care services within a specialized field to eligible Medicaid recipients. To receive reimbursement for these services, the provider must agree to abide by the rules and regulations set forth by the program.

Medicaid Recipients: The purpose of Medicaid is to make health services available to the needy. Determining eligibility of Medicaid recipients is the responsibility of the BHSF. The BHSF reports the eligible recipients to Paramax.

In Louisiana, Medicaid recipients are classified as Categorically Needy or Medically Needy. The recipients, in either classification, will be issued a medical eligibility card on a monthly basis. The purpose of this card is to serve not only as a notice to recipients of their eligibility for Medicaid, but also to identify eligible recipients to providers of medical care services. A detailed explanation of the Medicaid Eligibility Care can be found in the Recipient Eligibility section of this manual.

,

UNDERSTANDING MEDICAID OF LOUISIANA

ADMINISTRATION OF THE PROGRAM

The administration of Medicaid of Louisiana is a cooperative effort on the part of the federal and state government.

The United States Department of Health and Human Services (DHHS) publishes the guidelines for the states' participation in Medicaid and monitors the different state programs. These guidelines not only give Medicaid programs structure and direction, but they also allow for a degree of consistency in the scope of Medicaid from state to state. In addition, they allow the states to have flexibility with the administration of their Medicaid programs.

The Louisiana Department of Health and Hospitals (DHH), Bureau of Health Services Financing (BHSF), determines policies for complying with state laws and federal guidelines. It is directly responsible for the administration and monitoring of Medicaid of Louisiana and for distributing information to providers.

The BHSF determines who is eligible for Medicaid and forwards this information to Paramax to establish a computer eligibility file. Updates are transferred weekly.

UNDERSTANDING MEDICAID OF LOUISIANA

STANDARDS FOR PARTICIPATION

Provider participation in Medicaid of Louisiana is entirely voluntary. State regulations and policy define certain standards for providers who choose to participate. These standards are listed as follows:

- Provider agreement and enrollment with BHSF;
- Agreement to charge no more for services to eligible recipients than is charged on the average for similar services to others;
- Agreement to accept as payment in full the amounts established by the BHSF and not to seek additional payment from the recipient for any unpaid portion of a bill, except in cases of Spend-Down Medically Needy recipients;
- Agreement to maintain medical records (as are necessary) and any information regarding payments claimed by the provider for furnishing services; and
 - NOTE: Records must be retained for a period of three years and be furnished, as requested, to the BHSF, its authorized representative, representatives of the DHHS, or the state Attorney General's Medicaid Fraud Control Unit.
- Agreement that all services to and materials for recipients of public assistance be in compliance with Title VI of the 1964 Civil Rights Act, Section 504 of the Rehabilitation Act of 1973, and, where applicable, Title VII of the 1964 Civil Rights Act.

PICKING AND CHOOSING SERVICES

On March 20, 1991, Medicaid of Louisiana adopted the following rule:

Practitioners who participate as providers of medical services shall bill Medicaid for all covered services performed on behalf of an eligible individual who has been accepted by the provider as a Medicaid patient.

This rule prohibits Medicaid providers from "picking and choosing" the services for which they agree to accept a client's Medicaid card as payment in full for services rendered. In other words, providers must bill Medicaid for all services covered by Medicaid that they provide to their clients.

UNDERSTANDING MEDICAID OF LOUISIANA

INDICATION OF AGREEMENT

Although this is a voluntary program, providers should note that their signature on a claim form will serve as their agreement to abide by all policies and regulations of Medicaid of Louisiana. This agreement also certifies that, to the best of the provider's knowledge, information contained on the claim form is true, accurate, and complete.

7		

UNDERSTANDING MEDICAID OF LOUISIANA

OUT-OF-STATE MEDICAL CARE

Medicaid of Louisiana provides medical care to eligible recipients who are residents of Louisiana but who may be absent from the state in the same manner that it furnishes assistance to eligibles in the state.

Medicaid of Louisiana, however, will honor out-of-state medical claims for services rendered to eligible recipients only under one of the following conditions:

- When an emergency is caused by accident or illness;
- When the health of the recipient would be endangered if the recipient undertook travel to return to Louisiana;
- When the health of the recipient would be endangered if medical care were postponed until the recipient returns to Louisiana;
- When it is the general practice of recipients in a particular local to use medical facilities in areas outside of Louisiana; or
- When medical care or needed supplemental resources are not available in Louisiana (However, prior approval of the Louisiana Medicaid Director is required.).
 - These limitations do not apply to out-of-state independent laboratories when these services are ordered by a physician residing in Louisiana.

RECIPIENT ELIGIBILITY

RECIPIENT ELIGIBILITY

Recipient eligibility is determined by the BHSF. Provided in this section is an explanation of the different types of Medicaid eligibles, as well as samples of the different types of Medicaid eligibility cards.

CLASSIFICATIONS OF ELIGIBLE RECIPIENTS

There are two classifications for eligible recipients of Medicaid of Louisiana:

Categorically Needy

Recipients classified as Categorically Needy have met the requirements, including the income requirement, for Medicaid of Louisiana. No payment can be accepted from these recipients for benefits billed to Medicaid of Louisiana.

Medically Needy

The Medically Needy recipients may be either Regular Medically Needy or Spend-Down Medically Needy. In either classification, these recipients will be eligible for all Medicaid benefits, except for services provided by Long Term Care (LTC) Facilities.

Regular Medically Needy. No payment can be accepted from a Regular Medically Needy recipient for covered services.

Spend-Down Medically Needy. These recipients may, at times, be required to pay for a portion of their medical services.

NOTE: Eligibility for these recipients begins on the exact date that medical expenses incurred by these recipients allow them to "spend-down" to the level of income which will qualify them for Medicaid. These recipients are then responsible for co-payment on some of the expenses.

RECIPIENT ELIGIBILITY

Any provider who has medical bills from the exact date of the recipient's spend-down will receive a Spend-Down Medically Needy Notice (Form 110-MNP) from the BHSF (A sample of this form is provided on the following page.). This form will notify the provider of the co-payment amount due by the recipient for the bill and of the amount to be billed to Medicaid of Louisiana. The provider should attach this form to the claim and submit it to Paramax for processing.

NOTE: The provider cannot bill the recipient for any amount over the amount specified on the 110-MNP Form under *Recipient Liability*.

Page 4-3

La. OFS Form 110-MNP Revised 1/89

OFFICE OF ELIGIBILITY DETERMINATIONS MEDICAL ASSISTANCE PROGRAM SPEND-DOWN MEDICALLY NEEDY NOTICE

Recipients listed on the medical card are eligible FROM: 07 / 15 / 90 (spend-down date) THROUGH: 10 / 31 / 90

3601012345601

Š.

Anna M. Doar CASE NAME

in the "OED Liability" column. Payment by the FI shall be made in accordance with the usual, reasonable, and customary payments made by the Medicaid program. The patient payment eligibility). Payment by the FI will be made only for services listed below and only if a copy of this form is attached to the invoice. The FI shall only be billed for the amount indicated NOTICE TO PROVIDERS: Only the providers listed below are entitled to bill the Fiscal Intermediary (FI) for services rendered on the spend-down date (beginning date of amount shall be indicated in the "Recipient Liability" column on the FI billing document.

Patient Name and ID No. (include Recipient No.)	Date of Service	Provider Name and Vendor No.	Service or R, Received On Spend-Down Date	Total Unpaid Charges for Services Received	Recipient Liability	OED Liability (Amt. and Fl's actual payment may differ)
Anna M. Бoar 3601012345601	07/15/90 mo/dy/yr	1312345 Dr. George Burns	Hospital Care	\$250.00	\$20.00	\$230.00
Anna M. Doar 3601012345601	07/15/90 mo/dy/yr	1223344 Rexall Drugs	Prescriptions	\$75.00	\$0.00	\$75.00
Anna M. Doar	07/15/90 mo/dy/yr	1732345 ABC Hospital	Inpatient Care	\$500.00	\$0.00	\$500.00
Anna M. Doar	7/15/90 mo/dy/yr	1412345 Home Health	Physical Therapy	\$45.00	\$0.00	\$45.00
Anna M. Doar	7/15/90 mo/dy/yr	1181234 Crit. Care Amb.	Ambulance	\$85.00	\$0.00	\$85.00
Anna M. Doar	7/15/90 mo/dy/yr	1801234 Dr. O. Verbite	Dental Exam	\$35.00	\$0.00	\$35.00
Worker:	Title: Par	Title: Parish Worker	Parish: South	•	Date: 10/15/90	

Figure 4-1. Spend-Down Medically Needy Notice

RECIPIENT ELIGIBILITY

IDENTIFICATION OF ELIGIBLE RECIPIENTS

A Louisiana Medical Eligibility Card is issued to each eligible recipient and/or family each month. These cards may be issued by the Department of Social Services (DSS), the recipient's parish Office of Family Support, or the fiscal intermediary (FI), Paramax. Included in this section are reproductions of sample cards for both the Categorically Needy and the Medically Needy recipients. Providers may want to refer to these samples to assist in understanding the information appearing on the recipient monthly Medical Eligibility Card.

We begin with examples of the cards issued by DSS. These examples are only facsimiles of the cards; they do not represent the actual size of the cards.

JUN 90-MAR 92

LOUISIANA MEDICAL ELIGIBILITY CARD SSW805B

OFFICE OF FAMILY SECURITY 604 SECOND STREET FRANKLIN, LA. 70538

> BOB D. JONES P O BOX 2222 SOMEWHERE LA 70381

> > *ELIG FOR EPSDT

ID. NUMBER ELIGIBLE RECIPIENTS BIRTHDATE TPL 5101018291901 JONES BOB D 01 24 78 *

A=MEDICARE A B=MEDICARE B C=MEDICARE A & B

D=OTHER INSURANCE E=AMBULANCE COVERAGE

Figure 4-2. Sample One Medical Eligibility Card Issued by DSS

RECIPIENT ELIGIBILITY

9PF LOUISIANA MEDICAL ELIGIBILITY CARD PAD163

PRESUMPTIVE ELIGIBILITY

P.O. BOX 2343

BATON ROUGE LA 70896

ERMA SMITH

555 BROWN STREET ANYTOWN, LA 70000

ID NUMBER

NAME

BIRTHDATE

10-30-73

17-16-0-012350-20

ERMA SMITH

PRESUMPTIVE ELIGIBILITY PERIOD BEGINS ***01-02-89*** SERVICES LIMITED TO AMBULATORY PRENATAL CARE ONLY HOSPITALIZATION. LONG TERM CARE SERVICES NOT AUTHORIZED **MAY NOT EXCEED 45 DAYS AND MAY BE SHORTENED IF RECIPIENT IS INELIGIBLE OR FAILS TO COMPLY WITH ELIGIBILITY REQUIREMENTS

H

Figure 4-3. Sample Presumptive Eligibility Card

NOTE: Authorized for outpatient services only. Card has a 45 day limit maximum.

LOUISIANA MEDICAL ELIGIBILITY CARD

PAD973

ISSUE DATE: 09/25/91

A=MEDICARE A

B=MEDICARE B

OFFICE OF FAMILY SUPPORT

C=MEDICARE A & B D=PRIVINS/DRUGS

P.O. BOX 51870

E=AMBULANCE COVERAGE

NEW ORLEANS, LA. 70151

F=PRIVINS/NO DRUGS

000262

G=PRIVINS/IV-D/PAYCHASE

LONG TERM CARE SERVICES NOT AUTHORIZED

SPEND-DOWN NEEDY ELIG PERIOD 08-13-90 THRU 09-90

NEIL BUSH

4000 LOAN STREET

NEW ORLEANS, LA 70126

ID. NUMBER 3904568290101

ELIGIBLE RECIPIENTS

BIRTHDATE TPL

BUSH NEIL

01 11 54

Figure 4-4. Sample Two Eligibility Card Issued by DSS

RECIPIENT ELIGIBILITY

Provided below is a sample Medical Eligibility Card issued by the parish Office of Family Support. Both the front and the back of the card have been illustrated.

BHSF Form 9 REV. 03/92 Prior Issue Usable LOUISIANA MEDIC						
ID NUMBER	ID NUMBER ELIGIBLE BENEFICIARY(IES)			ATE	T.P.L	\$
		- Annonini de	-			
Agency Representative Signature		Date	of Issu	9	Charles and the second	
IMPORTANT: Show this card to each above. * SEE CODES ON REVERSE	provider who has provided or will provide service(s) t	о уон б	luring th	ie dates	shown	

Figure 4-5. Sample Front Side of OFS Issued Medical Eligibility Card

*THIRD PARTY LIABILITY (T.P.L.) CODES

COLUMN 1

D=Private Health Insurance - Drug Coverage; E=Ambulance Insurance; F=Private Health Insurance - No Drug Coverage; G=Private Health Insurance (IV-D) - Pay & Chase

COLUMN 2

Medicare, Part A; B=Medicare, Part B; C=Medicare, Parts A& B

IMPORTANT: PATIENT MUST SHOW THIS CARD WHEN APPLYING FOR MEDICAL SERVICES
The person(s) shown on the reverse side is (are) eligible for the payment of certain medical services authorized by Medicaid of
Louisiana. Benefits under other insurance coverage, including Medicare, must be used first. Eligibility for medical services is
effective only for the dates shown on the reverse side.

Use of this card to obtain medical services to which a person is not entitled will subject that person to arrest and trial under state and federal laws and regulations.

Figure 4-6. Sample Back Side of OFS Issued Medical Eligibility Card

RECIPIENT ELIGIBILITY

Provided below are four different examples of Medical Eligibility Cards issued by the fiscal intermediary, Paramax.

OFFICE OF FAMILY	SUPPORT	26		
ST. CHARLES		* KI	DMED/EPSD	r
P.O. BOX 453				
HAHNVILLE LA	70057			
TYPE CASE: 01	ELIGIBLE	BIRTH	TPL	CARRIER
ID. NUMBER	RECIP. NAME	DATE		CODE
4503495788301 *	FRAN SUE	09/28/89	F	126100
4509839202802 *	fran Jane	11/07/91	F	126100
4567284920020	FRAN DORA	01/26/60	F	126100
DOR 4 200 W	A FRAN VEST ST. REHAN LA 70047	********	*************	######################################

Figure 4-7. Sample One Medical Eligibility Card Issued by Paramax




Figure 4-8. Sample Dual QMB Medical Eligibility Card Issued by Paramax

RECIPIENT ELIGIBILITY




Figure 4-9. Sample Three Medical Eligibility Card Issued by Paramax




Figure 4-10. Sample Pure QMB Medical Eligibility Card Issued by Paramax

RECIPIENT ELIGIBILITY

LOCK-IN PROGRAM

The BHSF has developed a program to educate recipients who may be misusing program benefits and to ensure that program funds are used to provide optimum health services for recipients. Recipients who misuse pharmacy and physician benefits may be restricted to the use of one pharmacy and one physician.

A Lock-In recipient is asked to choose one physician provider and one pharmacy provider to be his Lock-In providers. Under most circumstances the recipients named on the Lock-In Medical Eligibility Card are restricted to receiving physician and pharmacy services from the providers named on their Lock-In Medical Eligibility Cards.

The Lock-In Medical Eligibility Card is the same size as the regular card and is printed on green paper (See the sample provided on page 11.). Recipients who present this card to providers not named on the Lock-In Medical Eligibility Card should be reminded that only those providers named on the front of the card can offer those recipients services. No payment will be made to a physician or pharmacist whose name does not appear on the card for services provided under usual circumstances.

The BHSF recognizes that there will be unusual circumstances when it is necessary for a pharmacy or physician provider to grant services for a Lock-In recipient when the provider is not named on the Medical Eligibility Card. Payment will be made to any physician or pharmacist enrolled in Medicaid of Louisiana who grants services to a Lock-In recipient in emergency situations or when life sustaining medicines are required. If a physician who is not named on the recipient's Medical Eligibility Card renders an emergency service to the recipient, the provider should submit a claim to Paramax and write *Emergency* in the diagnosis section of the claim form. The physician should also write *Emergency Rx* on any prescription resulting from such an emergency.

There may be circumstances under which it is necessary for a Lock-In physician to refer the Lock-In recipient for consultation on a one-time basis. The consulting physician may be reimbursed for the consultation if that consulting physician enters the name of the referring Lock-In physician in the Referring Physician block on the claim. If the consulting physician subsequently becomes the treating physician, that physician should remind the recipient to report this information to the BHSF because reimbursement cannot be made for continued services until the provider's name and number are entered on the recipient's Medical Eligibility Card.

RECIPIENT ELIGIBILITY

Pharmacists other than those named on the Lock-In recipient's Medical Eligibility Card may fill prescriptions for life sustaining medication or upon receiving a prescription containing the term *Emergency Rx*. However, they should certify that the prescription is an emergency on their claim forms.

The Lock-In system affects the recipients only in the areas of physician and pharmacy services. Providers other than physicians or pharmacists may provide the services which they normally do for any eligible recipient.

The Lock-In program and the CommunityCARE program are different programs set up to achieve different objectives (See explanation of CommunityCARE eligibility card.

RECIPIENT ELIGIBILITY




Figure 4-11. Sample Front Side of a Lock-In Eligibility Card

IMPORTANT: PATIENT MUST SHOW THIS CARD WHEN RECEIVING MEDICAL SERVICES The person shown on the reverse side is eligible for the payment of certain medical services authorized by Medicaid of Louisiana. Benefits under other insurance coverage, including Medicare, must, with certain exceptions, be used first. Eligibility for medical services will terminate at the end of the month shown. This beneficiary is participating in a special program to educate him/her as to the most efficient use of medical benefits so as to assure maximum health benefits. This beneficiary IS NOT eligible to receive routine physician or pharmacy services from providers other than those listed on this card. Other physicians who provide emergency services to this beneficiary MUST certify that an emergency existed by writing "Emergency" in the remarks section of the claim form. He/she shall write "Emergency RX" on any prescription resulting from such a situation. Pharmacists filling a prescription from physicians who are not listed shall verify that the term "Emergency RX" is shown on the prescription by writing "Emergency" on the service claim. Pharmacists other than the one listed may fill prescriptions ONLY for life sustaining medication or upon receipt of a prescription containing the term "Emergency RX" and shall certify that the prescription was for an emergency on the service claim. Medical providers other than physicians or pharmacists are not restricted to these limitations. Use of this card to obtain medical services to which a person is not entitled will subject that person to arrest and trial under state and federal laws and regulations. *THIRD PARTY LIABILITY (T.P.L.) CODES COLUMN I D=Private Health Insurance - Drug Coverage; E=Ambulance Insurance; F=Private Health Insurance - No Drug Coverage; G=Private Health Insurance (TV-D) - Pay & Chase COLUMN 2

Figure 4-12. Sample Back Side of a Lock-In Eligibility Card

A=Medicare, Part A; B=Medicare, Part B; C=Medicare, Parts A & B

RECIPIENT ELIGIBILITY

CommunityCARE recipients receive a monthly Medicaid eligibility card showing the name and telephone number of the selected/assigned CommunityCARE provider in the lower right hand corner. A sample of the CommunityCARE card is provided on the following page. The recipient will receive the initial Medicaid card approximately 60 days after the selection or assignment of a primary care physician is made.

One Medicaid card will be issued for each certified household. Each eligible recipient in a certification may select or be assigned to a different CommunityCARE provider. If members of a family unit select different participating providers, each primary care physician will be listed on the card. For example, a pediatrician may be selected for an infant, and a general practitioner may be selected for the parents.

Reissuance of lost or stolen Medicaid cards is the responsibility of the parish offices. Replacement cards will be issued manually, listing the recipient's assigned primary care physician. Parish OFS facilities, Medicaid offices, and enrollment centers will receive monthly printouts showing primary care physician assignments for eligible recipients.

RECIPIENT ELIGIBILITY

LOUISIANA MEDICA	AL ELIC	GIBILITY	CARD	1 ELIG.	FOR - MAR	CH 92
OFFICE OF FAMILY	SUPPO	RT	640			
CLAIBORNE				*KIDMED/I	EPSDT	
P.O. DRAWER 210						
HOMER	LA	71040				
TYPE CASE 10						
			ELIGIBLE	BIRTH	TPL	CARRIER
ID. NUMBER		RECIP	. NAMI	E DATE		CODE
9033312457891	* 1JO	NES	GARY	03/14/79		
9003321456890	* 1JO	NES	TOM	03/22/86		
9003456789123	* 1SM	UTH	JACK	10/16/89		
9002534567892	* 1JO	NES	BOB	12/22/90		
9002345678196	2JO		SUE	05/03/63		
· · · · · · · · · · · · · · · · · · ·	· 古在全全宫宫宫	(常多会会会会会会)	222222222222222	: A = A A A A A A A A A A A A A	· · · · · · · · · · · · · · · · · · ·	188
sssssss CAR	R-RT SO	RT ** B0	001	CON	MMUNITY CARE	PATIENT
JONES SUE				PROVIDER	NAME	TEL.#
PO BOX 280				1 ABC CLA	AIBORNE CLINIC	3183453255
LISBON LA	71048-0	215				
				2 XYZ CLI	NIC	3185679876

Figure 4-13. Sample CommunityCARE Medicaid Card

RECIPIENT ELIGIBILITY

THIRD-PARTY LIABILITY (TPL)

Federal regulations and applicable state laws require that third-party resources be used before Medicaid is billed. *Third-party* refers to those payment resources available from both private and public health insurance and from other liable sources, such as liability and casualty insurance, that can be applied toward the Medicaid recipient's medical and health expenses. The lack of a third-party code on the eligibility card does not negate the provider's responsibility for asking recipient's if they have insurance coverage.

In most cases, except for those services provided to EPSDT eligibles, it is the provider's responsibility to bill the third-party carrier prior to billing Medicaid. However, in those situations, where the insurance payment is received after Medicaid has been billed and has made payment, the provider must reimburse Medicaid, not the recipient. Reimbursement must be made **immediately** to comply with federal regulations. Providers may reimburse Medicaid by forwarding a check or by submitting an adjustment request. Checks must have identifying information, such as date of service, Internal Claim Number (ICN), recipient name and number, and the reason for the reimbursement.

EPSDT providers need not bill a third-party insurance carrier before billing Medicaid of Louisiana. Paramax will pay the provider for services rendered and "chase" or pursue collection on the portion of the bill that is due by another income source.

	,		

PROVIDER ENROLLMENT

PROVIDER ENROLLMENT

Providers who wish to participate in Medicaid of Louisiana should contact Paramax, Provider Relations, to request an enrollment packet. They must then complete the packet and submit it to the Provider Enrollment Unit at the Bureau of Health Services Financing (BHSF). Enrollment will be approved if the provider meets all qualifications and licensure requirements, as well as the standards for participation in Medicaid of Louisiana.

Each enrolling provider must enter into an agreement with Medicaid of Louisiana. The agreement requires that providers adhere to regulations, including the requirements contained in this provider manual. To participate in Medicaid of Louisiana, providers must complete a Medicaid PE-50 enrollment form and a Medicaid Supplement Agreement.

Copies of enrollment packets may be obtained from the following address:

Paramax Provider Relations P.O. Box 91024 Baton Rouge, LA. 70821

2 (504) 924-5040

Completed forms should be submitted to the following address:

Bureau of Health Services Financing Provider Enrollment Section P.O. Box 91030 Baton Rouge, LA. 70821-9030

(504) 342-9454

If additional information is required, the applicant will be notified. Notification of provider enrollment in Medicaid of Louisiana is the assignment of a provider number to be used when submitting claims.

,

PROVIDER ENROLLMENT

CHANGE OF ADDRESS/ENROLLMENT STATUS

Providers who have address changes should notify the Provider Enrollment Unit of Medicaid of Louisiana in writing. Giving notification of address changes will allow correspondence, checks, and rejected claims to be delivered to the appropriate providers in a timely manner (See the addresses and telephone numbers on the preceding page.).

Also, providers who change their group affiliation should notify Provider Enrollment to eliminate the possibility of payments being delivered to the wrong provider/group.

	,		

I. SUBSTANCE ABUSE SERVICES

Substance Abuse Services under the Louisiana Medicaid Program are designed to treat Medicaid recipients who are known substance abusers and who have been diagnosed as having a substance abuse problem. The services provided in the clinics are all designed to treat users and persons in recovery from using chemical substances. These clinics must be licensed by the Department of Health and Hospitals.

A. Covered Services

Alcohol and Substance Abuse services must be provided in a clinic setting. A clinic is a facility which is not a part of a hospital but which is organized and operated to provide medical care to outpatients. Clinic services are defined as those preventative, diagnostic, therapeutic, rehabilitative or palliative items or services that are furnished to an individual recipient on an outpatient basis. These services must be provided under the personal supervision of a physician and the patient must have a diagnosis related to substance abuse. Refer to pages 6-3 and 6-4 for acceptable codes.

To be payable by Medicaid, the services must be performed by a physician or by a qualified person working under the personal supervision of the physician.

Inpatient treatment services other than medical detoxification are not reimbursable.

B. Service Limits

Reimbursement will be made for one service per day per recipient. In addition, the following service limits apply to all recipients, 21 years of age or older:

Individual Counseling Therapy: 26 visits per year per recipient Group Counseling Therapy: 26 visits per year per recipient Family Counseling: 12 visits per year per recipient

Group Counseling Therapy is limited to a minimum of two (2), and no more than six (6) persons to a group.

SUBSTANCE ABUSE SERVICES

B. Services And Procedure Codes

The following procedure codes and descriptions must be used to bill for substance abuse services.

Procedure Code	Description
X0140	Individual Counseling/Therapy is treatment by individual interview to aid the recipient in meeting the goals outlined in the recipient's plan of treatment.
X0141	Group Counseling/Therapy is treatment by use of group dynamics or group interaction for the purpose of achieving the goals in their respective treatment plans.
X0142	Family Counseling/Therapy is treatment applied to couples, the family as a unit, or other significant family members which includes treatment of a child by working with the parents, treatment of an elderly family member by working with other family members, etc.
X0144	Medical Treatment is the continuing provision of services related to monitoring, reviewing and/or regulating usage of medications. Includes counseling/education related to the use of or effects of prescribed medications and antabuse (except methodone).
X0150	Screening and Intake is the initial interview to gather preliminary information about a program area in order to determine level of care required to resolve presenting concern.

SUBSTANCE ABUSE SERVICES

Procedure Code	Description
X0151	Psychosocial Evaluation is an assessment of the recipient's social history and functioning which addresses appropriately the following: Presenting problem Previous use of substance abuse services Domestic/household relationships including abuse and neglect issues Cultural, ethic and spiritual factors and expectations Emotional and health factors of family and expectations Alcohol and drug abuse by other family members Educational, occupational, vocational, financial, military and legal status Peer group Human sexuality Leisure skills Family's potential for providing care
X0145	Medical Injection is injectable medication treatment, short or long term, for treating condition requiring medication given by subcutaneous or intramuscular route, e.g., allergic reaction, side effects from medication, acute anxiety or agitation, or long action neuroleptic drugs.
X0152	Psychiatric Evaluation is the psychodiagnostic process, including a medical history and an evaluation of mental status which notes the attitudes and behavior; an estimate of intellectual functioning; orientation; an inventory of the patient's assets in a descriptive fashion; impressions; and recommendations.
X0153	Medical Evaluation is the determination by a qualified professional of the recipient's present physical condition, diagnosis, and treatment recommendations, or if indicated after examination, referral to an appropriate medical facility. Includes pediatric evaluation.
X0154	Other Evaluation refers to other evaluating or assessment services not covered above, including speech and hearing evaluation, occupational therapy and nursing assessment.

SUBSTANCE ABUSE SERVICES

SUBSTANCE ABUSE SERVICES

C. Diagnostic Codes

A person must have a diagnosis in the diagnosis code range of 303 (Alcohol Dependence Syndrome) through 304.9 (Unspecified Drug Dependence) as found in the ICD-9-CM book for 1997 to qualify to receive substance abuse services.

DESCRIPTION OF MENTAL HEALTH SERVICES

DESCRIPTION OF MENTAL HEALTH SERVICES

Provided in this section is an explanation of the Medicaid services covered under the *Mental Health Program*.

COVERED SERVICES

Covered services include clinic services. *Clinic Services* are defined as those preventive, diagnostic, therapeutic, rehabilitative, or palliative items or services that are furnished to an outpatient by or under the direction of a physician in a facility which is not a part of a hospital but which is organized and operated to provide medical care to outpatients.

These clinics must be licensed by the Department of Health and Hospitals, Division of Licensing and Certification. Also, payment to public clinics is made on a cost basis.

Covered services also include the following:

- Evaluation and Assessment Services,
- Treatment and Counseling Services, and
- Rehabilitation or Rehabilitation Services.

These services are described in more detail on the following pages.

DESCRIPTION OF MENTAL HEALTH SERVICES

Evaluation and Assessment Services

Evaluation and assessment services include the following:

- Psycho-social Evaluations; i.e., the determination and examination of the social situation of the individual as it relates to family background, family interaction, living arrangements, psycho-economic problems, or socioeconomic problems.
- Psychiatric Evaluations; i.e., the psychodiagnostic process, including a medical history and a mental status, which notes the attitudes and behavior; an estimate of intellectual functioning; orientation; an inventory of the patient's assets in a descriptive fashion; impressions; and recommendations.
- Psychological Evaluations; i.e., the evaluation of the cognitive processes, emotions, and problems of adjustment through interview and/or the administration and interpretation of tests of mental abilities, aptitude, interests, attitudes, motivations, and personality characteristics.
- Physical Evaluation; i.e., an examination of the body's functional processes, noting observations and findings, supplemented by diagnosis, if indicated.

DESCRIPTION OF MENTAL HEALTH SERVICES

Treatment and Counseling Services

Treatment and counseling services include those services which are intended to change favorably the recipient or his situation through the reduction or remedy of disability or discomfort, the amelioration of signs and symptoms, and the attainment of change in specific physical, mental, or social functioning. These services are usually formal and scheduled, but they may be provided on an emergency basis. They include the following:

- Individual Counseling or Therapy; i.e., treatment by individual interview to aid the recipient in meeting the goals outlined in the recipient's plan of treatment which includes psychotherapy, psychoanalysis, case work, play therapy, behavior modification, etc.;
- Group Counseling or Therapy; i.e., treatment by the use of group dynamics or group interaction;
 - Services are provided simultaneously to 2 or more recipients who are grouped together for the purpose of achieving the goals in their respective treatment plans. Group counseling or therapy includes psychotherapy, psychoanalysis, play therapy, psychodrama, behavior modification, etc.
- Family or Couple Counseling or Therapy; i.e., treatment applied to couples, the family as a unit, or other significant family members which includes treatment of a child by working with the parents, treatment of an elder family member by working with other family members, etc.;
- Medication Management; i.e., activities related to the dispersing, review, and regulation of a medication program for individuals or counseling/education related to the use of or effects of medication; and
- Medication Injection; i.e., injectable medication treatment, short or long term, for treating conditions requiring medication given by subcutaneous or intramuscular route, e.g., allergic reaction, side effects from medication, acute anxiety or agitation, or long action neuroleptic drugs.

DESCRIPTION OF MENTAL HEALTH SERVICES

Rehabilitation or Rehabilitation Services

These services are related to preparing or training a person to function within the limits of the original or residual disability by the acquisition, return, or accommodation to the loss of skills and knowledge.

In state mental health centers, most rehabilitative efforts take the form of social rehabilitation services which are designed to help an individual in his psychosocial adjustment to learn or relearn skills that will increase social and personal functioning and relieve social isolation. These services include the following:

- Occupational therapy,
- Recreational therapy,
- Music therapy, and
- Art therapy.

DESCRIPTION OF MENTAL HEALTH SERVICES

SERVICE LIMITS

Inpatient services are not reimbursed. Also, all general assistance recipients are not eligible for the service. However, these recipients' Medicaid identification cards will state specifically that substance abuse clinic services are not authorized.

MENTAL HEALTH SERVICES PROCEDURE CODES

Provided below is a table of procedure codes and descriptions that should be used to bill for mental health services.

MEN	TAL HEALTH SERVICES PROCEDURE CODES
X0071	Psychosocial Evaluation
X0072	Psychiatric Evaluation
X0073	Psychological Evaluation
X0074	Physical Evaluation
X0075	Other Evaluation/Assessment Service (Specify)
X0076	Individual Counseling/Therapy
X0077	Group Counseling/Therapy
X0078	Family/Group Counseling/Therapy
X0079	Medication Management
X0080	Medication Injection
X0081	Occupational Therapy
X0082	Recreational Therapy
X0083	Music Therapy
X0084	Art Therapy
X0085	Consultation
X0086	Individual Screening
X0087	Counseling/Consultation

MEDICAL SERVICES MANUAL MENTAL HEALTH REHABILITATION SERVICES

DESCRIPTION OF MENTAL HEALTH REHABILITATION SERVICES

Mental health rehabilitation services consist of the planning, delivery, and management of mental health therapeutic services. These services differ from those provided under the Medicaid Clinic Option by the location(s) in which they are provided. Mental health rehabilitation services are not restricted to a community mental health clinic or an inpatient setting. They may be provided in community settings or in any facility which does not provide mental health services as part of its program. They differ from case management services for the chronically mentally ill which involve arranging access to and coordination of a wide range of services of which mental health rehabilitation is only a part.

Mental health clinics may enroll as providers of mental health rehabilitation services. A separate provider number will be assigned, and services as outlined in this section may be billed with the procedure codes assigned to the mental health rehabilitation provider number. Enrolled mental health rehabilitation providers will receive a different manual with specific information for that service.

Mental health rehabilitation services in Louisiana are divided into five component services, each of which has specific services and procedure codes. Some services have separate codes for filing with Medicare for those recipients eligible for that service.

Tables of the mental health rehabilitation procedure codes are provided on the following pages.

MENTAL HEALTH REHABILITATION SERVICES

MENTAL HEALTH REHABILITATION PROCEDURE CODES

COMPONENT: MENTAL HEALTH REHAB MANAGEMENT		
CODE	DESCRIPTION	
X0100	Medical Assessment For Medicare, use the appropriate CPT code for the office visit.	
X0101	Psychological Evaluation	
90801	Medicare Code	
X0102	Psychosocial Evaluation	
X0103	Other Evaluations	
90830	Medicare Code	
X0104	Rehabilitation Plan Development	
X0105	Rehabilitation Plan Update	
X0106	Collateral Consultation	

COMPONENT: MENTAL HEALTH REHAB COUNSELING AND THERAPY		
CODE	DESCRIPTION	
X0107	Individual Counseling or Therapy	
90843	Medicare Code	
X0108	Family Counseling or Therapy	
90847	Medicare Code	
X0109	Group Counseling or Therapy	
90853	Medicare Code	
X0110	Treatment Integration	
X0106	Collateral Consultation	



MENTAL HEALTH REHABILITATION SERVICES

COMPONENT: MENTAL HEALTH REHAB PSYCHOSOCIAL SKILLS TRAINING		
CODE	DESCRIPTION	
X0111	Skills Training	
X0110	Treatment Integration	
X0106	Collateral Consultation	

COMPONENT: MENTAL HEALTH REHAB MEDICATION MANAGEMENT		
CODE	DESCRIPTION	
X0112	Medication Administration	
X0113	Medication Monitoring	

COMPONENT: MENTAL HEALTH REHAB CRISIS SERVICES				
CODE	DESCRIPTION			
X0114	Crisis Intervention			
X0115	Crisis Support			

TIMELY FILING GUIDELINES

TIMELY FILING GUIDELINES

To be reimbursed for services rendered, all providers must comply with the following timely filing guidelines set by Medicaid of Louisiana:

- Straight Medicaid Claims must be filed within 12 months of the date of service.
- Medicare Crossover Claims must be filed within 12 months of the date of service or 6 months from the date of the Explanation of Medicare Benefits (EOMB).
- Claims with Third-Party Payment must be filed within 12 months of the date of service.
- Claims for Recipients with Retroactive Coverage, e.g., spend-down medically needy recipients, should be sent to Paramax with a note of explanation or a copy of the recipient's Medicaid identification card as soon as possible. The mailing address for Paramax is as follows:

Paramax Provider Relations P.O. Box 91024 Baton Rouge, LA. 70821

All claims for recipients with retroactive coverage will be forwarded to the BHSF for review and authorization.

Medicaid claims received after the maximum timely filing date cannot be processed unless the provider is able to furnish proof of timely filing. Such proof may include the following:

 A Remittance Advice indicating that the claim was processed earlier (within the specified timeframe)

OR

• Correspondence from either the state or parish Office of Family Support concerning the claim and/or the eligibility of the recipient.

When resubmitting the claim and documentation, providers must be certain that the claim is legible to ensure accurate processing. Documentation must reference the individual recipient and date of service. Claims which are over the two-year billing limitation cannot be considered for processing. Providers should not resubmit these claims.

HCFA-1500 (12/90) BILLING INSTRUCTIONS

HCFA-1500 (12/90) BILLING INSTRUCTIONS

Providers should bill for substance abuse and mental health services on the HCFA-1500 claim form. Provided in this section are some general billing reminders and specific instructions for billing on the HCFA-1500 (12-90) claim form.

GENERAL REMINDERS

Providers should note the following:

- Providers may submit more than one claim per envelope to reduce provider postage costs and to aid Paramax in handling mail.
- Providers should always notify the Bureau of Health Services Financing (BHSF) when a mailing address change occurs to allow rejected claims to be returned more quickly to providers. Many claims are returned to Paramax because forwarding orders at the post office have expired.
- Claims should be filed immediately after services have been provided.
- Medicaid is the payer of last resort.
 - A sample claim form is provided on the following page.

,	

3

6

	•		
	2257		
			150

PICA	HEALIHIN	SURANCE CLAIM I	ORM PICA	
EDICARE MEDICAID CHAMPUS CHAMPU (Medicare #) (Medicaid #) (Sponsor's SSN) (VA Fil	HEALTH PLAN BLK LUNG	R 1a. INSURED'S I.D. NUMBER	(FOR PROGRAM IN ITE	EM 1
. PATIENT'S NAME (Last Name, First Name, Middle Initial)	3. PATIENT'S BIRTH DATE SEX	4. INSURED'S NAME (Last Name	, First Name, Middle Initial)	
. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED Self Spouse Child Other	7. INSURED'S ADDRESS (No., SI	reet)	
ITY STATI	E 8. PATIENT STATUS	CITY	STATE	E
IP CODE TELEPHONE (Include Area Code)	Single Married Other	ZIP CODE	TELEBRIONE (NOLLIDE ADEA CO.	205:
()	Employed Full-Time Part-Time	ZIP CODE	TELEPHONE (INCLUDE AREA COL	JUE)
OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP	OR FECA NUMBER	
OTHER INSURED'S POLICY OR GROUP NUMBER	a. EMPLOYMENT? (CURRENT OR PREVIOUS)	a. INSURED'S DATE OF BIRTH	SEX F	7
OTHER INSURED'S DATE OF BIRTH SEX	b. AUTO ACCIDENT? PLACE (State)	b. EMPLOYER'S NAME OR SCHO		
M F	YES NO			
EMPLOYER'S NAME OR SCHOOL NAME	c. OTHER ACCIDENT?	c. INSURANCE PLAN NAME OR F	POGRAM NAME	
INSURANCE PLAN NAME OR PROGRAM NAME	10d. RESERVED FOR LOCAL USE	d. IS THERE ANOTHER HEALTH	BENEFIT PLAN?	
			yes, return to and complete item 9 a	
READ BACK OF FORM BEFORE COMPLETIN PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the opposess this claim. I also request payment of government benefits eith below.	ne release of any medical or other information necessary		PERSON'S SIGNATURE I authorize the undersigned physician or supplie	
SIGNED	DATE	SIGNED		
DATE OF CURRENT: ILLNESS (First symptom) OR 1 DD YY	5. IF PATIENT HAS HAD SAME OR SIMILAR ILLNESS. GIVE FIRST DATE MM DD YYY	16. DATES PATIENT UNABLE TO MM DD YY	WORK IN CURRENT OCCUPATION MM DD YY TO	N
	ra. I.D. NUMBER OF REFERRING PHYSICIAN	18. HOSPITALIZATION DATES RE	ELATED TO CURRENT SERVICES MM ; DD ; YY	
RESERVED FOR LOCAL USE		FROM 20. OUTSIDE LAB?	TO \$ CHARGES	
		YES NO		
DIAGNOSIS OR NATURE OF ILLNESS OR INJURY. (RELATE ITEMS	S 1,2,3 OR 4 TO ITEM 24E BY LINE)	22. MEDICAID RESUBMISSION CODE	DRIGINAL REF. NO.	-
	3	23. PRIOR AUTHORIZATION NUM	IBER	
	4			
A B C DATE(S) OF SERVICE Place Type PROCEDU	D E JRES, SERVICES, OR SUPPLIES DIAGNOSIS	F G DAYS EPS	H I J K	
DATE(S) OF SERVICE	lain Unusual Circumstances)	SCHADGES OR Fai	mily emg COB RESERVED F	
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
				-
FEDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S	(For govt. claims, see back)	1	MOUNT PAID 30. BALANCE D	DUE
	ADDRESS OF FACILITY WHERE SERVICES WERE (If other than home or office)	\$ \$ 33. PHYSICIAN'S, SUPPLIER'S BIL & PHONE #	LING NAME, ADDRESS, ZIP CODE	E
			1	
SNED DATE		PIN#	GRP#	

CARRIER

HCFA-1500 (12/90) BILLING INSTRUCTIONS

SPECIFIC BILLING INSTRUCTIONS

The instructions provided below should be followed carefully for accurate and prompt processing of claims.

1.

Check the box that says "Medicaid" (Medicaid #).

*1a. INSURED'S ID NUMBER

Enter the recipient's 13-digit Medicaid ID number exactly as it appears on the recipient's monthly medical identification card. In the case of a family, make certain that the last 2 digits of the identification number are the correct individual suffix for the family member who is being treated. If the number does not match the patient's name in Block 2, the claim will be denied. If this item is blank, the claim will be returned.

*2. PATIENT'S NAME

Enter in this space the name of the recipient. Enter the last name first, the first name next, and the middle initial last. Spell the name exactly as it appears on the client's medical identification card.

3. PATIENT'S BIRTH DATE AND SEX

Enter the patient's date of birth exactly as it appears on the medical identification card using the six-digit MM/DD/YY format. If there is only one digit in a field, precede that digit with a zero. Put an X in the appropriate box to indicate the patient's sex.

4. INSURED'S NAME.

Leave this space blank.

5. PATIENT'S ADDRESS

Enter the client's permanent address.

6. PATIENT

RELATIONSHIP TO INSURED

Leave this space blank.

7. INSURED'S ADDRESS

Leave this space blank.

HCFA-1500 (12/90) BILLING INSTRUCTIONS

8. PATIENT STATUS

Leave this space blank.

9. OTHER INSURED'S NAME

Enter the insured's name, if applicable.

9A. OTHER INSURED'S POLICY OR GROUP NUMBER

Enter the TPL Carrier Code Number (if applicable).

NOTE: The other resource must be billed first, with the exception of pay and chase claims, since Medicaid is the payer of last resort (See page 4-14 for an explanation of Pay and Chase.)

9B. OTHER INSURED'S DATE OF BIRTH

Leave this space blank.

9C. EMPLOYER'S NAME OR SCHOOL NAME

Leave this space blank.

9D. INSURANCE PLAN NAME OR PROGRAM NAME

Leave this space blank.

10. WAS CONDITION RELATED TO:

A.

Check the appropriate box.

B.

Check the appropriate box.

C.

Check the appropriate box.

If the patient's condition is the result of an injury or illness and there is potential for insurance coverage or compensation as a result of accident or illness, check the appropriate blocks in Items A - C.

The insurance must be billed first since Medicaid is the payer of last resort.

HCFA-1500 (12/90) BILLING INSTRUCTIONS

11 a-d.

Leave these spaces blank.

12. PATIENT'S OR
AUTHORIZED
PERSON'S SIGNATURE

Leave this space blank.

13. INSURED'S OR
AUTHORIZED
PERSON'S SIGNATURE

Leave this space blank.

14. DATE OF CURRENT ILLNESS

Using the 6-digit MM/DD/YY format, enter the month, day, and year of the date of the illness (first symptom), injury (accident), or pregnancy. If there is only one digit in a field, precede that digit with a zero.

15. DATE OF SAME OR SIMILAR ILLNESS

Leave this space blank.

16. DATES
PATIENT UNABLE TO WORK

Leave this space blank.

*17. NAME OF REFERRING PHYSICIAN OR OTHER SOURCE

If you are billing for a consult, if the patient is a Lock-In and the provider is not indicated on the card, or if the provider is an independent laboratory, enter the physician's name. Also, all claims for CRNA services must have the name of the physician who provides the medical direction.

18. HOSPITALIZATION DATES
RELATED TO CURRENT SERVICES

Complete this block when a medical service is furnished as a result of or subsequent to a related hospitalization.

19. RESERVED FOR LOCAL USE

Leave this space blank.

HCFA-1500 (12/90) BILLING INSTRUCTIONS

20. OUTSIDE LAB

Was Lab Work Performed Outside Your Office:

Check the appropriate box.

Charges:

Not applicable.

*21. DIAGNOSIS

All claims must contain a medically accepted description of the diagnosis. You must enter the numeric code and literal description. Use of ICD-9-CM coding is mandatory. Accepted abbreviations are appropriate.

22. MEDICAID RESUBMISSION CODE

Leave this space blank.

23. PRIOR AUTHORIZATION

Enter the prior authorization number when applicable.

24. *A. DATE OF SERVICE

Enter the month, day, and year for each item billed. If "from" and "to" dates are shown here for a series of identical services on the same day or on consecutive days, enter the number of services in Item 24G.

NOTE: Surgical procedures may not be span-dated.

*B. PLACE OF SERVICE

Enter the appropriate place of service code. A table of the valid codes is provided on the following page.

HCFA-1500 (12/90) BILLING INSTRUCTIONS

NEW PLACE OF SERVICE CODES

CODE	DEFINITION	CODE	DEFINITION
00-99	Unassigned	51	Inpatient Psych. Fac.
11	Office	52	Psych. Fac. Partial Hosp.
12	Ноте	53	Community Mental Health
10,13,19	Unassigned	54	Intermediate Care Fac./ Mentally Retarded
21	Inpatient Hospital	55	Residential Substance Abuse Treatment Facility
22	Outpatient Hospital	56	Psych Residential Treatment Facility
23	Emergency Room-Hospital	50,57-59	Unassigned
24	Ambulatory Surgical Ctr.	61	Comprehensive Inpatient Rehabilitation Facility
25	Birthing Center	62	Comprehensive Outpatient Rehabilitation Facility
26	Military Treatment Fac.	65	End Stage Renal Disease Treatment Facility
27-29	Unassigned	60,63,64	Unassigned
31	Skilled Nursing Facility	66-69	Unassigned
32	Nursing Facility	71	State or Local Public Health Clinic
33	Custodial Care Facility	72	Rural Health Clinic
34	Hospice	70,73-79	Unassigned
30,35-39	Unassigned	81	Independent Laboratory
41	Ambulance - Land	80,82-89	Unassigned
42	Ambulance - Air or Water	99	Other Unlisted Facility
40,43-49	Unassigned	90-98	Unassigned

MEDICAL SERVICES MANUAL	MEDI	CAL	SERV	ЛCES	MANI	JAL
-------------------------	------	-----	------	------	------	-----

HCFA-1500 (12/90) BILLING INSTRUCTIONS

C. TYPE OF SERVICE

Leave this space blank.

*D. PROCEDURE CODE

Enter the procedures, services, or supplies using CPT-4 or HCPCS codes. Also, show applicable modifiers, if any are necessary. A description of the service is no longer required unless you are billing with a miscellaneous procedure code. In such instances, enter the description in Item 24D or on an attachment.

*E. DIAGNOSIS CODE

Refer to the diagnosis entered in Item 21 and indicate the most appropriate diagnosis for each procedure by using either a 1, 2, 3, or 4.

NOTE: More than one diagnosis may be related to a procedure/service. Do not put an ICD-9-CM diagnosis code in this item.

*F. CHARGES

Enter your usual or customary charges for this service/procedure.

G. DAYS OR UNITS

Enter the number of services billed. For anesthesia, show the elapsed time in minutes.

H. EPSDT FAMILY PLANNING

Enter "Y" if the services are the result of an EPSDT referral or a family planning referral.

I. EMG

Leave this space blank.

J. COB

Leave this space blank.

*K. RESERVED

FOR LOCAL USE

Enter the individual physician number if the group is billing for the provider.

25. FEDERAL TAX ID NO.

Leave this space blank.

HCFA-1500 (12/90) BILLING INSTRUCTIONS

26. YOUR PATIENT'S ACCOUNT NUMBER

If you enter your patient's account (medical record) number, it will appear on your Remittance Advice. It may consist of letters and/or numbers, and it may be a maximum of 16 positions.

27. ACCEPT ASSIGNMENT

For Medicaid only claims, leave this space blank. Medicaid does not make payments to the recipient. Claim filing indicates acceptance by the provider.

NOTE: Claims which require filing to Medicare must be completed in accordance with Medicare instructions. Assignment must be accepted for dual Medicare/Medicaid eligibles.

*28. TOTAL CHARGE

Total all charges listed on the claim. If more than one claim form is used, total each form separately and do not carry forward the total charge.

*29. AMOUNT PAID

If Item 9 is completed showing other health insurance, the amount paid will be the amount received from the other insurance, and it will require an Explanation of Benefits attached to the claim. When filing a Spend-Down Medically Needy claim, a Form 110-MNP must be attached for any service provided on the first date of the period of eligibility. This form will reflect patient liability. Do not enter patient payment from the 110-MNP in this item. Do not enter any amount paid by Medicare.

*30. BALANCE DUE

Enter the balance due for services listed on the claim form.

HCFA-1500 (12/90) BILLING INSTRUCTIONS

31. SIGNATURE OF PHYSICIAN/SUPPLIER & DATE

The claim form must be signed. Signature stamps or computer-generated signatures are acceptable, but they must be initialed by the provider or the provider representative. If Item 31 is left blank, or if the stamped or computer-generated signature is not initialed, the claim will be returned to the provider. Also, enter the date the claim is signed.

32. NAME AND ADDRESS WHERE SERVICES WERE RENDERED

Enter the name and address of the facility where services were rendered if the facility was not the physician's office or the patient's home.

*33. PHYSICIAN'S OR MEDICAL ASSISTANCE SUPPLIER'S NAME, ADDRESS, ZIP CODE AND TELEPHONE NUMBER & PROVIDER ID NUMBER

Enter the provider's name, address, and Medicaid provider number. This number must be entered in the space adjacent to "Grp. No." This is a 7-digit number.

* If these items are not completed, the claim will be denied.

,

HCFA-1500 (12/90) BILLING INSTRUCTIONS

Providers billing for medications for substance abuse or mental health recipients must bill on the pharmacy claim form.

Instructions for completing this claim form and information concerning covered pharmacy services are provided in the Prescription Drug Services provider manual. Copies of this manual may be obtained from Paramax.

THE REMITTANCE ADVICE

THE REMITTANCE ADVICE

The purpose of this section is to familiarize the provider with the design and content of the Remittance Advice (RA). This document plays an important communication role between the provider, the BHSF, and Paramax. Aside from providing a record of transactions, the Remittance Advice will assist providers in resolving and correcting possible errors and reconciling paid claims.

THE PURPOSE OF THE REMITTANCE ADVICE

The RA is the control document which informs the provider of the current status of submitted claims. It is sent out with all provider checks.

On the line immediately below each claim a code will be printed representing denial reasons, pended claim reasons, and payment reduction reasons. Messages explaining all codes found on the Remittance Advice will be found on a separate page following the status listing of all claims. The only type of claim status which will not have a code is one which is paid as billed.

If you use a medical record number (It may consist of up to 16 alpha and/or numeric characters.), it will appear on the line immediately following the recipient's number.

WHAT HAPPENS TO YOUR INVOICE?

When your invoice is received in the mailroom, addressed to the proper Post Office Box for the claim type, it will be edited for missing data. If the signature, recipient Medicaid identification number, service dates, or provider name and/or number is missing, the claim will be rejected and returned.

Returned Claims

If the invoice is rejected because of missing or incomplete items, the original invoice you submitted will be returned to you accompanied by a return letter. The return letter will indicate why the invoice has been returned. Complete the missing or incomplete items on the original invoice, and resubmit it. A returned claim will not appear on the Remittance Advice because it will not enter the processing system. In addition, it will not be microfilmed and given a unique 13-digit Control Number before being returned to the provider.

THE REMITTANCE ADVICE

Claims which have all the necessary items for claims processing completed pass the first screening process, are microfilmed, are given a unique 13-digit Control Number, and are entered into the computer for processing.

WHAT HAPPENS TO A PROCESSED CLAIM?

Claims which enter the processing system will be either approved (paid), pended to Medical Review, or denied.

All claims which have been processed will fall into one of these three classifications. You will receive a Remittance Advice for each payment cycle in which you have claims processed.

Approved Claims

A claim which is correctly completed for a covered service provided to an eligible recipient/patient by an enrolled provider will be approved for payment and paid. It will appear on the Remittance Advice on the first page or the page which lists all claims to be paid on that Remittance Advice. If the payment is different from the billed charges, an explanation will appear on the RA via a three-digit message code.

Denied Claims

A claim will be denied for the following reasons:

- If the recipient is not eligible on the date of service;
- If the provider is not enrolled on the date of service;
- If prior authorization is required, but not reflected;
- If the service is not covered by the program;
- If the claim is a duplicate of a prior claim;
- If the date is invalid or logically inconsistent; or
- If the program limitations are exceeded.

Three-digit message codes giving the reason(s) for the denial will be printed on the line immediately following the claim information. An explanation of all codes appearing on the Remittance Advice will be printed on a separate page.

THE REMITTANCE ADVICE

Pended Claims

Pended claims are those claims held for in-house review by Paramax. If after the claim is reviewed, it is determined that a correction by the provider is required, the claim will be denied. If the correction of a claim can be made during the review, the claim will be paid.

Claims can pend for many reasons. The following are a few examples:

- Errors were made in entering data from the claim into the processing system.
- Errors were made in submitting the claim. These errors can be corrected only by the provider who submitted the claim.
- The claim must receive Medical Review.
- Critical information is missing or incomplete.

HOW TO CHECK THE STATUS OF A CLAIM - CONTROL NUMBER

A unique 13-digit number is given to each claim. The Control Number reflected on the RA can be used to track the status of your claims.

The first four digits of the Control Number are the actual year and day the claim was received. The next seven digits tell whether the claim is a paper claim or whether it was submitted on tape and what the batch and sequence numbers are which were entered into the processing system. All claim lines on a given claim form will have the same first 11 digits.

The last two numbers will help you to determine which line of a claim form is being referenced:

EXAMPLE: 1365023456700 - refers to first claim line

 $13650234567\underline{01}$ - refers to second claim line $13650234567\underline{02}$ - refers to third claim line

For those claim types which are not processed by line (inpatient hospital, screening, and pharmacy), the Control Number for the claim will always end in 00. All multiple-line claim forms with just one service billed on line 0 will also end in 00.

The unique 13-digit Control Number can be used to determine the status of claims from receipt to final adjudication.

THE REMITTANCE ADVICE

REMITTANCE ADVICE COPY REQUESTS

A fee of \$0.25 per page, which includes postage, is charged to any provider who requests an additional copy of a Remittance Advice of one or more pages. RAs can be requested for any of the reasons listed below:

- The RA was lost, destroyed, or misplaced (by the provider or by Paramax).
- The provider needs an additional copy of the RA.
- The provider is requesting an advance copy pending receipt of the original from a central billing office.

Upon receipt of a written request, the provider will be notified of the number of pages to be copied and of the cost for the entire request. The Remittance Advice will be forwarded to the provider once payment has been received.

ADJUSTING/VOIDING CLAIMS

ADJUSTING/VOIDING CLAIMS

Provided in this section are general reminders and specific billing instructions for adjusting or voiding a HCFA-1500 claim form.

GENERAL REMINDERS

To adjust or void a HCFA-1500 claim form, the provider must use a 213 Adjustment/Void Form.

Only a paid claim can be adjusted or voided. If a paid claim is being adjusted, the Provider Identification Number and the Recipient/Patient Identification Number cannot be changed.

For those claims where multiple services are billed, the Adjustment/Void Form allows the adjustment or voiding of only one line. A separate Adjustment/Void Form is required for each claim line if more than one claim line on a multiple line claim form needs to be adjusted or voided.

The provider should complete the information on the adjustment form exactly as it appeared on the original claim, changing only the item that was in error and noting the reason for the change in the space provided on the claim.

If a paid claim is being voided, the provider must enter all the information from the original claim exactly as it appeared on the original claim. After a voided claim has appeared on the Remittance Advice, a corrected claim may be resubmitted (if applicable).

When an Adjustment/Void Form has been processed, it will appear on the Remittance Advice under Adjustment or Voided Claim. The adjustment or void will appear first. The original claim line will appear in the section directly beneath the adjustment/void section.

An Adjustment/Void will generate Credit and Debit Adjustments which will appear in the Remittance Summary on the last page of the Remittance Advice.

A facsimile of 213 Adjustment\Void Form is provided on the following page.

MAIL TO: JNISYS O. BOX 91022 BATON ROUGE, LA 70821 800) 473-2783 24-5040 (IN BATON ROUGE)

STATE OF LOUISIANA DEPARTMENT OF HEALTH AND HOSPITALS

BUREAU OF HEALTH SERVICE FINANCING MEDICAL ASSISTANCE PROGRAM PROVIDER BILLING FOR HEALTH INSURANCE CLAIM FORM

								L				
VOID								FO	R OFFICE L	JSE ONLY		
1 1 1												
PATIENT AND INSURED (SI	UBSCRIBER) INFO	RMATION		<u> </u>								
PATIENT'S NAME (LAST NAME				S PATIEN	LS DATE OF	BIRTH		4 MEDIC	AID ID NUMB	ER		
■ PATIENT'S ADDRESS (STREET, CITY, STATE, ZIP CODE)				6 PATIENT'S SEX			INSURED'S NAME					
				MA	1		AALE					
				PATIENT:	S RELATIONSHI F SPOUSE		HER	INSURE	D'S GROUP	NO. (OR GRO	DUP NAME)
TELEPHONE NO.	E FATTER NAME OF BOLIO	AND DED AND		MI WAS CONDITION RELATED TO: INSURED'S ADDRESS (STREET, CITY, STATE, ZIP CODE)					- 710 CODE)			
OTHER HEALTH INSURANCE COVERAGE PLAN NAME AND ADDRESS AND POLICY	OR MEDICAL ASSISTANCE	NUMBER.		MAS CC		LATED TO: S EMPLOYMEN	т .	EKS INSURE	D'S ADDRES	5 (5 i HEE i, (JIIY, SIAII	E, ZIP CODE)
					YES	NC						
					B. AN AUTO	ACCIDENT)					
PHYSICIAN OR SUPPLIER	INFORMATION			1				 				
ATE OF	ILLNESS (FIRST SY	MPTOM) OF	l	14 DATE FIRST CONSULTED YOU FOR			15 HAS PA	TIENT EVER	HAD SAME C	R SIMILAR	SYMPTOMS?	
•	INJURY (ACCIDENT PREGNANCY (LMP)	OR		IHISC	ONDITION			YES		NO	1	
ATE PATIENT ABLE TO ETURN TO WORK	DATES OF TOTA	L DISABILIT	Υ		.,			DATES OF	PARTIAL DI	SABILITY		
	FROM			THROUG	ЗН			FROM			THROL	
NAME OF REFERRING PHYSICI	AN OR OTHER SOUR	CE IBA REF	ERRING ID	NUMBER				19 FOR SERV	ICES RELATED	TO HOSPITALI	ALIZATION GIVE HOSPITALIZATION DATES	
MIS AUD LEBERGE	OT / University		FD //F ==	CO TURE	WE 00 555			ADMITTED			DISCHARGED	
AME AND ADDRESS OF FACIL	LITY WHERE SERVICE	ES RENDER	ED (IF OTF	IER THAN HO	R THAN HOME OR OFFICE)				BORATORY			JTSIDE OF OFFICE?
DIAGNOSIS OR NATURE OF ILLN	IESS RELATE DIAGNO	SIS TO PRO	CEDURE IN	COLUMN D B	Y REFERENC	F TO NUMBERS	123 08	YES DX CODE	28 ATTEND	NO NUMBER		ARGES
			020071111111				.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	V	-			
								• .				
									PRIOR	IZATION NO.		
· · · DATE(S) OF SERV	ICE	B. PLACE	C.		· · · · · · · · · · · · · · · · · · ·		7	Γ	AOTHOR	E E	П	
From	То	OF SERVICE		55	OCEDURE		DIAG	D GNOSIS	E CHARGES	DAYS	EPSDT	
M DD YY MM		<u> </u>		, , ,	- I		1 0	ODE	CHARGES	UNITS	PLAN	TPL \$
	1 1					,			į			
			-	***************************************				5000				
CONTROL NUMBER						A PAID ITEM. (T. SHOWN ON T		DATE	OF REMITTA	NCE ADVICE	THAT LIST	TED CLAIM WAS PAID
				ADVICE IS A								
REASONS FOR ADJUSTMEN	T'											
									771 Î.	and the second		
01 THIRD PARTY LIAB								. er er i i i	1 1 1			
02 PROVIDER CORRE 03 FISCAL AGENT ERF									<u> </u>	<u> </u>		
90 STATE OFFICE USE												
99 OTHER - PLEASE E					1 1	11.0						MANUFACTURE OF THE PARTY OF THE
			· · · · · ·		1					·		
REASONS FOR VOID						1						
# * * *												
10 CLAIM PAID FOR W	RONG RECIPIENT			'		Y20.70						
11 CLAIM PAID TO WR		- · *										
99 OTHER - PLEASE E												
			******							To day		
TURE OF PHYSICIAN OR	SUPPLIER		M		SII PH	SICIAN'S OR S	UPPLIER	'S NAME. AL	DRESS, ZIP	CODE, AND	TELEPHON	VE.
TO THIS BILL AND ARE M	NTS ON THE REVERS NADE A PART HEREOR	F.)		*								
OUR PATIENT'S ACCOUNT NU	IMBER											

ADJUSTING/VOIDING CLAIMS

Void: Enter the information exactly

as it appears on the original

invoice.

SPECIFIC INSTRUCTIONS FOR COMPLETION OF THE 213

The instructions provided should be followed carefully for accurate and prompt processing of adjusted or voided claims:

*BLOCK 1	ADJ/VOID	Check the appropriate box.
*BLOCK 2	PATIENT'S NAME	Adjust: Enter the name exactly as it appears on the original invoice.
		Void: Enter the name exactly as it appears on the original invoice.
BLOCK 3	PATIENT'S DATE OF BIRTH	Adjust: Enter the date exactly as it appears on the original invoice.
		Void: Enter the date exactly as it appears on the original invoice.
BLOCK 4	INSURED'S NAME	Adjust: Enter the name exactly as it appears on the original invoice.
		Void: Enter the name exactly as it appears on the original invoice.
BLOCK 5	PATIENT'S ADDRESS AND TELEPHONE NUMBER	Adjust: Enter the address and telephone number exactly as they appear on the original invoice.

ADJUSTING/VOIDING CLAIMS

BLOCK 6 PATIENT'S SEX

Adjust: Enter the patient's sex exactly as it appears on the original invoice.

Void: Enter this information exactly as it appears on the original invoice.

*BLOCK 7 INSURED'S ID, MEDICAID NUMBER

Adjust: The ID number cannot be changed. If the number was entered incorrectly on the original claim form, the claim form must be voided.

Void: Enter the number exactly as it appears on the original invoice.

BLOCK 8 PATIENT'S

RELATIONSHIP TO INSURED

Leave this space blank.

BLOCK 9 INSURED'S GROUP NUMBER

Leave this space blank.

BLOCK 10 OTHER HEALTH INSURANCE COVERAGE

Adjust: If this information is not being adjusted, enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

ADJUSTING/VOIDING CLAIMS

BLOCK 11 WAS CONDITION RELATED TO:

Adjust: Enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

BLOCK 12 INSURED'S ADDRESS

Adjust: Enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

BLOCK 13 DATE OF ILLNESS:

Adjust: Enter the date exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

BLOCK 14 DATE FIRST CONSULTED YOU FOR THIS CONDITION

Adjust: Enter the date exactly as it appears on the original invoice.

Void: Enter the date exactly as it appears on the original invoice.

BLOCK 15 HAS PATIENT EVER HAD SAME OR SIMILAR SYMPTOMS?

Adjust: Enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

ADJUSTING/VOIDING CLAIMS

BLOCK 16 DATE PATIENT ABLE TO WORK

Adjust: Enter the date exactly as it appears on the original invoice.

Void: Enter the date exactly as it appears on the original invoice.

BLOCK 17 DATE OF TOTAL DISABILITY/ DATE OF PARTIAL DISABILITY

Adjust: Enter the dates exactly as they appear on the original invoice.

Void: Enter the dates exactly as they appear on the original invoice.

BLOCK 18 NAME OF REFERRING PHYSICIAN OR OTHER SOURCE

Adjust: Enter the name exactly as it appears on the original invoice.

Void: Enter the name exactly as it appears on the original invoice.

BLOCK 19 FOR SERVICES RELATED TO HOSPITALIZATION GIVE HOSPITALIZATION DATES

Adjust: Enter the dates exactly as they appear on the original invoice.

Void: Enter the dates exactly as they appear on the original invoice.

BLOCK 20 NAME AND ADDRESS OF FACILITY WHERE SERVICES WERE RENDERED (IF OTHER THAN HOME OR OFFICE)

Adjust: Enter the name and address as exactly they appear on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

ADJUSTING/VOIDING CLAIMS

BLOCK 21 WAS LABORATORY WORK PERFORMED OUTSIDE YOUR OFFICE?

Adjust: Enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

*BLOCK 22 DIAGNOSIS/NATURE OF ILLNESS

Adjust: Enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

BLOCK 23 EPSDT REFERRAL

Adjust: Enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

*BLOCK 24 ATTENDING PHYSICIAN

Adjust: Enter the information exactly as it appears on the original claim form.

Void: Enter the information exactly as it appears on the original invoice.

NOTE: When you enter a group number in Block 31, you must enter the individual provider number in this block.

ADJUSTING/VOIDING CLAIMS

*BLOCK 25 A THROUGH F

Adjust: If you are not adjusting the information, enter the information exactly as it appears on the original invoice.

Void: Enter the information exactly as it appears on the original invoice.

*BLOCK 26 DATE OF REMITTANCE ADVICE THAT LISTED CLAIM WAS APPROVED

Enter the correct Control Number shown on the Remittance Advice.

*BLOCK 27 DATE OF REMITTANCE ADVICE THAT LISTED CLAIM WAS PAID

Enter the date of the Remittance Advice.

*BLOCK 28 REASONS FOR ADJUSTMENT

Check the appropriate box and write a brief narrative to describe why this adjustment is necessary.

*BLOCK 29 REASONS FOR VOID

Check the appropriate box and write a brief narrative to describe why this void is necessary.

*BLOCK 30 SIGNATURE OF PHYSICIAN OR SUPPLIER

You must sign the form.

*BLOCK 31 PHYSICIAN OR SUPPLIER'S NAME, ADDRESS, ZIP CODE AND TELEPHONE NO.

Enter the requested information. Enter the provider number. If you are billing for a group, enter the group number in this block and the individual provider number in Block 24.

ADJUSTING/VOIDING CLAIMS

BLOCK 32 YOUR PATIENT'S ACCOUNT NO.

If you enter the patient's account (medical record) number, it will appear on the Remittance Advice. The number may consist of letters or numbers, but it should have no more than 13 positions.

* Providers must complete these marked items.

			•

FRAUD AND ABUSE

FRAUD AND ABUSE

To maintain the integrity of Medicaid of Louisiana, providers must understand and follow Medicaid of Louisiana's policy concerning fraud and abuse. This section of the manual defines the different types of fraud and abuse, and it sets forth specific sanctions for providers who commit fraud and who abuse Medicaid.

GENERAL

Federal regulations require that Medicaid of Louisiana establish criteria that are consistent with principles recognized as affording due process of law for identifying situations where there may be fraud or abuse, for arranging prompt referral to authorities, and for developing methods of investigation or review that ascertain the facts without infringing on the legal rights of the individuals involved.

FRAUD

Fraud, in all aspects, is a matter of law rather than of ethics or abuse of privilege. The definition of fraud that governs between citizens and government agencies is found in Louisiana R.S. 14:67 and Louisiana R.S. 14:70.01. Legal action may also be mandated under Section 1909 of the Social Security Act as amended by Public Law 95-142 (HR-3).

Prosecution for fraud and the imposition of a penalty, if the individual is found guilty, are prescribed by law and are the responsibility of the law enforcement officials and the courts. All such legal action is subject to due process of law and to the protection of the rights of the individual under the law.

FRAUD AND ABUSE

Provider Fraud

Cases involving one or more of the following situations shall constitute sufficient grounds for a provider fraud referral:

- Billing for services, supplies, or equipment which are not rendered to, or used for, Medicaid patients;
- Billing for supplies or equipment which are clearly unsuitable for the patient's needs or are so lacking in quality or sufficiency for the purpose as to be virtually worthless;
- Claiming costs for non-covered or non-chargeable services, supplies, or equipment disguised as covered items;
- Materially misrepresenting dates and descriptions of services rendered, the identity of the individual who rendered the services, or of the recipient of the services;
- Duplicate billing of the Medicaid Program or of the recipient, which appears to be a deliberate attempt to obtain additional reimbursement; and
- Arrangements by providers with employees, independent contractors, suppliers, and others, and various devices such as commissions and fee splitting, which appear to be designed primarily to obtain or conceal illegal payments or additional reimbursement from the Medicaid.

FRAUD AND ABUSE

Recipient Fraud

Cases involving one or more of the following situations constitute sufficient grounds for a recipient fraud referral:

- The misrepresentation of facts in order to become or to remain eligible to receive benefits under Medicaid of Louisiana or the misrepresentation of facts in order to obtain greater benefits once eligibility has been determined;
- The transferring (by a recipient) of a Medicaid Eligibility Card to a person not eligible to receive services under Medicaid of Louisiana or to a person whose benefits have been restricted or exhausted, thus enabling such a person to receive unauthorized medical benefits; and
- The unauthorized use of a Medical Eligibility Card by persons not eligible to receive medical benefits under Medicaid.

FRAUD AND ABUSE

ABUSE

Abuse of Medicaid of Louisiana by either providers or recipients includes practices which are not criminal acts and which may even be technically legal, but which still represent the inappropriate use of public funds.

Provider Abuse

Cases involving one or more of the situations listed below constitute sufficient grounds for a provider abuse referral:

- The provision of services that are not medically necessary;
- Flagrant and persistent overuse of medical or paramedical services with little or no regard for the patient's medical condition or needs or for the doctor's orders;
- The unintentional misrepresentation of dates and descriptions of services rendered, of the identity of the recipient of the services, or of the individual who rendered the services in order to gain a larger reimbursement than is entitled; and
- The solicitation or subsidization of anyone by paying or presenting any person money or anything of value for the purpose of securing patients (Providers, however, may use lawful advertising that abides by BHSF rules and regulations.).

Recipient Abuse

Cases involving one or more of the following situations constitute sufficient grounds for a recipient abuse referral:

- Unnecessary or excessive use of the prescription medication benefits of Medicaid of Louisiana;
- Unnecessary or excessive use of the physician benefits of the program; and
- Unnecessary or excessive use of other medical services and/or medical supplies that are benefits of the program.

FRAUD AND ABUSE

FRAUD AND ABUSE DETECTION

Provided in this subsection is the fraud and abuse detection process. The first step of the process is a referral of suspect claims to a review board.

Referrals

Situations involving potential fraud and/or abuse which are to be followed up for review by Medicaid of Louisiana may include any or all of the following:

- Cases referred by the U.S. Department of Health and Human Services [Medicaid of Louisiana in turn refers suspected cases of fraud in the Medicare Program to the Health Care Financing Administration (HCFA) and works closely with that agency in such matters.];
- Situations brought to light by special review, internal controls, or provider audits or inspections; and/or
- Referrals from other agencies or sources of information.

Recipient Verification Notices (REOMBs)

The federal regulations (Public Law 92-693, Sec 253 3) for MMIS require that Medicaid of Louisiana provides prompt written notice of medical services which are covered to the recipients of these services. The information contained in the notice includes the name of the person(s) furnishing medical services, the date on which the services were furnished, and the amount of payment required for the services. A predetermined percentage of the recipients who have had medical services paid on their behalf during the previous month will receive the required notice, that is, the Recipient's Explanation of Medical Benefits (REOMB). From time to time, Medicaid of Louisiana may send notices to 100% of the recipients receiving services from any provider for any given period.

FRAUD AND ABUSE

The REOMB contains the following information:

- The recipient's Medicaid identification number,
- The recipient's name,
- The date of the REOMB (monthly, on the 15th),
- The date of the service for the services provided,
- A narrative description of the services provided,
- The place of service for the services provided
- The provider of the services, and
- The amount paid for the services by Medicaid of Louisiana.

On the reverse side of the REOMB, preprinted instructions request the recipients to use the space provided to call attention to any mistakes they feel were made on their bill. For example, if a service is listed on the REOMB that was not received by a recipient, or if the recipient were made to pay for a service that is covered by Medicaid of Louisiana, that recipient is expected to write a brief explanation of the error. The recipient should include his phone number, and he should return the REOMB, postage paid, to Paramax. Paramax will then research the claim copy and provider remittance documents to make sure that the recipient, provider, and services on the returned REOMB are accurately presented. If the information on the returned REOMB is not accurate, then the REOMB and all documentation will be reviewed by the Paramax Surveillance Utilization Review System (SURS) Unit.

All situations that require further inquiry are reviewed by SURS. Situations that require criminal investigation are referred to the State Attorney's General's Medicaid Fraud Control Unit.

FRAUD AND ABUSE

Computer Profiling

Paramax can identify potential fraud and abuse situations by means of **profile reports**. A profile report is produced by a computer from information gathered in the state's claims payment operation. Providers are classified into peer groups according to geographic location, medical specialties, and other categories.

Profile reports include the following information:

- A statistical profile of each peer group classification to be used as a base line for evaluation:
- A statistical profile of each individual participant compatible with the peer group profile;
- An evaluation of each individual participant profile against its appropriate group profile; and
- A listing of individual participants who deviate significantly from their group norm (These individuals are reported as exceptional and are flagged for analysis.).

Each profile reported as exceptional is reviewed and analyzed by a trained staff and by medical consultants. The analysis can include a review of the provider's paid claims, a review of the provider's reply to Medicaid of Louisiana's written request for information, a review of hospital charges and patient records, and a review of other relevant documents. The overall review is not necessarily limited to areas identified as exceptional on the profile report.

,	

FRAUD AND ABUSE

ADMINISTRATIVE SANCTIONS

To ensure the quality, quantity, and need for services, Medicaid payments may be reviewed by Medicaid of Louisiana. Administrative sanctions may be imposed against any Medicaid provider who does not meet the guidelines listed in the following subsection. Administrative sanctions refer to any administrative actions taken by the single state agency against a medical service provider of Title XIX services. Any such administrative action is designed to remedy inefficient and/or illegal practices which are not in compliance with Medicaid of Louisiana policies and procedures, statutes, and regulations.

Levels of Administrative Sanctions

Listed below are the different levels of administrative sanctions that Medicaid of Louisiana may impose against a Medicaid provider:

- Issuing a warning to a provider through written notice or consultation;
- Requiring that the provider receive education in policies and billing procedures;
- Requiring that the provider receive prior authorization for services;
- Placing the provider's claims on manual review status before payment is made;
 - NOTE: Any provider of Medicaid services may be placed on prepayment review as an administrative sanction of misuse of Medicaid of Louisiana. Prepayment review may be limited to those types of procedures for which misuse has been detected, or it may include a complete review of all of the provider's claims.
- Suspending the provider or withholding payments from the provider;
 - NOTE: Medicaid of Louisiana may suspend or withhold payment to any provider who fails to meet the requirements for participation in Medicaid of Louisiana.



- Recovering money from the provider by deducting from future payments or by requiring direct payment for money improperly or erroneously paid;
- Referring a provider to the appropriate state licensing authority for investigation;
- Referring a provider for review by the appropriate professional organizations;
- Referring a provider to the Attorney General's Medicaid Fraud Control Unit for fraud investigation;
- Suspending a provider from participating in Medicaid of Louisiana; and
- Refusing to allow a provider to participate in Medicaid of Louisiana.

	,		

FRAUD AND ABUSE

Grounds for Sanctioning Providers

Medicaid of Louisiana may impose sanctions against any provider of medical goods or services if it discovers that any of the following conditions apply:

- A provider is not complying with Medicaid of Louisiana's policy, rules, and regulations or with the terms and conditions prescribed by Medicaid of Louisiana in its provider agreement and signed claim that set the terms and conditions applicable to each provider group's participation in the program.
- A provider has submitted a false or fraudulent application for provider status.
- Such a provider is not properly licensed or qualified, or such a provider's professional license, certificate, or other authorization has not been renewed or has been revoked, suspended, or otherwise terminated.
- Such a provider has engaged in a course or conduct; has performed an act for which official sanction has been applied by the licensing authority, professional peer group, or peer review board or organization; or has continued the poor conduct after having received notification by a licensing or reviewing, indication that his conduct should cease.
- Such a provider has failed to correct deficiencies in his delivery of services or his billing practices after having received written notice of these deficiencies from Medicaid of Louisiana.
- Such a provider has been excluded from participation in Medicare because of fraudulent of abusive practices pursuant to Public Law 95-142, or such a provider has been convicted of Medicaid fraud (Louisiana R.S. 14:70.1).
- Such a provider has been convicted of a criminal offense relating to performance of a provider agreement with the state, to fraudulent billing practices, or to negligent practice, resulting in death or injury to the provider's patient.
- Such a provider has presented false or fraudulent claims for services or merchandise for the purpose of obtaining greater compensation than that to which the provider is legally entitled.

- Such a provider has engaged in a practice of charging and accepting payment (in whole or in part) from recipients for services for which a charge was already made to Medicaid of Louisiana and for which payment was already made.
- Such a provider has rebated or accepted a fee or a portion of a fee for a patient referral.
- Such a provider has failed to repay or make arrangements to repay an identified overpayment or otherwise erroneous payment.
- Such a provider has failed, after having received a written request from Medicaid of Louisiana, to keep or to make available for inspection, audit, or copying, records regarding payments claimed for providing services.
- Such a provider has failed to furnish any information requested by Medicaid of Louisiana regarding payments for providing goods and services.
- Such a provider has made, or caused to be made, a false statement or a misrepresentation of a material fact in connection with the administration of Medicaid of Louisiana.
- Such a provider has furnished goods or services to a recipient which are in excess of the recipient's needs, harmful to the recipient, or of grossly inadequate or inferior quality (This determination would be based upon competent medical judgement and evaluation.).
- The provider, a person with management responsibility for a provider, an officer or person owning (either directly or indirectly) 5% or more of the shares of stock or other evidences of ownership in a corporate provider, an owner of a sole proprietorship which is a provider, or a partner in a partnership which is a provider is found to fall into one or more of the following categories:
 - Was previously barred from participation in Medicaid of Louisiana;

- Was a person with management responsibility for a previously terminated provider during the time of conduct which was the basis for that provider's termination from participation in Medicaid of Louisiana;
- Was an officer or person owning (directly or indirectly) 5% or more of the shares of stock or other evidences of ownership in a previously terminated corporate provider during the time of conduct which was the basis for that provider's termination from participation in Medicaid of Louisiana;
- Was an owner of a sole proprietorship or a partner of a partnership which was previously terminated during the time of conduct which was the basis for that provider's termination from participation in the program;
- Was engaged in practices prohibited by federal or state law or regulation;
- Was a person with management responsibility for a provider at the time that such a provider engaged in practices prohibited by state or federal law or regulation;
- Was an officer or person owning (directly or indirectly) 5% or more of the shares of stock or other evidences of ownership in a provider at the time such a provider engaged in practices prohibited by federal or state law or regulation;
- Was an owner or a sole proprietorship or partner or a partnership which was a provider at the time such a provider engaged in practices prohibited by federal or state law or regulation;
- Was convicted of Medicaid fraud under federal or state law or regulation;

- Was a person with management responsibility for a provider at the time that such a provider was convicted of Medicaid fraud under federal or state law or regulation;
- Was an officer or person owning (directly or indirectly) 5% or more of the shares of stock or other evidences of ownership in a provider at the time such a provider was convicted of Medicaid fraud under federal or state law or regulation; or
- Was an owner or a sole proprietorship or partner or a partnership which was a provider at the time such a provider was convicted of Medicaid fraud under federal or state law or regulation;

,		

FRAUD AND ABUSE

APPEALS

The Louisiana Department of Health and Hospitals (DHH) provides a hearing to any provider who feels that he has been unfairly sanctioned. Specifically, the Bureau of Appeals in the Department of Health and Hospitals is responsible for conducting hearings for providers who have complaints. Requests for hearings explaining the reason for the request should be made in writing and sent directly to the Bureau of Appeals.

Detailed information regarding the appeals procedure may be obtained form the Bureau of Appeals at the following address:

DHH Bureau of Appeals P.O. Box 4183 Baton Rouge, LA. 70821-4182

,	

ORDERING INFORMATION

ORDERING INFORMATION

CPT-4 AND ICD-9-CM CODE BOOK ORDER INFORMATION

The CPT-4 Procedure Code Book may be ordered from the following address:

American Medical Association OP 341/7 P.O. Box 10946 Chicago, IL. 60610

ICD-9-CM Code Books are to be used to obtain diagnosis codes. Volume 1 is a numeric listing of diagnosis codes, and Volume 2 is an alphabetical listing (Volume 3 is a listing of ICD-9-CM procedure codes that are used by hospitals only.). These books may be obtained from the following address:

ICD-9-CM P.O. Box 971 Ann Arbor, MI. 48106

Current prices for CPT and ICD-9-CM books may be obtained by phoning the publisher's office. Providers may obtain that number by calling Operator Assistance in the appropriate city. Also, Home Medical School bookstores stock these books.

RETURN/REFUND CHECKS

MEDICAL SERVICES MANUAL

RETURN/REFUND CHECKS

RETURN CHECKS

All return checks should be mailed to the following address:

Division of Fiscal Management Financial Management Section P.O. Box 91117 Baton Rouge, LA. 70821-9117

REFUND CHECKS

When errors in billing occur, e.g., duplicate payments, instead of simply refunding payments, providers should initiate claim adjustments or voids. However, should providers find it necessary to refund a payment, they should make checks payable to the Department of Health and Hospitals, Bureau of Health Services Financing, and mail the refunds to the following address:

Division of Fiscal Management Financial Management Section P.O. Box 91117 Baton Rouge, LA. 70821-9117

To reconcile an account with the Treasury Department, providers must attach a copy of the Remittance Advice to their return or refund. In addition, they must explain the reason for the return or refund.

To determine the amount of a refund, providers should consider the following rules:

- Whenever a duplicate payment is made, the full amount of the second payment must be refunded.
- If another insurance company pays after Medicaid has made its payment and the TPL is greater than the Medicaid payment, the full amount of the Medicaid payment should be refunded.

CHECKS SHOULD NOT BE MADE PAYABLE TO PARAMAX.

PARAMAX PROVIDER RELATIONS

PARAMAX PROVIDER RELATIONS

Paramax has a Provider Relations staff ready to assist providers with any questions they may have. There are individuals in the Baton Rouge office whose primary responsibility is to respond to telephone inquiries. These individuals can be reached at the following telephone numbers:

Baton Rouge Providers

(504) 924-5040

Providers Outside of Baton Rouge (Louisiana Providers only)

1-800-473-2783

Telephone service is available Monday through Friday from 8:00 A.M. to 5:00 P.M.

In addition, providers can mail written inquiries to the following address:

Attention: Provider Relations
Paramax
P.O. Box 91024
Baton Rouge, LA. 70821

Provider Relations also has a staff of Field Analysts who are available to help providers with billing problems and to help train new provider staff members. To request a visit with a Field Analyst, providers can call or write to Provider Relations.

NOTE: Written inquiries should contain a note or a letter explaining the nature of the problem. Inquiries submitted without explanations could be processed without additional consideration.

In addition, providers who are calling Paramax, Provider Relations, should telephone the Provider Relations directly; they should not call the main Paramax switchboard.

PARAMAX PROVIDER RELATIONS

RECIPIENT ELIGIBILITY VERIFICATION SYSTEM

The Provider Relations inquiry staff strives to respond to provider inquiries quickly and efficiently. Some provider inquiries, however, require lengthy policy discussions or file research, so providers who want to make a simple inquiry are having to hold until an operator becomes available.

However, there is a simple solution.

Providers who wish to ask the following questions may use our Recipient Eligibility Verification System (REVS) telephone service:

- Is a particular recipient eligible for services on a specific date of service?
- What are the service limits for a particular recipient?
- What other payment source does a particular recipient have?
- What is my current check amount?

The system is operational 24 hours a day, 7 days a week, except for a short period on Sunday when the system is being updated.

To access the system, you just have to dial (800) 776-6323 on a touch-tone telephone and have your provider identification number, the appropriate recipient identification number, and date of service ready. Once you are connected to the system, you will receive procedural instructions via voice response prompt messages. If you are familiar with the procedures for entering information, you need not wait for the prompt messages. Just begin entering the required information as soon as you have accessed the system.

We understand that there may be times when you need to speak to one of our inquiry representatives. When you have questions concerning printed policy, claims processing problems, or when you need to determine the status of a particular claim, we encourage you to call Provider Relations. To expedite your inquiry, please have all of the necessary information available when you call.

When you do not have time to speak to one of our representatives, use REVS. It's quick and easy.

MANUAL UPDATES


It is very important to read all the following documentation, as it contains information in addition to that found in the Substance Abuse and Mental Health Services Manual issued March 1, 1993.

Please note that the following pages were issued after the printing of the manual.

The information in the 1998 Professional Services Provider Training packet, Medicaid Issues for 1998, was published in September, 1998.



STATE OF LOUISIANA DEPARTMENT OF HEALTH AND HOSPITALS



May 20, 1998

To: All Medicaid Enrolled Providers

From: Thomas D. Collins

Re: Statutorily Mandated Revisions to all Provider Agreements

The 1997 Regular Session of the Legislature passed and the Governor signed into law the Medical Assistance Program Integrity Law (MAPIL) cited as LSA-RS 46:437.1-46:440.3. This legislation has a significant impact on all Medicaid providers. All providers should take the time to become familiar with the provisions of this law.

MAPIL contains a number of provisions related to provider agreements. Those provisions which deal specifically with provider agreements and the enrollment process are contained in LSA-RS 46:437.11-46:437.14. The provider agreement provisions of MAPIL statutorily establishes that the provider agreement is a contract between the Department and the provider and that the provider voluntarily entered into that contract. Among the terms and conditions imposed on the provider by this law are the following:

- (1) comply with all federal and state laws and regulations;
- (2) provide goods, services and supplies which are medically necessary in the scope and quality fitting the appropriate standard of care;
- (3) have all necessary and required licenses or certificates;
- (4) maintain and retain all records:
- (5) allow for inspection of all records by governmental authorities;
- (6) safeguard against disclosure of information in patient medical records;
- (7) bill other insurers and third parties prior to billing Medicaid;
- (8) report and refund any and all overpayments;
- (9) accept payment in full for Medicaid recipients providing allowances for copay authorized by Medicaid;
- (10) agree to be subject to claims review;
- (11) the buyer and seller of a provider are liable for any administrative sanctions or civil judgements;
- (12) notification prior to any change in ownership;
- (13) inspection of facilities; and,
- (14) posting of bond or letter of credit when required.

MAPIL's provider agreement provisions contain additional terms and conditions. The above is merely a brief outline of some of the terms and conditions and is not all inclusive.

The provider agreement provisions of MAPIL also provide the Secretary with the authority to deny enrollment or revoke enrollment under specific conditions.

The effective date of these provisions was August 15, 1997. All providers who were enrolled at that time or who enroll on or after that date are subject to these provisions. All provider agreements which were in effect before August 15, 1997 or became effective on or after August 15, 1997 are subject to the provisions of MAPIL and all provider agreements are deemed to be amended effective August 15, 1997 to contain the terms and conditions established in MAPIL.

Any provider who does not wish to be subjected to the terms, conditions and requirements of MAPIL must notify provider enrollment in writing within ten (10) working days of the date of this letter that the provider is withdrawing from the Medicaid program. If no such written notice is received, the provider may continue as an enrolled provider subject to the provisions of MAPIL.

			•
	,		



STATE OF LOUISIANA DEPARTMENT OF HEALTH AND HOSPITALS



August 18, 1998

MEMORANDUM

TO:

All Enrolled Medicaid Providers

FROM:

Thomas D. Collins, Director of Bureau of Health Services Finance

RE:

Office for Civil Rights Policy Memorandum

The Department of Health and Human Services, Office for Civil Rights, recently issued a policy memorandum regarding nondiscrimination based on national origin as it relates to individuals who are limited-English proficient. Enclosed is the Health Care Financing Administration (HCFA) Civil Rights Compliance Statement which expresses our Agency's commitment to ensuring that there is no discrimination in the delivery of health care services through HCFA programs.

We have committed ourselves to full compliance with the requirements contained in this policy statement. As our partner with the administration of the Medicaid program you likewise are obligated to comply with those statutory civil rights laws. As stipulated in the policy statement, these laws include: Act of 1990 as amended and Title IX of the Education Amendments of 1972. The Office of Civil Rights of the Department of Health and Human Services has previously advised HCFA that detailed implementation regulations for the Rehabilitation Act of 1973, as amended, are located at 45 Code of Federal Regulations, Part 85.

It has been asked that we share this policy statement with you and that you do likewise with health care providers and all others involved in the administration of HCFA programs.`

Questions regarding this memorandum should be directed to Don Fontenot at 342-1316.

HEALTH CARE FINANCING ADMINISTRATION (HCFA) CIVIL RIGHTS COMPLIANCE POLICY STATEMENT

The Health Care Financing Administration's vision in the current Strategic Plan guarantees that all our beneficiaries have equal access to the best health care. Pivotal to guaranteeing equal access is the integration of compliance with civil rights laws into the fabric of all HCFA program operations and activities. I want to emphasize my personal commitment to and responsibility for ensuring compliance with civil rights laws by recipients of HCFA funds. These laws include: Title VI of the Civil Rights Act, as amended; Section 504 of the Rehabilitation Act, as amended; the Age Discrimination Act of 1975, as amended; the Americans with Disabilities Act of 1990, as amended; and Title IX of the Education Amendments of 1972, as well as other related laws. The responsibility for ensuring compliance with these laws is shared by all HCFA operating components. Promoting attention to and ensuring HCFA program compliance with civil rights laws are among my highest priorities for HCFA, its employees, contractors, State agencies, health care providers, and all other partners directly involved in the administration of HCFA programs.

HCFA, as the agency legislatively charged with administering the Medicare, Medicaid and Children's Health Insurance Programs, is thereby charged with ensuring these programs do not engage in discriminatory actions on the basis of race, color, national origin, age, sex or disability. HCFA will, with your help continue to ensure that persons are not excluded from participation in or denied the benefits of its programs because of prohibited discrimination.

To achieve its civil rights goals, HCFA will continue to incorporate civil rights concerns into the culture of our agency and its programs, and we ask that all our partners do the same. We will include civil rights concerns in the regular program review and audit activities including: collecting data on access to, and the participation of, minority and disabled persons in our programs; furnishing information to recipients and contractors about civil rights compliance; reviewing HCFA publications, program regulations, and instructions to assure support for civil rights; and working closely with the Department of Health and Human Services (DHHS), Office of Civil Rights, to initiate orientation and training programs on civil rights. HCFA will also allocate financial resources to the extent feasible to: ensure equal access; prevent discrimination; and assist in the remedy of past acts adversely affecting persons on the basis of race, color, national origin, age, sex, or disability.

DHHS will seek voluntary compliance to resolve issues of discrimination whenever possible. If necessary, HCFA will refer matters to the Office for Civil Rights for appropriate handling. In order to enforce civil rights laws, the Office for Civil Rights may: 1) refer matters for an administrative hearing which could lead to suspending, terminating, or refusing to grant or continue Federal financial assistance; or 2) refer the matter to the Department of Justice for legal action.

HCFA's mission is to assure health care security for the diverse population that constitutes our nation's Medicare and Medicaid beneficiaries; i.e., our customers. We will enhance our communication with constituents, partners, and stakeholders. We will seek input from health care providers, states, contractors, and DHHS Office for Civil Rights, professional organizations, community advocates, and program beneficiaries. We will continue to vigorously assure that all Medicare and Medicaid beneficiaries have equal access to and receive the best health care possible regardless of race, color, national origin, age, sex, or disability.



STATE OF LOUISIANA DEPARTMENT OF HEALTH AND HOSPITALS



SECRETARY

November 8, 1999

MEMORANDUM

TO:

Substance Abuse Clinics

FROM:

Thomas D. Collins

Director

RE:

Medicaid Substance Abuse Services

In a recent meeting of representatives from the Attorney General's Medicaid Fraud Control Unit, the Unisys Surveillance and Utilization Review Unit, and three Bureau of Health Services Financing sections (Program Operations, Health Standards, and Program Integrity), several problem areas were identified in the Substance Abuse Program. This notice is a reminder of the policy that governs the coverage of substance abuse services under the Medicaid Program.

Please note that a recipient must have an assessment and a diagnosis of alcohol or substance abuse on file prior to services being rendered if Medicaid is to be billed. The licensing standards for substance abuse clinics allow twenty-one (21) days for the completion of an assessment. No billings can be made for services prior to the assessment. Only the ICD-9-CM diagnosis codes listed in the Medicaid provider manual are covered for reimbursement. These diagnoses are to be used only when there is a documented dependency to alcohol or a particular drug and the recipient is currently an active user who is unable to control his/her dependency. The diagnosis must be made in a face-to-face meeting with the recipient by one of the following licensed professionals: a physician, a psychologist, a board certified social worker, or a nurse practitioner. In addition, the recipient's clinical history must be consistent with the diagnosis in order for Medicaid reimbursement to be paid for services. Treatment for experimentation or casual drug or alcohol usage is not covered under the Medicaid Program and treatment for such usage shall not be billed to Medicaid as a covered service.



We have observed a significant increase in substance abuse services being provided to children under the age of twenty-one (21) primarily due to the fact that service limits are not applicable to children. Although it is our philosophy to provide services to eligible children, it is also our responsibility to ensure that the children meet the established criteria to receive these services. Children, like adults, must have an assessment and a diagnosis of alcohol or substance abuse prior to services being rendered. Medicaid reimbursement is not available for services provided to children who are at risk or high risk for dependency because of a family history of alcohol or substance abuse.

Recent surveys of clinic records indicate that services are being provided to children whose clinical histories do not support the Medicaid covered diagnoses for services. Inadequate documentation of clinical records was also noted during these surveys. Many clinical records only contained photocopies of a standard therapy session with a cover sheet to indicate the date of service. In fact, these therapy sessions appeared to be no more than "chat" sessions in which trivial information was discussed and documented. Such treatment and documentation is unacceptable. For services to be payable under the Medicaid Program, the sessions must consist of counseling for valid substance abuse problems and documentation must support this fact. In addition, the surveys revealed that the plans of care were redundant with little or no changes being made at update. It should be noted that all therapies must be consistent with the plan of care and be therapeutic in nature.

We want to remind you that insufficient clinical documentation to support the need for services or the therapeutic nature of therapy sessions may result in the recoupment of payments or more serious consequences such as a referral to the Attorney General's Medicaid Fraud Control Unit for further investigation.

In the coming weeks, the Bureau will be conducting on-site reviews of substance abuse clinics. The purpose of this monitoring is to evaluate the operations of the Medicaid Substance Abuse Program. Please note that only the Bureau of Health Services Financing is responsible for the interpretation of Medicaid policy regarding the coverage of services. If you have any questions regarding our policy or this notice, you may contact Mrs. Gail Williams at (225) 342-0127.

TDC/BEG/ji



STATE OF LOUISIANA DEPARTMENT OF HEALTH AND HOSPITALS



Frederick P. Cerise, M.D., M.P.H. SECRETARY

February 24, 2006

Dear Prescribing Practitioner:

RE: PDL # 06-01

Attached is the complete, most current listing of drugs on the Medicaid Prior Authorization (PA) Process' Preferred Drug List (PDL) "06-01." The listing includes preferred drugs and those drugs requiring prior authorization. This list will be effective April 1, 2006.

The PA process, in accordance with the program's "Continuity of Care" policy, does not impact original prescriptions (or refills) issued by a prescribing practitioner prior to effective PA dates of drugs as they are added to the PA process as long as they are within the 5 refills and 6-month program limits. An educational alert will notify the pharmacist that prescriptions (and their refills) will require a new prescription and prior authorization, if the prescription life exceeds six months or the refill exceeds the 5 refill limit. The educational alert will state, "NEW RX WILL REQUIRE PA AFTER (DATE)."

Information on the Prior Authorization process, including the PDL and Prior Authorization Request Form (copy is attached, Form RXPA01), is also available on the Louisiana Medicaid website (www.lamedicaid.com). This website will be updated when changes (additions or deletions) are made to the PDL. The program may also utilize the provider remittance advices to notify providers of PDL changes that must be implemented in short time frames.

The Department has received inquiries that drug products requiring PA are not reimbursable by Medicaid. Medicaid does reimburse for drug products requiring prior authorization when the prior authorization process is followed.

Thank you for your continued cooperation. We appreciate your participation in the Medicaid Program.

Sincerely,

Acting Medicaid Director

MJT/ht

Attachments (2)

Fax or Mail this form to: LA Medicaid Rx PA Operations ULM College of Pharmacy 1401 Royal Avenue Monroe, LA 71201 Fax: 866-RX PA FAX (866-797-2329)

State of Louisiana Department of Health and Hospitals

Bureau of Health Services Financing
Louisiana Medicaid Prescription Prior Authorization Program
REQUEST FOR PRESCRIPTION PRIOR AUTHORIZATION

Form RXPA01 Issue Date: 3/1/2002

Voice Phone: 866-730-4357

Please type or print legibly (fields followed with an asterisk * are required, all other fields are requested).

Date of Request:*	Number of Fax Pages:*
Practitioner Information	Patient Information
Name:*	Name (last, first):*
LA Medicaid Prescribing Provider Number:*	LA Medicaid CCN or Recipient Number.*
LA Medicaid Billing Provider Number:	Date of Birth (m/d/y):*
	1 1 1 1 1 1 1 1
Call-Back Phone Number (include area code):*	
Fax Number (include area code)*:	Projected Duration:*
Requested Drug Information	
Drug Name:*	Drug Strength:
Diagnosis Code (ICD-9-CM):	Diagnosis Description:*
1 1 1 1 1	
Please answer the following questions for your requent. Has the patient experienced treatment failure with the 2. Does the patient have a condition that prevents the use of YES, list the condition(s) in the box below:	
in TEG, list the condition(s) in the box below.	
3. Is there a potential drug interaction between another n If YES, list the interaction(s) in the box below:	nedication and the preferred product(s)? YES NC
4. Has the patient experienced intolerable side effects will If YES, list the side effects in the box below:	hile on the preferred product(s)?
Practitioner Signature:*	·
(If a signature stamp is used, the	n the prescribing practitioner must initial the signature)

CONFIDENTIALITY NOTICE

The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity to which it is addressed. If you are not the intended recipient, you are hereby notified that any review, disclosure/redisclosure, copying, distribution, or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy this information.

Page 1 of 12

	in
	Jeme
	anac
	ts M
	anefi
	y B
	rmag
i	ha

Hem Nur. Descriptive Therapeutic Class	Diugs de PD.	Druge which Require PA	Effective Date: April 1,:2006
Stimulants and Related Agents	Amphetamine Mixed Sait Amphetamine Mixed Sait (Adderall XR) Dexmethylphenidate (Focalin®) Dextroamphetamine Methylphenidate Methylphenidate Methylphenidate ER Methylphenidate ER Methylphenidate ER Methylphenidate ER (Concerta®, Metadate CD®) Methylphenidate LA (Ritalin LA®)	Atomoxetine (Strattera®) Methamphetamine (Desoxyn®) Modafini (Provigil®) Pemoline	
Antihistamines - Minimaliy Sedating	Cetirizine Syrup (Zyrtec® Syrup) - 12 years and under Loratadine Syrup OTC Loratadine OTC Loratadine-D OTC	Cetirizine (Zyrtec®) Cetirizine Chewable (Zyrtec® Chewable) Cetirizine Shup (Zyrtec® Syrup) - 13 years and older Cetirizine Syrup (Zyrtec® Syrup) - 13 years and older Cetirizine/Pseudoephedrine (Zyrtec-D®) Desloratadine (Clarinex®) Desloratadine Syrup (Clarinex Syrup®) Fexofenadine Fexofenadine Fexofenadine Fexofenadine	
Rhinitis Agents, Nasal	Flunisolide Spray Fulicasone (Flonase®) Ipratroplum (Atrovent®) Mometasone (Nasonex®) Triamcinolone AQ (Nasacort AQ®)	Azelastine (Astelin®) Beclomethasone AQ (Beconase AQ®) Budesonide Aqua (Rhinocort Aqua®) Fluntsolide Aqueous (Nasarel®)	
ALZHEIMER'S Alzheimer's Agents Cholinesterase Inhibitors	Donepezil (Aricept, Aricept ODT®) Galantamine (Razadyne®) Galantamine (Razadyne ER®) Rivastigmine (Exelon®) Memantine HCI (Namenda®)	Tacrine (Cognex®)	
Antipsychotic, Atypical Antipsychotic, Atypical	Clozapine Clozapine (Fazaclo®) Risperidone (Risperdal®) Quetlapine Fumarate+C336 (Seroquel®)	Aripiprazole (Ability®) Olanzapine/Fluoxetine (Symbyax®) Olanzapine (Zyprexa®) Ziprasidone (Geodon®)	

Page 2 of 12

5
5
5
č
C
5
4
-
4
č
ò
3
5
ř
5
5
4

ASTHMATOPD Bennitoditator, Beta-Adrenergic Albuerol Sulfate (Nebulizer and Inhaler) Albuerol Sulfate (Nebulizer and Inhaler) Albuerol Sulfate HFA MOI(Percentil HFA®) Albuerol Sulfate HFA MOI(Percentil HFA®) (Levalbuetor of Sulfate HFA MOI(Percentil HFA®) (Levalbuetor of Sulfate (Inhalaton Orly) Pribuerol Sulfate (Inhalaton Orly)	INHALATION bulizer and Inhaler) Albulerol Sulfate Nebulizer Solution (Accuneb®) A MDI(Proventil HFA®) A MDI(Proventil HFA®) A MDI(Ventolin HFA®) Be (Inhalation Only) Maxair Autohaler®) GRAL Albuterol Sulfate ER (Vospire ER®) te (InhaLATION INHALATION Arovent HFA®) Albuterol Sulfate ER (Vospire ER®) (QVAR\®) (QVAR\®) (QVAR\®) (QVAR\®) (QVAR\®) (QVAR\®) Budesonide DP! (Pulmicort Turbuhaler®) Budesonide Respules®)	
ilon	ŢŢŗŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢŢ	(9)
olinergics	▔ ▔▐▔▍▔▍▔▍▔▍▔▍▔▍▔▍▔▍▔▍▔▍▔	
iolinergics		
lion lion		
olinergies		
ilon		
tion		
ition		
tion		
Ilon		
Ilon		
ilon		
ition		
ition		
iton		
	T	
	Budesonide Respules (Pulmicort - Respules®)	Michaelisaja įraivarai irraikėja ir alto alto alto alto alto alto alto alto
	Control of the Contro	The state of the s
		manaka a ayaka kanina kaka aya a a a a a a a a a a a a a a a
	18 (150)	THE PROPERTY AND PROPERTY AND THE PROPERTY OF
	er (Asmanex	TO THE PARTY OF TH
		COLUMNIA AND AND AND AND AND AND AND AND AND AN
	MONE	
		en den Vermannen en
		THE REAL PROPERTY AND THE COMMENT OF THE PROPERTY OF THE PROPE
Nichazapine Mirtazapine Mirtazapine Soltab	Buproplon SR	
Mitazapine Soltab	Duloxetine (Cympaliaw)	
Nefazodone Transmissione monomente m		en det de manage per protes en 150 mar Antoneo Antoneo Antoneo Antoneo Antoneo Antoneo Antoneo Antoneo Antoneo Antoneo Antoneo
1 I GZOUNIA I I GZOUNIA I I GZOUNIA I I I GZOUNIA I I I I I I I I I I I I I I I I I I		meren beer en beneden beste bedeut en meren per menmer). De medent benede en men de de men de de men de men de
verigiazine (Effexor XR®)		
		en der vertrette der der der der der der der der der de
Selective Serotonin Citalopram	Fluoxetine ER (Prozac Weekly®)	
uptake inhibitors (SSRIs) Escitalopram (Lexapro®)	Fluoxetine (Sarafem®)	
Fluvoxamine		
Paroxetine HCI CR (Paxil CR®)		ладаў у Майдай ў Адайна аўдала аўдай паўдай падаў адай адай ададай адай адай адай ада
Paroxetine Mesylate (Pexeva®)	The particular terms of the conformation of th	

Prior Authorization PDL Implementation Schedule

Ciclopirox gel, shampoo (Loprox®) Ciclopirox gel, shampoo (Loprox®) Ciclopirox cream & tolon Nateonazole (Shampoo) (Rx only) Nystatin Non Metformin Metformin Metformin Metformin Crel Solution (Rlomet®) Rosiglitazone(Metformin (Avandamet®) Rosiglitazone(Metformin (Avandamet®)) RosiglitazoneMetformin (Avandamet®)	E	llem Descriptive Therapeutic Class	Druge on PDL	Dhys Which Require PA	Effective Date:
Antifungais - Topical Ciclopirox get, shampoo (Loprox®) Ciclopirox get, get, get, get, get, get, get, get,	-				
Ciciopirox ceam & foion Ciciop		Antifungals - Topical	Ciclopirox gel, shampoo (Loprox®)	Butenafine (Mentax®)	enderge ekonum jaar keena waxen aan daar daar hama endamen enderge ay disumbay ay disumbay of the sees of
Clotimazole Econazole Econazole Econazole Econazole Ketoconazole (Selambos) (Rx only) Ketoconazole (Selambos) (Rx only) Nysialin W Triamcinolone Sulconazole (Exedem) Nysialin W Triamcinolone Sulconazole (Exedem) Nysialin W Triamcinolone Sulconazole (Startice) Metornin Containing Metornin Containing Metornin Containing Metornin Containing Metornin Containing Metornin (Startice) Metornin Containing Metornin (Actobice) Resigliazone (Actore)			Ciclopirox cream & lotion	Ciclopirox (Penlac®)	and services and definitionally experience of a construction of a service of the service of the service of the
Colorinazole (Cream) Ketoconazole (Cream) Ketoconazole (Cream) Ketoconazole (Cream) Ketoconazole (Shampoo) (Tx only) Ketoconazole (Shampoo) (Tx only) Nystain Netormin Nystain Netormin Metormin Metormin Metormin Metormin Metormin Metormin Metormin Metormin Metormin Metormin (Actoplus Meto) Metormin Metormin (Actoplus Meto) Metormin Metormin (Actoplus Meto) Rosigliazone (Avandameto)			Clotrimazole	Naftifine (Naftin®)	
Reconazole (Cream) Ketoconazole (Shampoo) (Fx only) Nystain Invisition Inv	-	тана на при	Clotrimazole/Betamethasone	Oxiconazole (Oxistat®)	antical lond resembles consistent on the commentation of the special and security (Additionally Additionally A
Ketoconazole (Crean) Ketoconazole (Shampoo) (Fx only) Wystain Wytoglycemics, Metformin Containing Metformin Gal Solution (Romete) Wytoglycemics, Metformin Gal Solution (Romete) Wetformin Gal Solution (Romete) Rosigiliazone/Metformin (Avandamete) Rosigiliazone/Metformin (Avandamete) Rosigiliazone/Metformin (Avandamete) Rosigiliazone/Metformin (Avandamete) Rosigiliazone/Metformin (Avandamete) Rosigiliazone/Metformin (Avandamete) Wystain Gal Wystain (Wystain Gal Wystain Gal Wystai	***************************************	та тал, апанда тапанда на пределения положения подательной пределения подательной пределения подательной по	Econazole	Sertaconazole Nitrate (Ertaczo®)	Automotive (Africantino Africancia sympa Nobel) interest supplication and a supplication of the supplicati
Neteronazole (Shampoo) (Fx only) Nystatin Naterolimus (Eidelle)	******		(Ketoconazole (Cream)		A CONTRACTOR OF THE CONTRACTOR
Nystatin w Triemcinolone Sulconazole (Exeldern) Sulconazole (Exeldern) Sulconazole (Exeldern) Finecrolimus (Fidel®) Finecrolimus (Fidel®) Finecrolimus (Frotopic®) Finecrolimus (Frotopic®) Finecrolimus (Frotopic®) Metformin Exercitimus (Frotopic®) Metformin Exercitimus (Metformin Exercitimus (Metformin Exercitimus (Metformin Exercitimus Exercitimus (Metformin Exercitimus Exerc	-	MINISTERMENTAL LANGE AND	(Ketoconazole (Shampoo) (Rx only)	та ай базан на али интерна ней развили баране на пределение на интернации пределение на пределение н	
Nystatin w I riancinolore Sulconazole (Exeldem) Atopic Dermatitis Immunomedulators DIABETES Hypoglycemics, Meglitinides Hypoglycemics, Metformin Containing Metformin CR Metfo	-	MERCELLY MANY MERCELLY CHECKEN AND ACTIVE FREE MENDAL WAS A VERY FREE MERCHAN PROPERTY OF CHECKEN AND ACTIVE MERCHAN ACTIVE M	Nystatin	And a series where the series of the series and the	
Atopic Dermatitis Atopic Dermatitis DiABETES Hypoglycemics, Metformin Containing Hypoglycemics, Thiazolidinediones (TZDs) & Piggliazone (Actos®) Hypoglycemics, Thiazolidinediones (TZDs) & Pogliazone (Actos®) Rosigliazone (Actos®)	-	THE SEPTEMBER OF A PROPERTY OF THE PROPERTY OF	Nystatin w/ Triamcinolone	AND THE RESERVE AND THE PROPERTY OF THE PROPER	e de la company de la comp L
Atopic Dermatitis Immunomodulators Immunomodulators DIABETES Hypoglycemics, Metformin Containing Hypoglycemics, Metformin Containing Metformin RR Fortame(®) Metformin Carls Solution (Riome(®)) Metformin Gras Solution (Riome(®)) Metformin Gras Solution (Riome(®)) Metformin Gras Solution (Riome(®)) Rosiglifiazone (Actos ®) Rosiglifiazone (Aroadame(®)) Rosiglifiazone/Metformin (Arandame(®)) Rosiglifiazone/Metformin (Arandame(®)) Rosiglifiazone/Metformin (Arandame(®)) Rosiglifiazone/Metformin (Arandame(®)) Rosiglifiazone/Metformin (Arandame(®)) Rosiglifiazone/Metformin (Arandame(®))	-	TO A SERVICION CONTRACTOR DE C	Suicoliazoie - Suicoliazoie	And the second s	e de la companya de manación de constante de la constante de la constante de la constante de la constante de l
Atopic Dermettiis Atopic Dermettiis Immunomodulators Incrolimus (Protopic®) Incrolimus (Protopic®) Incrolimus (Protopic®) Increase	-	medicas amenda a	THE RESIDENCE OF THE PROPERTY		d and distinguished and all subsequently benefits (A. Arrest (A. Arrest (A. Arrest), A. Arrest (A.
Atopic Dermatitis Immunomodulators Immunomodulators Inacrolimus (Pridepic®) DIABETES Hypoglycemics, Meditornin Containing Hypoglycemics, Metformin Containing Metformin ER (Fortamet®) Metformin Carlo Solution (Riomet®) Rosigiliazone/Metformin (Actoplus Met®) Rosigiliazone/Metformin (Avandamet®) Rosigiliazone/Metformin (Avandamet®)					en elektrikaring bendikat devektrikaring interpessen in Arbent, interprete der besteten besteten besteten in d
Atopic Demaitis I Tacrolimus (Ficie®) I Tacrolimus (Protopic®) I Tacrolimus (Protopic®) I Tacrolimus (Protopic®) I Tacrolimus (Protopic®) I Tacrolimus (Starix®) I Metformin ER (Fortamet®) Metformin Carl Solution (Riomet®) Metformin Carl Solution (Riomet®) Metformin Carl Solution (Riomet®) Metformin Agents I TZD Combination Agents Plogitiazone (Actos®) Rosiglitazone/Metformin (Actoplus Met®) Rosiglitazone/Metformin (Avandamet®) Rosiglitazone/Metformin (Avandamet®)	1				de de l'amendament de la principa de l'amenda de l'amenda de l'amenda de l'amenda de l'amenda de l'amenda de l
Inmunomoduators Inacrolinus (Protopic®) UABETES Hypoglycemics, Metformin Containing Metformin RR (Fortame®) Metformin RR (Fortame®) Metformin RR (Mome®) Metformin (Mome®) Rosiglitazone(Metformin (Actoplus Me®) Rosiglitazone/Metformin (Avandame®) Rosiglitazone/Metformin (Avandame®)	1	Atopic Dermatitis		NONE	en i angle of f all process and the second territory for the second territory in the second territory in the second territory is a second territory to the second territory in the second territory is a second territory to the second territory in the second territory is a second territory to the second territory in the second territory is a second territory to the second territory in the second territory is a second territory to the second territory is a second territory to the secon
Hypoglycemics, Meditinides Hypoglycemics, Medicmin Containing Hypoglycemics, Medicmin Containing Medicmin RR (Fortame®) Medicmin RR Medicmin Containing Medicmin Cross Solution (Riome®) Medicmin Cross Solution (Riome®) Medicmin Cross Solution (Riome®) Medicmin Cross Solution (Riome®) Medicmin Agents Ploglitazone (Actos®) Rosiglitazone (Avandia®) Rosiglitazone (Avandia®) Rosiglitazone (Avandia®) Rosiglitazone (Avandia®)	T	Immunomodulators	i acrolimus (Protopic@)		a salayi yi salaa salami maa salami maa salama salah sal
Hypoglycemics, Megitinides Hypoglycemics, Metformin Containing Metformin ER (Fortamet®) Metformin ER (Fortamet®) Metformin SR Metformin AR Metformin (Riomet®) Metformin (Riomet®) Metformin (Riomet®) Metformin (Riomet®) Metformin (Riomet®) Ploglitazone (Actos®) Rosiglitazone (Actos®) Rosiglitazone(Metformin (Avandamet®)) Rosiglitazone(Metformin (Avandamet®))	1	01APFTES			Abende Saran (de saran mel mel salam mengelem saran memberapa persona de saran persona de saran de saran de me
Metformin Metformin ER (Fortamet®) Metformin GR (Fortamet®) Metformin Oral Solution (Riomet®) Metformin Oral Solution (Riomet®) Metformin Grass®) Pioglitazone (Actos®) Rosiglitazone (Avandia®) Rosiglitazone/Metformin (Avandamet®)	1	Hypoglycemics, Meglitinides	Nateglinide (Starlix®)	Repartitude (Prantin®)	And the second second control of the second
Metformin Metformin ER (Fortamet®) Metformin SR Metformin CRI Solution (Riomet®) Metformin Oral Solution (Riomet®) Metformin/Glyburide Pioglitazone (Actos®) Pioglitazone (Avandia®) Rosiglitazone/Metformin (Avandamet®)	IT	ora Para Montanta de la companya de Verezones en la companya de la comp			and the second
Metformin ER (Fortamet®) Metformin XR Metformin Gral Solution (Riomet®) Metformin/Glyburide Metformin/Glyburide Pioglitazone (Actos®) Pioglitazone (Actos®) Rosiglitazone/Metformin (Actoplus Met®) Rosiglitazone/Metformin (Avandamet®)	1				
Metformin Ex (f-oramete) Metformin Graf Solution (Riomet®) Metformin/Glyburide Metformin/Glyburide Plogilitazone (Actos®) Rosigilitazone (Avandia®) Rosigilitazone/Metformin (Avandamet®)	7	нуродіўсетісэ, мепогтіп соптаіпілд	Metrormin	Metrormin/Glipizide (Metaglip®)	
Metformin Chal Solution (Riomet®) Metformin Chal Solution (Riomet®) Metformin (Actos®) Pioglitazone (Actos®) Rosiglitazone/Metformin (Actoplus Met®) Rosiglitazone/Metformin (Avandamet®)	1		Menomin EK (Fortamette)		
Metformin Oral Solution (Atomete) Metformin Gran Solution (Atomete) Pioglitazone (Actos®) Rosiglitazone/Metformin (Actoplus Met®) Rosiglitazone/Metformin (Avandamet®)	_		Mellollilli AR	en es de la vision de la manda	
Pioglitazone (Actos®) Pioglitazone/Metformin (Actoplus Met®) Rosigiltazone/Metformin (Avandamet®)	T		Metionini Oral Solution (Riomete)	aries and descript of the state	
Pioglitazone (Actos®) Pioglitazone/Metformin (Actoplus Met®) Rosiglitazone/Metformin (Avandamet®)	7	ANTEREST OF COMMENDED AND AND A VARIANCE OF THE SECONDARY PROPERTY OF COMMEND AND AND AND ADDRESS AND	Metoring		
Pioglitazone (Actos®) Pioglitazone/Metformin (Actoplus Met®) Rosiglitazone/Metformin (Avandamet®)	1	THE STREET OF TH			the state of the s
Pioglitazone (Actos®) Pioglitazone/Metformin (Actoplus Met®) Rosigiltazone/Metformin (Avandamet®)	1	1984年,1984年,李元明的1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年,1984年	TO THE PROPERTY OF THE PROPERT		en la company de management de la company de la compan
Piogiliazone (Actos®) Piogiliazone/Metformin (Actoplus Met®) Rosigiliazone/Metformin (Avandamet®)	1	пинаменания в на на в в на в на в на в на в на в н		AND THE PROPERTY OF THE PROPER	AND
Pioglitazone/Metformin (Actoplus Met®) Rosigiliazone/Metformin (Avandamet®) Rosigiliazone/Metformin (Avandamet®)		Нуродјусетісs, Thiazolidinediones (TZDs) &		i NO	
Pioglitazone/Metformin (Actoplus Met®) Rosigiltazone(Metformin (Avandamet®) Rosigiltazone/Metformin (Avandamet®)		TZD Combination Agents			
Rosigiltazone (Avandamet®) Rosigiltazone/Metformin (Avandamet®)	1		Pionitazone/Metformin (Actual is Met®)		
Rosigilazone/Metformin (Avandameté)	-		Rocinitazone (Avandia®)		
	-		Rosiolitazone/Metformin (Avandamet®)		
	-				***************************************
	1				
	1				***************************************
	-				
	-				
	-	***************************************			
	_				
	-				
	+				

	-			***************************************	
	+				
	+				***************************************
	-	***************************************	-		
				The state of the s	

Prior Authorization PDL Implementation Schedule

9 DABETES conf Exentific (Betting) Humation (Core 16) years Insulfine & Related Agents Exentific (Betting) Humation (Core 16) years Insulfine & Related Agents Humation (Core) Humation (Core) Insulfine & Related Agents Humation (Core) Humation (Core) Insulfine & Related (Symiling) Humation (Core) Insulfine & Related (Symiling) Humation (Core) Insulfine & Related (Symiling) Humation (Core) Insulficación (Core) Dolaseiton (Azamaté) Insulfine & Related (Symiling) Corenestron (Coren. Zofan ODT®) GERO AND RELATED DISORDERS Escomeprazole (Nexium®) Escomeprazole (Nexium®) Orneprazole (Agentic) Proton Pump Inhibitors Lancoprazole Sulpanision (Prevacid®) Parteprazole (Agentic) ULCERATIVE COLITIS Messalemine Expense Balanciación (Cores. Sulpanision (Prevacid®) Parteprazole (Agentic) ULCERATIVE COLITIS Messalemine Expense Balanciación (Cores. Sulpanision (Prevacid®) Somatopin (Humation Septembre) GERO AND RELATED DISORDERS Somatopin (Garcalim®) Somatopin (Humation Septembre) Acconstropin (Salzam®) Somatopin (Humation Agentic) </th <th>S. cont'</th> <th>のでは、日本のでは</th> <th>THE RESIDENCE OF THE PROPERTY OF THE PARTY O</th>	S. cont'	のでは、日本のでは	THE RESIDENCE OF THE PROPERTY OF THE PARTY O
Insulina & Related Agents Exemine (Byeated)	1100 0		
Humatog (Children 18 years and under) Insulin Glasgine (Lantus®) Novolin N N	Related Agents	Exenalide (Byetta®)	Humalog (Over 18 years)
Insulin Glarghie (Lantus®) Novolin R Novolin T0/30 Novolin T0/30 Novolog Mix Pramilinide Acetate (Symlin®) DigESTIVE DISORDERS Antiemetic Agents Proton Pump Inhibitors Lansoprazole (Nexium®) Lansoprazole Capsule (Prevacid®) Lansoprazole Solukab (Prevacid®) Lansoprazole Capsule (Prevacid®) Lansoprazole Solukab (Prevacid®) Constantive Collis Agents Mesalamine (Pantasolio) Solukasiacine Somatropin (Variopin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	**************************************	Humalog (Children 18 years and under)	Humalog Mix 75/25
Novoiin N Novoiin N Novoiin Air Novoiin 7030 Novoiin Air Novoiin	- AND THE COMPANY AND AND THE COMPANY AND	Insulin Glargine (Lantus®)	Humulin L
Novolin RA Pramitride Acetate (Symiln®) Ordanseton (Zoiran, Zofran ODT®) Ordanseton (Zoiran, Zofran ODT®) Characterion (Zoiran, Zofran ODT®) Characterion (Zoiran, Zofran ODT®) Characterion (Zoiran, Zofran ODT®) Lansoprazole (Nexium®) Lansoprazole Soluba (Prevacid®) Mesalamine Rougoslitories (Canasa®) Nesalamine Rougoslitories (Canasa®) Nesalamine (Pentasa®) Sonatropin (Verotitropin®) Sonatropin (Serostin®) Sonatropin (Serostin®) Sonatropin (Serostin®)	гіл Малярия разаліция мерен деренен резененде у резененде у країни до провед мерененде да провед вижене да пред вижене да пред вижене да пред вижене да пред вижене да примене да пред вижене да пред	Novolin N	Humuin
Novoiln 7030	a Posterija (or osteria Posteria Posteria) (Adesejano (Adesejano) (Adesejano)	Novolin R	Humulin R
Novolog Mix Pramilintide Acetate (Symlin®) DIGESTIVE DISORDERS Antiemetic Agents Antiemetic Agents Aprepitant (Emend®) Condanseron (Zofran, Zofran ODT®) Condanseron (Zofran Cofran ODT®) Condanseron (Zofran Cofr	el/parties (section) de des sections de la company de des sections de la company l'agraga de la company de la comp	Novolin 70/30	Humalin U
Novolog Mix Aritémetic Agants Aritémetic Agants Aritémetic Agants Aritémetic Agants Aritémetic Agants OGAL Aprephant (Emend®) Ondansetron (Zofran, Zofran ODT®) Ondansetron (Zofran, Zofran ODT®) Lansoprazole Capsule (Pervacid®) Lansoprazole Capsule (Prevacid®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) ULCERATIVE COLITIS Mesalamine Enemas Mesalamine Enemas Mesalamine Enemas OSanatropin (Nutropin®) Suffassiazine Somatropin (Nutropin®) Somatropin (Nutropin®) Somatropin (Nutropin®) Somatropin (Salzan®)	OF PARTIES AND ADDRESS ME CARREST COMMON AND AND ADDRESS OF THE PARTIES OF THE PA	Novolog	Humulin 50/50
Pramiintide Acetate (Symiin®) DIGESTIVE DISORDERS Antiemetic Agents Antiemetic Agents Antiemetic Agents Aprepitant (Emend®) Ondansetron (Zofran, Zofran ODT®) Ondansetron (Zofran, Zofran ODT®) GERO AND RELATED DISORDERS Esomeprazole (Nexium®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) Mesalamine Enemas ULCERATIVE COLITIS Mesalamine Enemas Ulcerative Collis Agents Mesalamine (Pentasa®) Osalazine (Dientum®) Somatropin (Nerditropin®) Somatropin (Naropin Al2®) Somatropin (Sericstim®) Somatropin (Sericstim®) Somatropin (Sericstim®) Somatropin (Sericstim®)	THE PROPERTY OF THE PROPERTY AND THE PROPERTY OF THE PROPERTY	Novolog Mix	Humalin 70/30
Antiemetic Agents Antiemetic Agents Antiemetic Agents Antiemetic Agents Aprepitant (Emend®) Condansetron (Zofran, Zofran ODT®) Condansetron (Zofran, Zofran ODT®) Condansetron (Zofran, Zofran ODT®) Condansetron (Zofran, Zofran ODT®) Consequence Capsule (Freveaid®) Lansoprazole Solutab (Freveaid®) Lansoprazole Solutab (Freveaid®) Lansoprazole Subpositiones (Canasa®) Mesalamine (Fentasa®) Mesalamine (Fentasa®) Mesalamine (Pentasa®) Constropin (Sacosi®) Somatropin (Norditropin®) Somatropin (Norditropin®) Somatropin (Serositim®) Somatropin (Serositim®) Somatropin (Serositim®) Somatropin (Serositim®)		Pramlintide Acetate (Symlin®)	
Antitemetic Agents Antitemetic Agents Antitemetic Agents Aprepliant (Emend®) Ondansetron (Zofran, Zofran ODT®) GERD AND RELATED DISORDERS Esomeprazole (Nexium®) Lansoprazole Capaule (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) Mesalamine (Asacol®) Mesalamine (Asacol®) Mesalamine (Pentasa®) Mesalamine (Dipentum®) Olssiazine (Dipentum®) Somatropin (Norditropin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	e de la composito dela composito de la composito de la composito de la composi		
Antiemetic Agents Aprepliant (Emend®) Ondansetron (Zofran, Zofran ODT®) Ondansetron (Zofran, Zofran ODT®) Froton Pump Inhibitors Esomeprazole (Nexium®) Lansoprazole Suspension (Prevacid®) Mesalamine (Asacol®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Asacol®) Mesalamine (Asacol®) Suffasalazine Somatropin (Norditropin®) Somatropin (Saratin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	'E DISORDERS		
Aprepitant (Emend®) Condansetron (Zofran, Zofran ODT®) Condansetron (Zofran Coffan Zofran Coffan Zofran ODT®) Condansetron (Zofran Coffan Zofran ODT®) Condansetron (Zofran Coffan Zofran Coffa	c Agents	ORAL	
Ondansetron (Zofran, Zofran ODT®) GERD AND RELATED DISORDERS	***************************************	Aprepitant (Emend®)	Dolasetron (Anzemett)
GERD AND RELATED DISORDERS ESOMEPrazole (Nexium®) Lansoprazole Capsule (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) Mesalamine (Asacol®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Surfasalazine Somatropin (Norditropin®) Somatropin (Nutropin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	Provident marchine to apply for a color of the providence of the color	Ondansetron (Zofran, Zofran ODT®)	Granisetron (Kytril®)
Esomeprazole (Nexium®) Lansoprazole Capsule (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Solutab (Prevacid®) Lansoprazole Solutab (Prevacid®) ULCERATIVE COLITIS Mesalamine (Asacol®) Mesalamine (Pentlasa®) Solifasalazine Somatropin (Norditropin®) Somatropin (Salzen®)	D RELATED DISORDE	RS	
Lansoprazole Capsule (Prevacid®) Lansoprazole Suluta (Prevacid®) Lansoprazole Suspension (Prevacid®) Lansoprazole Suspension (Prevacid®) UICERATIVE COLITIS Mesalamine (Asaciol®) Mesalamine (Asaciol®) Mesalamine (Perlasa®) Mesalamine (Perlasa®) Mesalamine (Perlasa®) Mesalamine (Perlasa®) OISalazine (Dipentum®) Sulfasalazine Somatropin (Norditropin®) Somatropin (Salzen®) Somatropin (Salzen®) Somatropin (Salzen®) Somatropin (Salzen®)	ımp Inhibitors	Esomeprazole (Nexium®)	Omeprazole (generic legend only)
Lansoprazole Solutab (Prevacid®) Lansoprazole Suspension (Prevacid®) ULCERATIVE COLITIS ULCERATIVE COLITIS ULCERATIVE COLITIS ULCERATIVE COLITIS Mesalamine Enemas Mesalamine (Asacol®) Mesalamine (Pentasa®) OISalazine Sulfasalazine Sulfasalazine Somatropin (Norditropin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	ACCORDINATION OF THE PROPERTY	Lansoprazole Capsule (Prevacid®)	Omeprazole (Zegerid®)
Lansoprazole Suspension (Prevacid®) ULCERATIVE COLITIS ULCERATIVE COLITIS Mesalamine Enemas Ulcerative Collitis Agents Mesalamine (Asacol®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Sulfasalazine Sulfasalazine Somatropin (Norditropin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	in to commend and desired the control of the transport of the control of the cont	Lansoprazole Solutab (Prevacid®)	Pantoprazole (Protonix®)
ULCERATIVE COLITIS Mesalamine (Asacol®) Mesalamine (Asacol®) Mesalamine (Asacol®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Sulfasalazine Sulfasalazine Somatropin (Norditropin®) Somatropin (Tev-Tropin®) Somatropin (Serostim®) Somatropin (Serostim®)		Lansoprazole Suspension (Prevacid®)	Rabeprazole (Aciphex®)
ULCERATIVE COLITIS Ulcerative Colitis Agents Ulcerative Colitis Agents Mesalamine (Asacol®) Mesalamine (Asacol®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) Oisalazine (Dipentum®) Sulfasalazine GROWTH DEFICIENCY Growth Hormones Somatropin (Norditropin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	med jamen (1924) has been been been been been been been bee	THE PROPERTY OF THE PROPERTY O	
Ulcerative Colitis Agents Mesalamine (Asacol®) Mesalamine Suppositories (Canasa®) Mesalamine (Pentasa®) Olsalazine (Dipentum®) Sulfasalazine GROWTH DEFICIENCY Somatropin (Norditropin®) Somatropin (Norditropin®) Somatropin (Serostim®) Somatropin (Serostim®) Somatropin (Serostim®)	IVE COLITIS	Mesalamine Enemas	Balsalazide (Colazal®)
Mesalamine Suppositories (Canasa®) Mesalamine (Pentasa®) Mesalamine (Pentasa®) OIsalazine (Dipentum®) Sulfasalazine Somatropin (Norditropin®) Somatropin (Norditropin®) Somatropin (Tev-Tropin®) Somatropin (Serostim®) Somatropin (Serostim®)	Colitis Agents	Mesalamine (Asacol®)	
Mesalamine (Pentasa®) Olsalazine (Dipentum®) Suffasalazine GROWTH DEFICIENCY Growth Hormones Somatropin (Nutropin AQ®) Somatropin (Serostim®) Somatropin (Serostim®)		Mesalamine Suppositories (Canasa®)	AND AND THE WASHINGTON AND AND ADDRESS OF THE PROPERTY OF THE
Olsalazine (Dipentum®) Sulfasalazine GROWTH DEFICIENCY Growth Hormones Somatropin (Nutropin®) Somatropin (Nutropin®) Somatropin (Serostim®) Somatropin (Serostim®)	A V Minima de de describentes de la compansión de la comp	Mesalamine (Pentasa®)	
Suffasalazine GROWTH DEFICIENCY Growth Hormones Somatropin (Norditropin®) Somatropin (Nutropin AC®) Somatropin (Tev-Tropin®) Somatropin (Serostim®) Somatropin (Serostim®)	AND THE RESIDENCE AND THE PARTY OF THE PARTY	Olsalazine (Dipentum®)	
GROWTH DEFICIENCY Growth Hormones Somatropin (Norditropin®) Somatropin (Nutropin AQ®) Somatropin (Tev-Tropin®) Somatropin (Serostim®)	THE ARTHUR AND THE PROPERTY OF THE PROPERTY AND THE PROPERTY OF THE PROPERTY O	Sulfasalazine	
GROWTH DEFICIENCY Growth Hormones Growth Hormones Somatropin (Norditropin®) Somatropin (Tev-Tropin®) Somatropin (Selzen®) Somatropin (Serostim®)			
Growth Hormones Somatropin (Norditropin®) Somatropin (Nutropin AQ®) Somatropin (Serzetm®) Somatropin (Serostim®)	DEFICIENCY		
Somatropin (Nutropin AQ@) Somatropin (Tev-Tropin®) Somatropin (Serostim®)	Jemonas	Somatronia (Norditropia)	
	Andreas and a second section of the section of the second	Somatropin (Nutropin AQ®)	manusement of the second control of the seco
	reference Water expension of characteristics for their side as common to the characteristics of the delicement of the characteristics of	Somatronia (Tev-Tropin®)	Sonation (Nutron No. 1997)
Somatropin (Serostim®)	Wenter were property and provided the second form of the second form and the second form and s	Somatropin (Salzen®)	THE PROPERTY OF THE PROPERTY O
	en en en en el formatione formatione de prosessorance en la constanta de la constanta de la constanta de la co	Somatropin (Serostim®)	
	And the state of t		
	THE PROPERTY OF THE PROPERTY O	тура тараптара на принципара до на постора на принципара	
	nam e color de contracto es establica e es establica de e	тері Метерін тараттың іншенің іншенің іншенің іншенің караман караман жарын қараман жарында жарын жарын жарын ж	
		THE THE STREET S	NO CONTRACTOR OF THE PROPERTY
		М) Аң жетірі терінде іншен жанақы қанақы қанақы қанақы белері жене керінде керінде керінде керінде керінде кер	
	Abert and the state of the state and an experience and an experience of the state of the state of the state of		
	electronical description of the contract of th	THE PARTY OF THE P	THE PARTIES AND THE PARTIES AN
	The printer of the second country of the second factor shows that the second se	HETOPE INTERNATIONAL CONTROL OF THE	

March Ballon B	HYPERLIPIDEMIA Antihyperlipidemic Agents - Non Statins			The state of the s
Cholestyramine Colestipol (Colestid®) Fenofbrate (Lichtra®) Fenofbrate (Lichtra®) Fenofbrate (Lichtra®) Fenofbrate (Lichtra®) Fenofbrate (Lichtra®) Nacio ER (Niespan®) Nacio ER (Niespan®) Fluvastatin (Lescol®) Fluvastatin (Lescol®) Fluvastatin (Lescol®) Fluvastatin (Cocon®) Fluvastatin (Cocon®) Fluvastatin (Cocon®) Fluvastatin (Cocon®) Renazepril BenazeprilHCTZ FesinoprilHCTZ Fe	Antilyperlipidemic Agents -		如果我们的时候,我们就是我们的时候,我们就是我们的我们的我们就是我们的,我们就是我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我	
Colestipol (Colestid®) Fennificated (Trico®) Fennificated (Trico®) Fennificated (Trico®) Gennificated (Trico®) Gennificated (Trico®) Fennificated (Trico®	Non Statins	NATIONAL PROPERTY PRO	MANAGEMENT AND	***************************************
Fenofibrate (Lofbra®)	MOII Statilis	deconverses and the second control of the se	Coleseveral (Yveicino)	MANERAL PER LA LINE CONTRACTOR DE CONTRACTOR
Fenofibrate (Loftbra®)	THE RESIDENCE AND ASSOCIATION OF THE PROPERTY			***************************************
Terininaria (Loninare) Gemilbrozil Niacin EK (Niespan®) Niacin EK (Niespan®) Niacin Exesci®) Fluvastalin (Lescol XL®) Lovastalin (Lescol XL®) Lovastalin (Lescol XL®) Lovastalin (Exesci®) Fluvastalin (Alescol XL®) Niacin ER(Allopraw®) Niacin ER(Corstalin (Advicor®) Simvastalin (Zocor®) Rosuvastalin (Zocor®) Rosuvastalin (Zocor®) Rosuvastalin (Caslow®) Simvastalin (Zocor®) Rosuvastalin (Locor®) Rosuvastalin (Locor®) Simvastalin (Locor®) Rosuvastalin (Locor®) Enalaprill CTZ Enalaprill (Alacor®) Moexipril (Alacor®) Iterastrant (Avepro®) Iterastrant (Avepro®) Iterastrant (Avepro®) Iterastrant (Avepro®) Iterastrant (Avepro®) Iterastrant (Avepro®) Iterastrant (CTZ Enalaprill (Enalest HCT®) Valsartant (CTZ Enalaprill (CTZ Enalaprill CTZ Enalaprill (CTZ Enalaprill CTZ Enalaprill Enalaprill (Enalaprill Enalaprill Enalapr	CONTRACTOR OF A PROPERTY OF A	reministration and the second and th	renomenamente mentale (Antara@)	er en 2 mais en demandra esta en en 1900 en 19
Niacin EX (Niaspan®) Niacin FX (Niaspan®) Niacin FX (Niaspan®) Fluvastatin (Lescol®) Fluvastatin (Lescol®) Fluvastatin (Lescol®) Fluvastatin (Cestor®) Niacin ERLovastatin (Advicor®) Simvastatin (Zocor®) Simvastatin (Zocor®) Simvastatin (Zocor®) Simvastatin (Zocor®) Simvastatin (Zocor®) Simvastatin (Cestor®) Simvastatin (Advicor®) Simvastatin (Cocor®) Simvastatin (Cocor®) Simvastatin (Univasc®) Moexipil	enverse es anique es anique se manique qui pas instança para de sa presenta de la companique de la companique d		FENORGE (Ingilide®)	POTENTIAL PROPERTY AND ASSESSED AND ASSESSED ASSESSED.
Nilacin EX (Nilaspano) Nilacin RX Ezelimibe/Sinvastalin (Vytorin®) Fluvastalin (Lescol®) Fluvastalin (Lescol®) Fluvastalin (Lescol®) Fluvastalin (Coeston®) Rosuvastalin (Coeston®) Sinvastalin (Coeston®) Sinvastalin (Coeston®) Sinvastalin (Coeston®) Sinvastalin (Coeston®) Benazepril HCTZ Enalapril Capiopril HCTZ Enalapril (Univasc®) Moexipril (Univasc®) Moexipril (Univasc®) Moexipril (Univasc®) Anniodiprine/Benazepril (Lotel®) Verapami SRTrandolapril (Tarka®) Itandolapril (Allace®) Trandolapril (Allace®) Trandolapril (Mavk®) Itandolapril (Maradis®) Itandolapril (Mavk®)	en de en		Umega-J-acid ethyl esters (Omacord)	nie delan imm i fek fen finlinger, ungandagsfen (binst) i son (inicipas) generaken
Ezetimibe/Sinvastalin (Lytorin®) Fluvastalin (Lescol®) Fluvastalin (Lescol®) Fluvastalin (Lescol®) Fluvastalin (Lytorin®) Fluvastalin (Lytorin®) Fluvastalin (Lytorin®) Nision ENL(Lovastalin (Advicor®) Rosuvastalin (Zocol®) Sinvastalin (Zocol®) Sinvastalin (Zocol®) Benazepril Benazepril Enalapril Captopril Captopril Captopril Captopril Captopril Casinopril Fosinopril (Lorin®) Moexipril (Univasc®) Moexipril (Univasc®) Moexipril (Allace®) Trandolipril (Allace®) Trandolipril (Allace®) Trandolipril (Allace®) Itanastan (Aragin®)		Wacin EK (Waspang)	THE PROPERTY OF THE PROPERTY O	AND THE PROPERTY OF THE PROPER
Ezelimibe/Simvastalin (Vydorin®)	WATER AND THE PROPERTY OF THE		THE PROPERTY OF THE PROPERTY O	have a comparator to prediment polarity and property and
Fluvastatin (Lescol®) Fluvastatin XI (Lescol XI®) Lovastatin XI (Lescol XI®) Lovastatin ER (Altoprev®) Niacin ERU ovastatin (Advicor®) Rosuvastatin (Crestor®) Simvastatin (Crestor®) Simvastatin (Crestor®) Simvastatin (Crestor®) Simvastatin (Crestor®) Simvastatin (Crestor®) Fenalaphil Captopril C	Statins & Statin Combination Ager	Actions described by actions the described by the second of the second o	Atorvastatin (Cadue(®))	· · · · · · · · · · · · · · · · · · ·
Fluvastatin XI. (Lescol XI.®) Lovastatin Lovastatin Lovastatin Lovastatin (Anicor®) Naion ER/Lovastatin (Advicor®) Simvastatin (Zocor®) Simvastatin (Zocor®) Benazepril Benazepril Captopril Captopril			Atorvastatin (Lipitor®)	477A MARIA DO 2014 AND
Lovastatin Lovastatin Lovastatin Naicin ER(Lovastatin (Advicor®) Naicin ERLLovastatin (Crestor®) Rosuvastatin (Zocor®) Rosuvastatin (Zocor®) Rosuvastatin (Zocor®) Rosuvastatin (Zocor®) RosupphilhCTZ Captopril EnalaprilhCTZ Fosinopril EnalaprilhCTZ Fosinopril LisinoprilhCTZ Moexipril (Univasc®) Moexipril (Univasc®) Moexipril (Univasc®) Moexipril (Allace®) Trandolapril (Mavik®) Irandolapril (Mav	CONTRACTOR OF THE PROPERTY OF	Fluvastatin XL (Lescol XL®)	Pravatlin (Pravatlin (Pravacho))	MATERIALIA CONTINATORMINATORMINATOR AMBRANTOR A FRANCACO
Lovastalin ER (Altoprev®) Niacin ERU.ovastalin (Advicor®) Rosuvastalin (Zocor®) Simvastalin (Zocor®) Simvastalin (Zocor®) Simvastalin (Zocor®) BenazeprilHCTZ Caplopil CaptoprilHCTZ EnalaprilHCTZ Lisinopril Lisinopril Lisinopril Lisinopril Univasc®) Moexipril (Univasc®) Moexipril (Univasc®) Moexipril (Altac®) Ramipril (Altac®) Amiodipine/Benazepril (Lotre®) Amiodipine/Benazepril (Lotre®) Nerapamil SRTrandolapril (Tarka®) Irandolapril (Mavik®) I	W. France (Antine interferential production (Antine interferential Antine interferential	Lovastalin	Assume manufacture and manufac	ocontroller foreignelier dat totals addition; in total sisted, in the second section of
Niacin ERLovastatin (Advicor®) Rosuvastatin (Crestor®) Simvastatin (Crestor®) Simvastatin (Coor®) Benazepril Benazepril Benazepril Captopril Capto	A CONTRACTOR OF THE PROPERTY O	Lovastatin ER (Altoprev®)		AND AND AND AND AND AND AND AND ADDRESS OF THE AND AND ADDRESS AND
Rosuvastatin (Creston®) Simvastatin (Zocon®) Benazepril Benazepril Benazepril Captopril Captopril Captopril Captopril Calinopril Enalapril Enalapril Enalapril Calinopril Lisinopril Lisinopril Lisinopril Lisinopril Calinopril Lisinopril Calinopril	en (references presides de l'action des constitues des constitues des constitues de la constitue de la constit	Niacin ER/Lovastatin (Advicor®)	and the state of t	AND SECURITY OF THE PERSON OF
Simvastatin (Zocor®) Benazepril Benazepril Captopril/HCTZ Captopril Captopr		(Rosuvastatin (Crestor®)		A Commence of the Commence of
Benazepril Benazepril Captopril Captopril Captopril Captopril Captopril Enalaprii Enalaprii Enalaprii Enalaprii Fosinopril/HCTZ Lisinopril Lisinopril Lisinopril Usinopril (Univasc®) Moexipril (Univasc®) Moexipril (Univasc®) Moexipril (Univasc®) Moexipril (Altace®) Trandolapril (Mavik®) Trandolapril (Mavik®) Amtodipine/Benazepril (Lotre®) Verapamil SRTrandolapril (Tarka®) Insartan/HCTZ (Hyzaar®) Insartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Horalapril Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Biovan HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Simvastatin (Zocor®)		ad y rest formational day is a second as a constant of the second of the second of the second of the second of
Benazepril Benazepril/HCTZ Caplopril Caplopril Captopril/HCTZ Enalapril Enalapril Enalapril/HCTZ Ensorphil/HCTZ Lisinopril Lisinopril Usinopril (Univasc®) Moexipril (Univasc®) Moexipril (Univasc®) Auinapril/HCTZ (Uniretic®) Quinapril/HCTZ (Uniretic®) Trandolapril (Mavik®) Trandolapril (Mavik®) Amtodipine/Benazepril (Lotref®) Verapamil SRTrandolapril (Tarka®) Insartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Benicar HCT®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)			мандара үчүн дарын каландарын каландарын дарын каландарын каландары	THE PERSONNEL PROPERTY OF THE PERSONNEL PROP
Benazepril Benazepril/HCTZ Captopril/HCTZ Captopril/HCTZ Enalapril Fosinopril/HCTZ Lisinopril/HCTZ Lisinopril/HCTZ Usinopril/HCTZ Usinopril/HCTZ Usinopril/HCTZ Mooxipril/HCTZ Quinapril/HCTZ Amipril (Altace®) Trandolapril (Mavik®) Trandolapril (Mavik®) Trandolapril (Mavik®) Trandolapril (Mavik®) Nerapamil SPCTrandolapril (Tarka®) Intersartan/HCTZ (Hyzaar®) Intersartan/HCTZ (Hyzaar®) Intersartan/HCTZ (Hyzaar®) Intersartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Diovan HCT®) Valsartan (Diovan®) Valsartan/HCTZ (Diovan HCT®)	HYPERTENSION	тара Құралындарын алақ анастан бана дана дана дана баласын алақ жаласын алақ жаласын алақ жаласын алақ жаласын		
Benazepril/HCTZ Caplopril Captopril Captopril Enalaprii/HCTZ Enalaprii/HCTZ Fosinoprii/HCTZ Fosinoprii/HCTZ Andoprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Moexiprii/HCTZ Ramiprii/HCTZ Neraare Nerapamii SR/Trandolaprii (Tarka®) Irandolaprii (Mavik®) Irandolaprii (Marids HCT®) Irandolaprii/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)	ACE Inhibitors	Benazepril	Perindopril (Aceon®)	
Captopril Captopril Captopril/HGTZ Enalapril Fosinopril/HGTZ Lisinopril Lisinopril/HGTZ Lisinopril/HGTZ Lisinopril/HGTZ Lisinopril/HGTZ (Unretic®) Moexipril/HGTZ (Unretic®) Trandolapril (Mavik®) Trandolapril (Mavik®) Nerapamil SR/Trandolapril (Tarka®) Nerapamil SR/Trandolapril (Tarka®) Nerapamil SR/Trandolapril (Tarka®) Inesartan/HGTZ (Hyzaar®) Inesartan/HGTZ (Avaitde®) Olmesartan/HGTZ (Micardis HGT®) Telmisartan/HGTZ (Micardis HGT®) Valsartan/HGTZ (Diovan HGT®) Valsartan/HGTZ (Diovan HGT®)		Benazepril/HCTZ		
Captopril/HCTZ Enalaprii Enalaprii/HCTZ Fosinoprii Fosinoprii CTZ Lisinoprii Lisinoprii Lisinoprii (Univasc®) Moexiprii (Univasc®) Quinaprii (Univasc®) Quinaprii (Altace®) Trandolaprii (Mavik®) Amtodipine/Benazeprii (Lotrei®) Verapamii SRTrandolaprii (Tarka®) Iosartan/HCTZ (Hyzaar®) Iosartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Avalide®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Captopril		av beautige vertice of the franches and section of the following sections of the following secti
Enalapril Fosinopril Fosinopril Fosinopril Fosinopril Fosinopril Fosinopril Fosinopril Fosinopril Lisinopril L		Captopril/HCTZ		Weet and Wassers and Secure As a second and
Enalapril/HCTZ Fosinopril Lisinopril/HCTZ Lisinopril/HCTZ Lisinopril/HCTZ Moexipril/HCTZ Moexipril/HCTZ (Unitetic®) Moexipril/HCTZ (Unitetic®) Quinapril Quinapril (Allace®) Trandolapril (Mavik®) Trandolapril (Mavik®) Amilodipine/Benazepril (Lofrei®) Verapamil SR/Trandolapril (Tarka®) Insesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Benicar HCT®) Inbesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Biovan HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Enalapril		Address in the particular processors of Advantail Commissions of Aceta gramma, 1950
Fosinoprii HCTZ Lisinoprii HCTZ Lisinoprii HCTZ Moexiprii (Univasc®) Moexiprii (Univasc®) Moexiprii (Univasc®) Munaprii (Univasc®) Trandolaprii (Mavik®) Trandolaprii (Mavik®) Trandolaprii (Mavik®) Amtodiprie (Benazeprii (Lotrei®) Verapamii SR/Trandolaprii (Tarka®) Iosartan/HCTZ (Hyzaar®) Inbesartan (Avapro®) Inbesartan (Avapro®) Inbesartan (Meradis®) Olmesartan (Benicar HCT®) Telmisartan/HCTZ (Biovan HCT®) Telmisartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Enalapril/HCTZ		A A COLOMBIA DE LA COLOMBIA DEL COLOMBIA DEL COLOMBIA DE LA COLOMBIA DEL COLOMBIA DE LA COLOMBIA DEL COLOMBIA DE LA COLOMBIA DEL COLOM
FosinoprilHCTZ LisinoprilHCTZ LisinoprilHCTZ MoexiprilHCTZ (Unitetic®) MootyprilHCTZ (Unitetic®) Quinapril (Univasc®) Ramipril (Altacs®) Trandolapril (Mavik®) Amfodipine/Benazepril (Lotre®) Verapamil SR/Trandolapril (Tarka®) losartan/HCTZ (Hyzaar®) losartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Avaitde®) Comessartan/HCTZ (Avaitde®) Comessartan/HCTZ (Micardis HCT®) Telmisartan/HCTZ (Micardis HCT®) Telmisartan/HCTZ (Micardis HCT®) Valsartan (Diovan®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Fosinoprii		AND
Lisinopril Lisinopril LisinoprilHCTZ Moexipril (Univasc®) Auinapril (Univatc®) Ramipril (Altace®) Trandolapril (Mavik®) Amfodipine/Benazepril (Lotre®) Verapamil SRTrandolapril (Tarka®) Iosartan (Cozaar®) Iosartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Irbesartan/HCTZ (Avalide®) Olmesartan/HCTZ (Avalide®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)	The second secon	Fosinopril/HCTZ		1986-man personante personante managamente de la company d
Lisinopril/HCTZ Moexipril (Univasc®) Moexipril (Univasc®) Quinapril Quinapril (Altace®) Trandolapril (Mavik®) Trandolapril (Mavik®) Trandolapril (Mavik®) Amilodipine/Benazepril (Lotrei®) Verapamil SR/Trandolapril (Tarka®) Insartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Biovan HCT®) Telmisartan/HCTZ (Diovan HCT®) Valsartan (Diovan®) Valsartan/HCTZ (Diovan HCT®)	AND THE RESIDENCE OF THE PROPERTY OF THE PROPE	Lisinoprii	的 计分类 计图像 计	
Moexiprii (Univasc®) Moexiprii/HCTZ (Uniretic®) Quinaprii Quinaprii (Alace®) Trandolaprii (Mavik®) Trandolaprii (Mavik®) Amlodipine/Benazeprii (Lotrei®) Verapamii SR/Trandolaprii (Tarka®) Iosartan/HCTZ (Hyzaar®) Iosartan/HCTZ (Hyzaar®) Intesartan/HCTZ (Hyzaar®) Intesartan/HCTZ (Hyzaar®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Lisinopril/HCTZ		AND AN INDIVIDUAL WITHOUT WATER THE WATER AND MAINTAIN AND ASSESSED AND ASSESSED.
Moexipril/HCTZ (Unitetic®) Quinapril/HCTZ Ramipril (Altace®) Trandolapril (Mavik®) Amiodipine/Benazepril (Lotrel®) Verapamil SR/Trandolapril (Tarka®) Verapamil SR/Trandolapril (Tarka®) Iosartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Avalide®) Olmesartan/HCTZ (Avalide®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Moexipril (Unlvasc®)		
Quinapril Quinapril (Altace®) Trandolapril (Altace®) Trandolapril (Mavik®) Trandolapril (Mavik®) Amlodipine/Benazepril (Lotrel®) Verapamil SR/Trandolapril (Tarka®) Iosartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Availe®) Olmesartan/HCTZ (Availe®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Blovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Moexipril/HCTZ (Uniretic®)	те дене (Динанте в дене дене дене дене дене дене дене д	A CANCELLO DE LA CANCELLO DEL CANCELLO DEL CANCELLO DE LA CANCELLO
Quinapril/HCTZ Ramipril (Altace®) Trandolapril (Mavik®) Amlodipine/Benazepril (Lotrel®) Verapamil SR/Trandolapril (Tarka®) Iosartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Availde®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Quinapril		
Ramipril (Altace®) Trandolapril (Mavik®) Amfodipine/Benazepril (Lotrel®) Verapamil SR/Trandolapril (Tarka®) losartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Climesartan/HCTZ (Avalide®) Climesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Quinapril/HCTZ		WATER SHALL SERVICE AND A SHALL BY SAME AND AND A SHALL BY SAME AN
Trandolapril (Mavik®) Amiodipine/Benazepril (Lotrel®) Verapamil SR/Trandolapril (Tarka®) Iosartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Hyzaar®) Inbesartan/HCTZ (Availde®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)		Ramipril (Altace®)		and the second s
Amlodipine/Benazeptil (Lofrei®) Verapamil SR/Trandolaptil (Tarka®) losartan (Cozaaa®) losartan (Avapro®) Irbesartan (Avapro®) Irbesartan (Avapro®) Olmesartan (Benicar HCT®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)	THE THE PROPERTY OF THE PROPER	Trandolaprii (Mavik®)		
Amlodipine/Benazepril (Lotrei®) Verapamii SR/Trandolapril (Tarka®) Iosartan/HCTZ (Hyzaar®) Inbesartan (Avapro®) Inbesartan (Avapro®) Inbesartan/HCTZ (Avalide®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Biowan HCT®) Valsartan/HCTZ (Diowan HCT®)				
Amlodipine/Benazeptil (Lotrel®) Verapamil SR/Trandolaptil (Tarka®) losartan (Cozaa®) losartan/HCTZ (Hyzaar®) lubesartan/HCTZ (Availde®) Clinesartan/HCTZ (Availde®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan (Micardis HCT®) Telmisartan/HCTZ (Micardis HCT®) Valsartan (Diovan®) Valsartan/HCTZ (Diovan HCT®)	THE STREET PROPERTY OF			The second secon
Amiodipine/Benazepril (Lotrel®) Verapamil SR/Trandolapril (Tarka®) losartan/Gozaar®) losartan/HCTZ (Hyzaar®) lirbesartan/HCTZ (Availde®) Olmesartan/HCTZ (Availde®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)	HYPERTENSION	mente communicate proprieta de sistema de particio de describiros de ser		***************************************
Verapamii SR/Trandolaprii (Tarka®) losartan (Cozaar®) losartan/HCTZ (Hyzaar®) lrbesartan (Avapro®) lrbesartan/HCTZ (Avalide®) Olmesartan (Anelide®) Olmesartan (Anelide®) Telmisartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Valsartan (Diovan®) Valsartan/HCTZ (Diovan HCT®)	ACE Inhibitors/Calcium Channel	(Amlodipine/Benazepril (Lotrel®)	Felodipine/Enalapril (Lexxel®)	
Iosartan (Cozaar®) Iosartan/HCTZ (Hyzaar®) Irbesartan/HCTZ (Hyzaar®) Irbesartan/HCTZ (Avaide®) Olmesartan/HCTZ (Benicar HCT®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan/HCTZ (Benicar HCT®) Yalsartan/HCTZ (Micardis HCT®) Valsartan/HCTZ (Diovan HCT®)	Blockers Combination Products	Verapamii SR/Trandolaprii (Tarka®)	THE COLUMN TWO IS NOT THE OWNER OF THE OWNER OWNE	***************************************
losartan/HCTZ (Hyzaa@) losartan/HCTZ (Hyzaa@) Irbesartan/HCTZ (Hyzaa@) Irbesartan/HCTZ (Avalide@) Olmesartan/HCTZ (Benicar HCT@) Telmisartan/HCTZ (Benicar HCT@) Telmisartan/HCTZ (Micardis HCT@) Valsartan/HCTZ (Micardis HCT@) Valsartan/HCTZ (Diovan HCT@)	and the state of t	үн надаган аламдан аламдан айында жасын аламдан айын айын айын айын айын айын айын ай		P
Insertant Cozaer®) Inseration (Avapro®) Inbesartan (Avapro®) Intesartant (Benicar®) Olmesartant (Benicar®) Telmisartant (Micardis MC) Telmisartant (Colovant HCT®) Yalsartant (Dlovant HCT®) Valsartant (Clovant HCT®)		To a fact of the f		***************************************
Inbesartan (Avapro®) Irbesartan (Avapro®) Irbesartan (Benica®) Olmesartan/HCTZ (Avalide®) Olmesartan/HCTZ (Benicar HCT®) Telmisartan (Micardis®) Telmisartan/HCTZ (Micardis HCT®) Valsartan/HCTZ (Diovan HCT®) Valsartan/HCTZ (Diovan HCT®)	Anglotensiii ii keceptor		Caridesarian (Alacando)	
	BIOCKERS (AKES)	Iosarar/hC (h/yzar@)	Candesaran/HCIZ (Alacand HCI®)	
Ulmosardan (benicarW)		Irpesarian/HCTZ (Availded)	Eprosaran/HCIZ (I evelen HCIW)	
Olmesaftan/HCTZ (Benicar HCT@) Telmisaftan (Micardis HCT@) Valsaftan (Dlovan@) Valsaftan/HCTZ (Dlovan HCT@) Valsaftan/HCTZ (Dlovan HCT@)		Olmesartan (Benicar®)		
Telmisardan (Micardis HCT®) Valsardan/HCTZ (Diovan HCT®) Valsardan/HCTZ (Diovan HCT®)		Olmesartan/HCTZ (Benicar HCT®)		***************************************
Valsartan/HCTZ (Diovan HCT@)		(elmisarian (Micardis@)	***************************************	
Valsartan/HCTZ (Diovan HCT®)				***************************************
Valsatatino I Convertino II		Valsarial (Olovaria)		
			THE PROPERTY OF THE PROPERTY O	***************************************
		антайдунаттуу бардаган раздаган канатанатукаттанатукаттан канатан канатана Фанация канатана ба	. The second control of the second control o	***************************************

2/20/2006

Principle of Pri	FEGATION INHIBITORS STEGATION INHIBITORS STATEMATICALES NTS, INJECTABLES		Druge Which Require PA	Effective Date:
HEATE DESIGNED	HEART DISEASE cont' HEART DISEASE cont' HYPERTENSION Beta Adrenergic Receptor Blocking Agents PLATELET AGGREGATION INHIBITORS Jatelet Aggregation Inhibitors INTICOAGULANTS, INJECTABLES Intelest Aggregation Inhibitors Inticoagulants, Indicoagulants, Indicoagulants, Indicatable	の行うないというでは、日本の日本の一	さんかん こうしゅうしゅう こうしゅう こう こうしゅう こうしゅう こうしゅう こうしゅう こうしゅう こうしゅう こう こうしゅう こうしゅう こうしゅう こう こうしゅう こうしゅう こうしゅう こう こうしゅう こう こうしゅう こう こうしゅう こうしゅう こうしゅう こうしゅう こうしゅう こう こうしゅう こうしゅう こう こうしゅう こう こう こうしゅう こう	Control of the Contro
HIGART ENERGY	HEART DISEASE cont' HYPERTENSION Beta Adrenergic Receptor Blocking Agents PLATELET AGGREGATION INHIBITORS PLATELET AGGREGATION INHIBITORS ANTICOAGULANTS, INJECTABLES Anticoagulants, Injectable			April 1, 2006
REGATION INHIBITORS RECATION	el Blockers ation inhibitors NTS, INJECTABLES	В под дава да положения под положения под		
re Receptor Acebudol Belaxolol Belaxolol Belaxolol Carvedilol (Corego) Laberation Carvedilol (Corego) Laberation Metoprolol XI, (Toprol XI, 0) Nadolol Propranolol Affer Propranolol Propranolol Affer Timolol Meleate Sotialol AF Timolol Meleate Dilliazem SR Felotipine ER Intracipine ER	el Blockers atlon Inhibitors NTS, INJECTABLES			
Alanoloi Belazoloi Carvadioi (Corage) Laberialoi Aleoproloi Ternaria Carvadioi (Corage) Laberialoi Nacioriol Alaneiale Pindoloi Alaneiale Solaidoi Af Timoloi Maleate Dilitazem ER (Cardizem LA®) Solaidoi Af Timoloi Maleate Nicolopine ER Felodipine ER Indolopine ER Nicolopine ER Nicolop	el Blockers ation inhibitors NTS, INJECTABLES		Penbutolol (Levatol®)	
Beleacold Bisoproid Chromate Carvadiol (Corage) Labetaiol Metoproiol I Afford XL®) Nadolol Propranoiol Affordianoio ER (Cardizem LA®) Social Socialol Aff Timotol Maleate Timotol Maleate Inicidine ER Nilecidine ER Nilecid	el Biockers ation inhibitors NTS, INJECTABLES		Propranolol XL (Innopran XL®)	en e
el Blockers Electrical (Carego) Esteration Esterati	el Blockers ation inhibitors nTS, INJECTABLES	***************************************	ORIGINAL SOR MANUSCONING FROM AND THE TOTAL SOR AND THE PROPERTY OF AN ARCHITECTURAL ARCHITECTURAL SOR AND THE SOR	pares bregging of part, third a text bregging a materia, included district of a detection of the bytest of the last
Carvediol (Coreg®) Labetaiol Metoproiol Tartate Metoproiol XL (Toprol XL®) Nadolol Propranolol LA (Inderal LA®) Sotalol AF Timolol Maleate Timolol Maleate Dilliazem ER (Cardizem LA®) Sotalol AF Timolol Maleate Nicadipine ER Eledopine ER Nicadipine SN (Dynacirc CR®) Nicadipine Sula®) Verapamil ER (Verelan PA®) Verapamil ER (Verelan PA®) Verapamil Verapamil ER (Verelan PA®) Verapamil SR Nicadipine Sula®) Nicadipine Sula®) Verapamil Verapamil Cregmin®) Enocapamil Cregmin®) Enocapamin (Cregmin®) Enocapamin (Cregmin®) Enocapamin (Cremtox®) Fondapaminux (Arixtra®)	SREGATION INHIBITORS atlon Inhibitors NTS, INJECTABLES	porolol Fumarate	A CONTRACTOR OF THE PROPERTY O	And and a first a special poly of many special special poly of the special spe
Metoprolol Tartate Metoprolol Tartate Metoprolol Tartate Metoprolol Tartate Metoprolol Metoprolol Proplanolol Proplanolol Proplanolol Proplanolol Aff Timolol Maleate Timolol Maleate Dilliazem BR Reducione ER Fetodipine ER Fetodipine ER Insadipine SR (Dynaciro CR®) Nifedipine BR Insadipine SR (Ponaciro CR®) Nifedipine BR Ni	el Blockers ation Inhibitors NTS, INJECTABLES	vedilol (Coreg®)	THE PROPERTY OF THE PROPERTY O	of Abstract of Superior of Decimal Confession of publication of the Confession of th
Metoprolol Tantale Metoprolol Tantale Metoprolol XI, (Toprol XI.@) Naciolol Propranolol LA (Inderal LA®) Sotalol Bilitazem Dilitazem ER Felodipine ER Isradipine ER Nicardipine ER Nicardipine ER Nicardipine ER Nicardipine ER Nicardipine ER Nicardipine (Suar®) Verapamil SR Verapamil SR Verapamil SR Dilitazem Colological (Plavix®) Dipyridamole ER (Aggenox®) Dipyridamole Dipyridamole Dipyridamole Dipyridamole Dipyridamole Dipyridamole Dipyridamole Dipyridamole Fenosaparin (Lovenox®)	el Blockers ation Inhibitors NTS, INJECTABLES	etalol	AND	or of characteristics where the first of the transfer of the t
Metoprolol XL (Toprol XL®) Madolol Pindolol Propranolol LA (Inderal LA®) Sotalol AF Timolol Maleate Timolol Maleate Dilliazem ER (Cardizem LA®) Neardpline ER (Marchine ER (Marchin	el Blockers ation inhibitors NTS, INJECTABLES	oprolol Tartrate	THE CHARGE CHARGE OF THE CHARGE CHARG	an province of the last of the
NREGATION INHIBITORS AspirinDipyridamole ER (Aggrenox®) Frogramin (Fragamine) Fredamine ER (Cardizem LA®) Dillazem ER (Cardizem LA®) Dillazem ER (Cardizem LA®) Dillazem SR Fedolpine ER Isradipine ER Isradipine ER Inschipine ER Inschip	el Blockers ation inhibitors ation inhibitors NTS, INJECTABLES	oprolol XL (Toprol XL®)		na bodo dena zazura bandon estana
Production Programotor Angular Programor Ang	el Blockers atlon Inhibitors NTS, INJECTABLES	10101	THE PROPERTY OF THE PROPERTY O	o de la company de la comp
Propranolol Propranolol Propranolol Propranolol Populolol Populolol Populolol Populolol Populolol Populolol Populolol Populolo Per Imalolo Maleade El Blockers Dilliazem ER (Cardizem LA®) Dilliazem SR Federic RR (Cardizem LA®) Dilliazem SR Federic RR Federic RR (Paralpine BR Isradipine SR (Dynacirc CR®) Nicardipine SR (Dynacirc CR®) Nicardipine RR (Nerelan PM®) Verapamil ER (Verelan PM®) Verapamil SR (Spenox®) Verapamil SR (Spenox®) Dipyridamole ER (Aggrenox®) Enoxaparin (Fragmin®) Frondaparinux (Arixtra®) Frondaparinux (Arixtra®) Frondaparinux (Arixtra®)	el Blockers RREGATION INHIBITORS ation Inhibitors NTS, INJECTABLES	1010I	TO THE PROPERTY OF THE PROPERT	s der standur of efficientes endazindes sammions de sammions de sammer de sammer y sur juite des besteuns
Station Solution (LA (Inderal LA®) Solution (Solution AF Timolol Maleate Timolol Maleate Dilitazem ER (Cardizem LA®) Dilitazem ER (Cardizem LA®) Dilitazem SR Felodipine ER Isradipine ER Isradipine RN Nisradipine ER Nisradipine RN N	el Blockers ation inhibitors NTS, INJECTABLES	oranie in weight in the contract of the contra	MENINDA PARIODA ANTICONA ANTICONA PROPERTY OF THE CONTROL OF THE C	Afferensiele wellegen verenzijink den rizijin koddunum jesty samikin karman je jet den, a zigas;
Station AF Timolol Maleate Station AF Timolol Maleate Dilitazem ER (Cardizem LA®) Oilitazem SR Feodopine ER Isradipine SR (Dynacirc CR®) Nicadipine SR (Dynacirc CR®) Nicadipine SR (Dynacirc CR®) Nicadipine SR (Perelan PM®) Verapamil SR Verapamil SR Verapamil SR Verapamil SR Verapamil SR Oilpyridamole ER (Aggrenox®) Ciopidogrel (Plavix®) Dipyridamole Dipyridamole Enoxeparin (Fragmin®) Frondeparinx (Arixtra®) Frondeparinx (Arixtra®)	el Blockers ation inhibitors ation inhibitors NTS, INJECTABLES	oranolol LA (Inderal LA®)	THE PROPERTY AND	alah misat datan bersasalan misakkasan sa sa atau datan datan datan datan datan datan da sa sa sa sa sa sa sa
Sotatol AF Timolol Maleate Timolol Maleate Dilitazem ER (Cardizem LA®) Dilitazem SR Elodiphie ER Isradiphie SR (Dynacirc CR®) Nicadiphie ER Ni	ation inhibitors NTS, INJECTABLES	Notices to the second plant was to the second part of the second part	THE STREET CANDELLINES TO A STREET OF THE ST	department of the second about the contribution of the second of the sec
Innoid Maleate Innoid Maleate Diliazem Diliazem SR Diliazem SR Diliazem SR Felodipine ER Isradipine SR (Dynacirc CR®) Nicadipine ER	REGATION INHIBITORS ation Inhibitors NTS, INJECTABLES	alol AF	· 1945年,194	A CHAIRMAN AND A GARAGE LANGE AND A CHAIRMAN A CHAIRMAN AND AND AND AND AND AND AND AND AND A
Blockers Dilitazem Dilitazem Dilitazem Dilitazem SR Felodipine ER Isradipine SR (Dynacirc CR®) Nicrdipine Nicrdipine Nicrdipine Nicrdipine ER Nisoldipine (Suar®) Verapamil ER (Verelan Plw®) Verapamil SR Nisoldipine (Suar®) Verapamil SR Verapamil SR Dipyridamole ER (Aggrenox®) Clopidogrel (Plavix®) Dipyridamole Dipyridamole Enoxaparin (Lovenox®) Fondaparinux (Arixtra®) Fondaparinux (Arixtra®)	el Blockers SREGATION INHIBITORS ation inhibitors NTS, INJECTABLES	olo Malaata	A COMMINION OF THE PROPERTY OF	A VALUE OF WAS A SECURIAL WAY AND SECURITIES OF THE SECURITIES OF
Blockers Dilitazem ER (Cardizem LA®) Dilitazem SR Felodipine ER Isradipine SR (Dynactrc CR®) Niedipine BR Ni	el Blockers SREGATION INHIBITORS ation inhibitors NTS, INJECTABLES		《 A STATE OF THE	energies en comparte de la communication de la communication de la comparte de la comparte de la comparte de l
Dilitazem ER (Cardizem LA®) Dilitazem SR Dilitazem SR Felorigine ER Isradiplne SR (Dynacirc CR®) Nicardiplne Nifediplne ER Nicardiplne Nifediplne (Sular®) Verapamil ER (Verelan PM®) Verapamil SR Nicardiplne Nifediplne (Sular®) Verapamil SR Nicardiplne Dipyridamole ER (Aggrenox®) Clopidogrei (Plavix®) Dipyridamole Encapagini (Fragmin®) Encapagini (Fragmin®) Fondaparinux (Arixtra®) Fondaparinux (Arixtra®)	ation inhibitors NTS, INJECTABLES			
Dilliazem SR Felodigine ER Isradigine SR (Dynacirc CR®) Nicadigine SR (Stata®) Nicadigine SR (Verelan PM®) Verapamil ER (Verelan PM®) Verapamil SR Verapamil SR Ciopidogiel (Plavix®) Dipyridamole Ciopidogiel (Plavix®) Dipyridamole Enoxaparin (Fragnin®) Enoxaparin (Lovenox®) Fondaparinux (Arixta®)	RREGATION INHIBITORS atlon Inhibitors NTS, INJECTABLES		Amindinine (Nonzeer®)	AAT, MINISTERATURE AND
Interdiptine ER Felodiptine ER Isradiptine SR (Dynacinc CR®) Nicardiptine Niterdiptine ER Niteriptine (Sular®) Verapamil ER (Verelan PM®) Verapamil SR Verapamil SR Verapamil SR Verapamil SR Verapamil SR Dipyridamole ER (Aggrenox®) Dipyridamole Dipyridamole Encapaparin (Fragmin®) Encapaparin (Fragmin®) Encapaparin (Fragmin®) Fondaparinux (Arixtra®)	REGATION INHIBITORS ation inhibitors NTS, INJECTABLES		eradicina (Dynaelre ID®)	African construction of the second construction
REGATION INHIBITORS NITS, INJECTABLES Dalteparin (Fragmin®) NIS, INJECTABLES Dalteparin (Fragmin®) Enoxaparin (Fragmin®) Dipyridamole Dipyridamole Ciopidogrei (Plavix®) Dalteparin (Fragmin®) Enoxaparin (Fragmin®) Enoxaparin (Fragmin®) Enoxaparin (Arixtra®)	SREGATION INHIBITORS ation inhibitors NTS, INJECTABLES	С. D.	licardialno CD (Cardono CD®)	
Isracipine SR (Dynacirc CR®) Nicardipine Nicardipine ER Nerapamil ER (Vereian PM®) Verapamil SR Sepirin/Dipyridamole ER (Aggrenox®) Ciopidogrei (Plavix®) Dipyridamole Ciopidogrei (Plavix®) Dalleparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®) Fondaparinux (Arixtra®)	REGATION INHIBITORS ation inhibitors NTS, INJECTABLES	Vertender (Account of the second of the seco		
Nitedipline Nitedipline Nitedipline Nitedipline ER Nitedipline Nitedipline ER Nitedipline Nitedipline ER Nitedipline	ation inhibitors NTS, INJECTABLES	Discolar Colon		en e
Nitedipine ER Nitedipine ER Nisoldipine (Sular®) Verapamil ER (Verelan PM®) Verapamil SR Aspirin/Dipyridamole ER (Aggrenox®) Clopidogrei (Plavix®) Dipyridamole Dipyridamole Dipyridamole Fondaparinux (Arixtra®) Fondaparinux (Arixtra®)	REGATION INHIBITORS ation inhibitors NTS, INJECTABLES	n (Dynaciic Che)		and design the second of the second s
Nitedipine ER Nisolipine (Sular®) Verapamil ER (Verelan PM®) Verapamil Verapamil SR Aspirin/Dipyridamole ER (Aggrenox®) Clopidogrei (Plavix®) Dipyridamole Dipyridamole Enoxaparin (Fragmin®) Fondaparinux (Arixtra®)	SREGATION INHIBITORS ation inhibitors NTS, INJECTABLES	ITOIDINE	AN COLUMN DESCRIPTION OF DESCRIPTION OF THE PROPERTY OF THE PR	-
Nisotipine ER Nisotipine (Sula®) Verapamil ER (Verelan PM®) Verapamil SR Verapamil SR Verapamil SR Aspirin/Dipyridamole ER (Aggranox®) Clopidogrei (Plavix®) Dipyridamole Dipyridamole Enoxaparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	REGATION INHIBITORS ation inhibitors NTS, INJECTABLES	dipine		Терат (ал артигрализманна удально вы Маваррой МДС засублерій полубуюю сублюбуюванда двергандля
Nisoldipine (Sular®) Verapamil ER (Verelan PM®) Verapamil SR Verapamil SR Aspirin/Dipyridamole ER (Aggrenox®) Clopidogrei (Plavix®) Dipyridamole Clopidogrei (Plavix®) Dipyridamole Enoxaparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	ation inhibitors TS, INJECTABLES	dipine ER	Мендей (д. д. усту,) посту мендей мендей (устуденский устанований и деней мендей и деней устуденский устанований устанований устанований устанований устуденский устанований	
Verapamil ER (Verelan PM®) Verapamil SR Verapamil SR Aspirin/Dipyridamole ER (Aggrenox®) Clopidogrei (Plavix®) Dipyridamole Dipyridamole Dipyridamole Enoxaparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	ation inhibitors ation inhibitors NTS, INJECTABLES	oldipine (Sular®)		
Verapamil SR Verapamil SR SREGATION INHIBITORS Aspirin/Dipyridamole ER (Aggranox®) Clopidogrei (Plavix®) Dipyridamole Dipyridamole Dipyridamole Dalteparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	SREGATION INHIBITORS ation inhibitors NTS, INJECTABLES	apamil ER (Verelan PM®)		
Nerapamil SR RREGATION INHIBITORS Clopidogre (Plavix®) Clopidogre (Plavix®) Dipyridamole Dipyridamole Dipyridamole Enoxaparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	REGATION INHIBITORS ation inhibitors NTS, INJECTABLES	pamil		
ation inhibitors Aspirin/Dipyridamole ER (Aggrenox®) Ciopidogrei (Plavix®) Dipyridamole Dipyridamole Dipyridamole Dipyridamole Dipyridamole Dipyridamole Finoxaparin (Fragmin®) Finoxaparin (Lovenox®) Fondaparinux (Arixtra®)	ATION INHIBITORS ation inhibitors NTS, INJECTABLES	apamil SR		
RREGATION INHIBITORS atlon Inhibitors Clopidogrei (Plavix®) Clopidogrei (Plavix®) Dipyridamole Dipyridamole Dipyridamole Encaparin (Fragmin®) Encaparin (Lovenox®) Fondaparinux (Arixtra®)	ation inhibitors ation inhibitors NTS, INJECTABLES			
Aspirin/Dipyridamole ER (Aggrenox®) Clopidogrel (Plavix®) Dipyridamole	ation inhibitors ation inhibitors NTS, INJECTABLES	об политично принципалний достигнува получений принципалний политичной получений получ		
Aspirin/Dipyridamole ER (Aggranox®) Clopidogrei (Plavix®) Dipyridamole Dipyridamole Dipyridamole Dipyridamole Dipyridamole Enoxaparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	ation inhibitors NTS, INJECTABLES			
ation Inhibitors Aspirin/Dipyridamole ER (Aggrenox®) Clopidogei (Plavix®) Dipyridamole Dalteparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	ation inhibitors NTS, INJECTABLES	A STATE OF THE PARTY AND	од 1992 до 1944 Ад од 1944 год да на усучение од достава на усучение на 1940 год на 1944 год од 1944 год 1944	CONTRACTOR OF CO
Aspirin/Dipyridamole ER (Aggrenox®) Ciopidogrel (Plavix®) Dipyridamole NTS, INJECTABLES Dalteparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	NTS, INJECTABLES	THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COL	reasson the statement of the distribution of the statement of the statemen	
Clopidogrei (Plavix®) Dipyridamole NTS, INJECTABLES Dalteparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	NTS, INJECTABLES	***************************************	iclopidine	
Dipyridamole NTS, INJECTABLES Dalteparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	NTS, INJECTABLES	oidogrel (Plavix®)		
NTS, INJECTABLES Dalteparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	NTS, INJECTABLES	ridamole	лан част балада (ден надаледында дарын арын меналанын дарын арын арын дарын дарын дарын дарын дарын дарын дарын	
Dalteparin (Fragmin®) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)	NTS, INJECTABLES	O promotor di protoco esta esta del protoco esta esta esta esta esta esta esta esta	ANY TRANSPORTED TO THE PROPERTY OF THE PROPERT	menta rapositiva kapanina rrop del mente fremnisti recompten produntaroppa menera
NIS, INJECTABLES Dalteparin (Fragmin®) Enoxaparin (Lovanox®) Fondaparinux (Arixtra®)	NIS, INJECTABLES	THE THE PROPERTY OF THE PROPER		AMERICA (Managedon) (Panderon) i dan (Managedon) (Mana
Ualeparin (Fragminė) Enoxaparin (Lovenox®) Fondaparinux (Arixtra®)		THE PARTY STREET AND THE PARTY	THE PARTY OF THE P	
			inzaparin (Innohep®)	the track and an existence of a many physicism work counts the pair this techniques of the commences of the counts
Fondsparinux (Arixita®)	Fondaparinux (Arixtra®)	xaparin (Lovenox®)		to the second of the second second content of the second of the second second second second second second second
		daparinux (Arixtra®)	та да серения для подряга до продения на принада на пределения на преде	A Prince to And A Mark State of State of State of Anderson and Anderson and Anderson and Anderson and Anderson
				VAN VARIANTE EN CONTRACTOR VAN
				erde bereicht beweichen der Abertaleichte der Bestellichte bestellt und der Bestellichte bestell
				AVORTONIA VALLANDO POR LA
		THE PROPERTY OF THE PROPERTY O		
		AND DESCRIPTION OF THE PROPERTY OF THE PROPERT	THE PROPERTY OF THE PROPERTY O	e anima an' amballa angka malaparanam mapa amim lair yi an' alay alay alay an' an' an' an' an' an' an' an' and
		ALI PARTE PA	ALTERNATURA PARAMANA MARIAM MARIAM MARIAMANANANANANANANANANANANANANANANANANANA	, milet (company) de la company a company a man de la company de la comp
	10000000000000000000000000000000000000	THE STATE OF THE PROPERTY OF T	ТОЛУТИКИ ТОЛЬКОН НЕТИДИНИМИКИМИЛИ МИДИНИМИКИМИКИМИКИМИКИМИКИМИКИМИКИМИКИМИКИМ	PRESENTATION CONTRACTOR AND
	THE PROPERTY OF THE PROPERTY O	THE THE PROPERTY OF THE PROPER	TO THE POPULATION OF THE PROPERTY OF THE PROPERTY OF THE POPULATION OF THE POPULATIO	
	RESIDENT STATES AND ADDRESS OF THE PROJECT AND ADDRESS OF THE PROJECT OF THE PROJ	THE PROPERTY OF THE PROPERTY O	THE PROPERTY OF THE PROPERTY O	

2/20/2006

12 HEMATOLOGIC AGENTS HEMATOPOIETIC AGENTS Erythropoletins Anticoagulants - refer to HEART DISEASE			を記する場合に対象を対象がある。これを対象を対象を対象を
Erythropoletins Erythropoletins Anticoagulants - refer to HEART DISEASE	· 中国,一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个	TO STATE OF THE ST	
Anticoagulants - refer to HEART DISEASE	Epoetin alfa (Procri®)	Epoetin alfa (Epogen®)	
Anticoagulants - refer to HEART DISEASE	Uaroepoeur aria (Aranespe)		والمعار المعار والمعار
HEAR UISEASE	TO THE THE PARTY OF THE STATE OF THE PARTY O		A PARTICIPATION OF THE PARTICI
and contention of the state of		eringi (Aradanista) mine kama yang man di kamana apini di katan ining sejamini kepaman dan mana kamana penganan dan manang menganan dan manang menganan dan mengan Menganan dan menganan da	A-VANCOURANT MANAGEMENT COLOR CONTRACTOR CON
-		の できまっています (日本の) 日本の) 日本の (日本の) 日本の (日本の) 日本の (日本の) 日本の) 日本の) 日本の) 日本の) 日本の) 日本の) 日本の)	AND AND THE PROPERTY OF THE PARTY AND THE PARTY AND THE PARTY OF THE P
13 HEMODIALYSIS			AND THE REAL PROPERTY OF THE P
Phosphate Binders	Calcium Acetate (PhosLo®)	Magnesium Carbonate, Calcium Carbonate, Folic Acid (Magnebind 400 Rx)	
	Lanthanum (Fosrenol®) Sevelamer (RenaGel®)		
14 HORMONE THERAPY			
Combination Estrogen Agents	176-Estradiol/Norethindrone Acetate (Activella®)	17B-Estradiol/Levonorgestrel (Climara Pro®)	***************************************
нентельника профессиональная пределения пределения пределения пределения пределения пределения пределения пред	178-Estradiol/Norethindrone Acetate (CombiPatch®)		
terini dende interinterinterinterinterinterinterinter	Conjugared Campain (Chino-Fieles)	and the control of th	
	CONJUGATED L'ESTUGETTS TRECTONY progesterone recetted Consense (Parthy Estration/Norethindrone Acetale (Fembria))		
			Abother and company of the company o
HYPERLIPIDEMIA - REFER TO HEART DISEASE	36		
IMMUNE DISORDERS - REFER TO MULTIPLE			***************************************
INFECTIOUS DISORDERS	ones consumerations and the construction of th		eren armen desercità delercit padite deserbad sessada emercate presentative
Cephalosporin and Related	Amoxicilin/Clavulanate Suspension	Centalexin (Panixine)	
Antiblotics	Amoxicillin/Clavulanate XR (Augmentin XR®)	Loracarbef (Lorabid®)	aternament constitution of the Articles of the
	Ceftibuten (Cedax®)		AND THE PROPERTY OF THE PROPER
	Cefaclor		
	Cefaclor ER	***************************************	***************************************
	Cefadroxil Monohydrate		***************************************
***************************************	Cefditoren Pivoxil (Spectracef®)		
	Cefixime (Suprax®)		
	Cefpodoxime Proxetil	es para de la compansión de la manesta de compansión de co	is a fore constitution of the state of the s
	Cefprozil (Cefzil®)		
WARANIA MAKEE BUREEL BUREEL BUREEL MAKEEL MAKEEL BUREEL BUREE	Cefuroxime axetil		
AND THE PROPERTY OF THE PROPER	Cephalexin		
ARTINI AR	андар жана жана жана жана жана жана жана жа		a ben en alle de la companya de la completa de la completa de la companya de la companya de la companya de la c
тара стана, правинеродинено обезнова почина обезностоя почина поч			e de la company de semant de semant de semant proprieta de servicio de sente de la company de semant de la comp La company de semant
minima principali menina piama principana proportamente proportamente de menina de la menina del menina de la menina della	emen den en e	AND THE PROPERTY OF THE PROPER	T SPRE PARTS FOR SCHOOL PROTECTION AND AND AND AND AND AND AND AND AND AN
			e de la companya de La companya de la co
			ere e distantiaminate emisso antono esta de la composição de la composição de la composição de la composição d
time the second			
Ментен такен барақты ең бетіне берекен берекен терекен терекен берекен жерекен берекен беретіне берекен береке	THE PROPERTY OF THE PROPERTY O	THE PARTY OF THE P	
Burderson and "Marines of France and Anthropic Control of Control	THE PROPERTY OF THE PROPERTY O	VIANO ARTA MARKATANA MANAYANA MANAYANIANAYIMI ARTA MINI ARTA MINI ARTA MINI ARTA MANAYANI ARTA ARTA ARTA ARTA ARTA ARTA ARTA ART	TANAMATAN MANAMATAN PARTITION (ANTINOMANAMATAN PARTITION PARTITION PROPERTY ANTINOMANAMATAN PARTITION PART

Interpretation of Control of Co				
Fluoroquinolones Ciprofloxacin	Fluoroquinolones	ORAL		
Monitonacin (Avelox®)		-	Circles Control Contro	AND
Peginterferon alia 2A (Pegasya) Peginterferon alia 2B (Peg-Intron 0) Ribavin (Copegus®) Ribavi		(Moxifloxacin (Avelox®)	Ciprofloxacin FR (Progula XR®)	
Peginterferon alfa 2A (Pegasys ®) Peginterferon alfa 2B (Peg-intron ®) Ribavirin (Copegus®) Ribavirin (Copegus®) Ribavirin (Copegus®) Ribavirin (Catelol®) Ribavirin (Catelol®) Ribavirin (Catelol®) Carithromycin Et (Blaxin XL®) Erythromycin Stearate Erythromycin Estolate Erythromycin E		Offoxacin	Ciprofloxacin Suspension (Ciprofl)	of each in his sequence of management with a service of the second of management of the second of the second of
Hepatitis C Agents Peginterferon alia 2A (Pegasya ©) Peginterferon alia 2B (Peg-Intron ©) Peginterferon alia 2B (Peg-Intron Redipen®) Ribawirin (Copegus®) Ribawirin (Copegus®) Ribawirin (Cathromycin (Zithromax®) Carithromycin (Zithromax®) Carithromycin ER (Blaxin XL®) Erythromycin Sarate Erythromycin Elevisarie Erythromycin Elevisarie Erythromycin Elevisarie Coltrinazole Erythromycin Elevisarie Erythromycin Elevisarie Coltrinazole Erythromycin Elevisarie Ribawirin (Mycostalin Pasillies®) Terchinafine (Lemisli®)			Gatifloxacin (Tequin®)	
Hepatitis C Agents Peginterferon alia 2A (Pegasys ©) Peginterferon alia 2B (Peg-Intron ©) Peginterferon alia 2B (Peg-Intron ©) Peginterferon alia 2B (Peg-Intron ©) Ribawinin (Copegus©) Ribawinin (Copegus©) Ribawinin (Copegus©) Ribawinin (Capegus©) Ribawinin (Rabeio) Ripaminin (Rabeio) Ribawinin (Rabeioo) Ribawinin (Rabeiooo) Ribawinin (Rabeioooo) Ribawinin (Rabeioooo) Ribawinin (Rabeioooooooooooooooooooooooooooooooooooo			Gemifloxacin Mesylate (Factive®)	errorren error derri derri errorre erro error error errorren errorren errorren errorren errorren errorren erro
Hepatilis C Agenis Peginteriorn alia 2A (Pegasys ®) Peginteriorn alia 2B (Peg-Intron Redipen®) Reprinderiorn alia 2B (Peg-Intron Redipen®) Ribavirin (Capegus®) Ribavirin (Capegus®) Ribavirin (Rabetol®) Ribavirin (Capegus®) Ribavirin (Capeg			Levofloxacin (Levaquin®)	
Hepatitis C Agents Peginterferon alia 2A (Pegasys®) Peginterferon alia 2B (Peg-Intron®) Ribavvini (Copegus®) Ribavini (Copegus®) Ribavini (Copegus®) Caritromycin ER (Biaxin Xi.®) Caritromycin ER (Biaxin Xi.®) Caritromycin ER (Biaxin Xi.®) Caritromycin Ex (Biaxin Xi.®) Caritromycin Erytromycin		н жана жана жана жана жана жана жана жа	Lomefloxacin (Maxaquin®)	
Hepatitis C Agants Peginierteron alia 28 (Pegasys ©)	THE OF THE PROPERTY OF THE PRO		Norfloxacin (Noroxin®)	
Peginterieron alfa 28 (Peg-intron 6) Peginterieron alfa 28 (Peg-intron Redipene)	Hepatitls C Agents	Peginterferon alfa 2A (Pegasys®)	Interferon affacon-1 (Inferrence)	me of the man many processed occurrency was made an extension of processes around an extension () of
Peginterfaron alfa 28 (Peg-Intron Recipen®) Ribavrinn (Cobegus®) Ribavrinn (Cobegus®) Ribavrinn (Cobegus®) Ribavrinn (Cobegus®) Ribavrinn (Calmitronnychen ER (Blaxin XL®) Calmitronnychen ER (Blaxin XL®) Erythronnychen ER (Blaxin XL®) Erythronnych	AND THE PROPERTY OF THE PROPER	Peginterleron alfa 28 (Peg-Intron®)	Ribavirin	ter seem states a transfer property and the states and the seems of the special property and the seems and the
Ribavirin (Copegus®) Ribavirin (Copegus®)		Peginterferon alfa 2B (Peg-Intron Redipen®)		eres de la composition della c
Macrolides Azilhromycin (Zithromax®) Macrolides Azilhromycin (Zithromax®) Clarithromycin Elevator Erythromycin Estolate Erythromycin		Ribavirin (Copegus®)	A CONTRACTOR OF THE PROPERTY O	
Macrolides Azithromycin (Zithromax®) Clarithromycin (Sithromax®) Clarithromycin Siteariae Erythromycin Basse Erythromycin Estolate		Ribavirin (Rebetol®)		
Clarithromycin ER (Blaxin XL®)	Macrollas	Azithromocin (Zithromax®)	Talithromodia (Katak®).	
Clarithromycin ER (Blaxin XL®)	AAN TENENT TO AND THE PROPERTY OF THE PARTY	Clothromism	The second secon	tod fundament depen symbolish (spiritessampenspersons) same that top annual see some where to annual and
ANTIFUNGALS Antifungals, Oral Antifungals, Oral Antifungals, Crafe Below (Lamisil®) MULTIPLE SCLEROSIS Multiple Sclerosis Agents Interferon beta - 1a (Akonex®) Interferon beta - 1a (Rebit®)	**************************************	Claring Commence of the Commen	THE CONTRACT PROPERTY AND AND A STATE OF THE CONTRACT AND	er of Arthurs Ary Arthurs and Arthurs Arthurs and the second and and any any any and any
ANTIFUNGALS Griscotluvin (Gris-Peg®) Ilraconazole Fluconazole Fluc	ANA SHEETAN, DO SHEETAN SHEETAN SHEETAN SHEETAN SHOWNER SHOWNERS S	Calumoni Calaman Calam		e proposition of the country to the last of the plane of the country of the country (and the country to country to country to the country to
ANTIFUNGALS ANTIFUNGALS Antifungals, Oral Antifungals	AND THE PROPERTY OF THE PROPER	Elymonia de la	AND MAKES AND	
Erythromycin Estolate Erythromycin Ethylsuccinate	The second law and desired the second	ETYINTOMYCIN BASE	WAS THE OF THE PROPERTY OF THE	
ANTIFUNGALS Antifungals, Oral Griseofulvin Suspension Griseofulvin Suspension Griseofulvin Gris-Peg®) Irraconazole Fluconazole Fluconazole Ketoconazole Ketoconazole Ketoconazole Nystatin Nystatin Nystatin Nystatin Nystatin Irraconazole Fluconazole Fluconazole Fluconazole Fluconazole Fluconazole Irraconazole Irraconazole Irraconazole Multiple Sclerosis Agents Interferon beta - 1a (Avonex®) Interferon beta - 1a (Rebif®) Interferon beta - 1a (Rebif®)		Enylinemycin Estolate		
OPHTHALMIC ANTIBIOTICS - refer to OTIC ANTIBIOTICS - refer to OTIC Agents Antifungals, Oral Antifungals, Oral Griscolulin Suspension Griscolulin Suspension Griscolulin Gris-Peg®) Inconazole Fluconazole Fluconazole Ketoconazole Fluconazole Ketoconazole Fluconazole Nystatin Nystatin Nystatin Nystatin Interferon beta - 1a (Avonex®) Interferon beta - 1a (Rebit®) Interferon beta - 1a (Rebit®) Interferon beta - 1a (Rebit®)		Erymomycin Emylsuccinate	HA (PERSON PROPERTY OF THE PRO	
ANTIFUNGALS ANTIFUNGALS Antifungals, Oral Antifungals, Oral Antifungals, Oral Antifungals, Oral Antifungals, Oral Griseofulvin Suspension Griseofulvin Gris-Peg@) Irraconazole Fluconazole Ketoconazole Irraconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Interferon beta - 1a (Avonex®) Interferon beta - 1a (Rebif®) Interferon beta - 1a (Rebif®)				
ANTIFUNGALS Antifungals, Oral Antifungals, Oral Antifungals, Oral Griseofuvin (Gris-Peg®) Itraconazole Fluconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Ketoconazole Terbinafine Nystatin Nystatin Nystatin Nystatin Interferon beta - 1a (Avonex®) Interferon beta - 1a (Rebi®) Interferon beta - 1a (Rebi®)	OPHTHAI MIC ANTIBIOTICS - refer to	под в потем в потем об применения в подованения на подованения подованения в подованен		
ANTIFUNGALS Antifungals, Oral Antifungals, Oral Giseofulvin Suspension Griseofulvin Suspension Griseofulvin Gris-Peg®) Ilraconazole Fluconazole Ketoconazole Ketoconazole Ketoconazole Nystatin Nystatin Nystatin Nystatin Nystatin Nystatin Nystatin Interferon beta - 1a (Avonex®) Interferon beta - 1a (Rebif®) Interferon beta - 1a (Rebif®)	OTO A OTTO A STATE OF THE STATE	or of the second control of the second contr	· 有一种,一种,一种,一种,一种,一种,一种,一种,一种,一种,一种,一种,一种,一	ment of security to the second second of the
ANTIFUNGALS Antifungals, Oral Griseofulvin Suspension Griseofulvin (Gris-Peg®) Griseofulvin (Gris-Peg®) Griseofulvin (Gris-Peg®) Itraconazole Fluaconazole Fluconazole Fluco				emeker, ima an yan manasa saan saan saan saan saan saan
Antifungals, Oral Griseofulvin Suspension Griseofulvin (Gris-Peg®) Ilraconazole Fluconazole Fluconazole Ketoconazole Nystatin Nystatin Nystatin Nystatin Nystatin Nystatin Interferon beta - 1a (Avonex®) Interferon beta - 1a (Rebit®) Interferon beta - 1a (Rebit®)	ANTIFUNGALS	AND THE PROPERTY OF THE PROPER		ere de la comparta d
Griseofulvin Suspension Griseofulvin (Gris-Peg®) Itraconazole Fluconazole Fl	Antifungals, Oral	Clotrimazole	Flucytosine (Ancobon®)	direct district of A valuable decreases resolute (statement and and dispetation decreases and a
Griseofuvin (Gris-Peg®) Ilraconazole Fluconazole Ketoconazole Ketoconazole Nystatin (Mycostatin Pastilles®) Terbinafine (Lamisil®) Terbinafine (Lamisil®) Interferon beta - 1a (Avonex®) Interferon beta - 1a (Rebif®) Interferon beta - 1a (Rebif®)	And the second s	Griseofulvin Suspension	Greenfully (Gift Ilvin VII)	يعوب ويستوي والمهام والمستوام والمراورة والمراوة والمراوة والمراوة والمراوة والمراوة والمراوة والمراوة والمراوة
Itraconazole		Grissofiskin (Gris-Doo@)	Vodeserale (VERID)	
Fluctoriazole Fluctoriazole Fluctoriazole Ketoconazole Nystatin N	The second secon	Oliscolul (Olis-Tego)	VUICUIIAZUIA (VEEND)	STOP CONTROL AND CONTROL PROPERTY OF CONTROL AND CONTROL OF CONTRO
Ketoconazole	THE CONTRACT OF THE PROPERTY O	- I'll acollaton	an teles in the Contract of th	THE REPORT OF THE PARTY OF THE
Nystatin (Mycostafin Pastilles®) Nystatin (Mycostafin Pastilles®) Terbinafine (Lamisil®) Terbinafine (Lamisil®) MuLTIPLE SCLEROSIS Interferon beta - 1a (Avonex®) (Immunomodulatory Agents) Interferon beta - 1a (Rebif®)	With the second	FIUCONAZOIG	AND ASSESSMENT OF THE PROPERTY	
Nystatin Nystatin (Mycostatin Pastilles®) Terbinafine (Lamisil®) Terbinafine (Lamisil®) MULTIPLE SCLEROSIS Interferon beta - 1a (Avonex®) Interferon beta - 1b (Betaseron®) Interferon beta - 1a (Rebit®)		Ketoconazole		
Nystatin (Mycostain Pasilles®) Terbinafine (Lamisi®) MULTIPLE SCLEROSIS Interferon beta - 1a (Avonex®) Multiple Scierosis Agents Interferon beta - 1a (Rebit®) (Immunomodulatory Agents) Interferon beta - 1a (Rebit®)	терен у предеринентуру развитеру развитеру (предерие задене задене задене предерие денье развительной предерие	Wystall III		
MULTIPLE SCLEROSIS Interferon beta - 1a (Avonex®) Multiple Scierosis Agents Interferon beta - 1a (Rebit®) Interferon beta - 1a (Rebit®)	A debate and the contraction of	Nystatin (Mycostatin Pastilles@)	Vier (market and Melanter entre protestation of the Columbia desirable policy and the Columbia and the Colum	ender de se de
MULTIPLE SCLEROSIS Interferon beta - 1a (Avonex®) Multiple Sclerosis Agents Interferon beta - 1b (Betaseron®) (immunomodulatory Agents) Interferon beta - 1a (Rebif®)	mainimineratumas etiminetalli jad kini imperioriste primeteletatud kristiani etiminerisiani olehani marinimine Antari imperiorista kristiani internationa kristiani internationa kristiani kantari internationa marinimineta	Terunian (Terunian)		en de Pareille en de pareille de pareille de pareille de la médica de des de la destace de la medica de pareil La companya de la companya de la companya de la companya de la medica de la companya de la companya de la comp
MULTIPLE SCLEROSIS Interferon beta - 1a (Avonex®) Multiple Sclerosis Agents Interferon beta - 1a (Rebit®) (Immunomodulatory Agents) Interferon beta - 1a (Rebit®)	-			annyana musenyana di katan di dana (nanyanyan di dana di dana dana dana dana dana d
(15)		Interferon beta - 1a (Avonex®)	Glatiramer (Copaxone®)	
(ts)	Multiple Sclerosis Agents	[Interferon beta - 1b (Betaseron®)		
	(Immunomodulatory Agents)	Interferon beta - 1a (Rebif®)		
				en la formación y commission en entre de la desta della dell
			ALTON PROPERTY AND THE	والمقادس وكالما والمتعدد المستحد المتعدد والمتعدد والمتعدد والمتعدد والمتعدد والمتعدد والمتعدد والمتعدد

Mainstit Conjunctivinis Comolor Sodium Consistent Control Sodium Consistent Control Sodium Consistent Control Sodium Consistent Control Co			April 1, 2006
Comparative Conjunctivities Comparative Solding Solding Epinasitive Hot (Elestate) Epinasitive Hot (Elestate) Lidepredroit (Attares) Lidepredroit (Attares) Lidepredroit (Attares) Intracoular Pressure (IOP) Betaxoloi (Betaxoloi (B		таманда та аңы каларын көрде адары, тарар кашарында өнкенде бакка каларында канарында керенде	
Epinastria H.O. (Episastal)	Allergic Conjunctivitis	Cromolyn Sodium	Azelastine Hydrochloride (Optivar®)
Network Tremstantine (Acutade)	ANALY DESIGNATE AND ANALY	Epinastine HCI (Elestat®)	Emedastine Difumarate (Emadine®)
Lubprachio (Alexe)	THE PROPERTY OF THE PROPERTY O	Ketorolac Tromethamine (Acular®)	Ketotifen Fumarate (Zaditor®)
Olopatadine Hydrochloride (Palanol®)		Loteprednol (Alrex®)	Lodoxamine Tromethamine (Alomide®)
Betaxolol Betaxolol		Olopatadine Hydrochloride (Patanol®)	Nedocromil Sodium (Alocril®)
Betavoid (Beloptic SØ) Birmonidine (Alphagan PØ) Dorzclamide (Timolo (Cosopia®) Lovobronoid Meliparanoid Pircapiam PØ) Dorzclamide (Timolo (Cosopia®) Timolo (Bellino®) Timolo Maleate Dorgova PØ) Timolo (Bellino®) Timolo Maleate Bellinos PØ) Timolo Maleate Dorgova PØ) Dorzclamide (Bellino®) Timolo Maleate Dorgova PØ) Dorzclamide (Bellino®) Timolo Maleate Dorgova PØ) Dorzclamide (Bellino®) Dorzcla			Pemirolast Potassium (Alamast®)
Betaxolof (Belopic S@) Betaxolof (Belopic S@)			
Bestavoid (Beoplic 59) Bestavoid (Beoplic 59)	Glancome Aceste		***************************************
Reducers Betavoiol (Beloptic S®)	Intraccular Droseura (IOD)	innertimentemmentemmentemmentemperature intermentemperature intermentemperature described palamentem intermentementemperature intermentemperature	Times and the second se
Brimonidine (Aphagan Pe)	Reducers	Betaxolof (Betonic S@)	Timoloi Maleate (Istaloiw)
Brimonidine Tartrate Brimonidine (Azopi®) Carteolo Carteolo Carteolo Carteolo Diczolamide (Azopi®) Carteolo Carteolo Diploefin Dorzolamide (Trusopi®) Dorzolamide (Trusopi®) Dorzolamide (Trusopi®) Dorzolamide (Trusopi®) Trimolo (Beltimol®) Becitracion (Toyanian®) Ciprofloxacin (Solidan Ciprofloxacin (Solidan Coloralyzin (Trimethoptim Solifacetamide Triple Antibolic Dolzanyzin (Trimethoptim Solifacetamide Triple Antibolic Triple Antibolic Dolzanyzin (Tricol®) Neomycin/Polymyxin/H.C Fluoroquinolones Ciprofloxacin/Dosamethasone (Ciprodax OTIC®) OSTEOPOROSIS Bone Resorption Suppression Alendronate (Fosamax Plus D®) Calcitorini-salmon (Mamin D3 (Fosamax Plus D®) Risedronate (Actone(®)) Risedronate (Actone(®)) Risedronate (Actone(®))	THE RESERVED AND ASSESSED AND ASSESSED	Rimonidae (Albanan Da)	
Carteolol Characterists Carteolor Cart	OFFICE AND THE PROPERTY	THE CONTROLL OF THE CONTROL	
Carteoid Car	A STATE OF THE STA	intermental control of the second control of	SANDY THE PROPERTY OF THE PROP
Optoverin Dorzolamide (Trusopt®) Louzolamide (Trusopt®) Louzolamide (Trusopt®) Louzolamide (Trusopt®) Louzolamide (Trusopt®) Louzolamide (Trusopt®) Trunolol Mateate Ilmiolol Mateate Bilmatoprost (Lumigan®) Travoprost (Travatan®) Travoprost (Travatan®) Bacitracin Bacitracin Coloxacin (Zyman®) Galtioxacin (Zyman®) Galtioxacin (Zyman®) Galtioxacin (Zyman®) Galtioxacin (Zyman®) Galtioxacin (Zyman®) Galtioxacin (Zyman®) Sulfacetamide Triple Antibolite Tobramycin Sulfate Neomycin/Polymyxin/HC (Pediotic®) Aldendronate (Fosamax®) Aldendronate (Fosamax®) Risedronate (Actone®) Risedronate (Actone®)	Amende sentimente de séries des pareces en entre de cabantes de cabantes construires de sentimentes de cabantes de	DIII KOI OILI OILI OILI OILI OILI OILI OI	ASSISTED PROPERTY AND THE PROPERTY OF THE PROP
Dorzolamide (Trusopk®) Levobunolol Melipranolo Pliocarpine Timolol Maleate Ciprofloxacin Solution Erythromycin Gentamicin Sulfate Ofloxacin Polymyxin/Trimethoprim Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide Timple Antibotitc Tobramycin/Collistin/Thonzonlum/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC Neomycin/Polymyxin/HC Neomycin/Polymyxin/HC Ofloxodin/Solin/Polymyxin/HC Neomycin/Polymyxin/HC Neomycin/Polymyxin/HC Ofloxodin/Solin/Triantedin(B) Neomycin/Polymyxin/HC Sulfacetamide Sulfac	DV VARRETAN ACREMINAN ACRE	or (1807) Olivianismenter of the contract of	APPRISED AND AND AND AND AND AND AND AND AND AN
Dorzolamide/Timolol (Cosopt®) Levobunolol Metipranolol Pilocarpine Timolol Maleate Bactiracin/Polymyxin Ciprofloxacin Solution Erythromycin Gatifloxacin Solution Erythromycin Gatifloxacin (Zymar®) Gentamicin Sulfate Oloxacin Dolymyxin/Timethoprim Sulfacetamide Timple Antibotic Tobramycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Aldendronate/Vitamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacatcin®) Risedronate (Actonel®)	er großen geweingen besonderwei feweinen (standene standene standen sich Weder before und der Landen sich der L	and we have the continues and	在我们的时候,我们就是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个
Levobunciol Metipranolol Metipranolol Metipranolol Timolo (Maleate Timolol Maleate Meditracin/Polymyxin Getipracin Getificacin (Zymar®) Meomycin/Polymyxin/HC (Peciotic®) Neomycin/Polymyxin/HC (Peciotic®) Neomycin/Polymyxin/HC Ciprofloxacin (Floxin OTIC®) Ofloxacin (Floxin OTIC®) Aldendronate (Fosamax Plus D®) Gacitlonin-salmon (Miacalcin®) Risedronate (Actonel®)		Corolamicania de la Corolamida Cimolo (Corolamia)	AN ATTENDATION OF THE PROPERTY
Metipranolol Pilocarpine Timolol (Beltimole) Timolol (Beltimole) Timolol Maleate Timolol Maleate Timolol Maleate Bimatoprost (Lunigan®) Travoprost (Travatan®) Travoprost (Travatan®) Travoprost (Travatan®) Bacitracin Bacitracin Bacitracin Ciprofloxacin Solution Erythromycin Erythromycin Catifloxacin (Zymar®) Gentamicin Sulfate Ofloxacin Polymyxin/Trimethoprim Sulfacetamicin Sulfate Triple Antibolite Triple Antibolit	(IAPPROPRIATE AND	innervanienten en e	
Pilocarpine Pilocarpine Pilocarpine Timolol (Betimol®) Timolol (Betimol®) Timolol Maleate Timolol Maleate Timolol Maleate Tavoprost (Turnigan®) Tavoprost (Tavatan®) Tavoprost (Tavatan®) Tavoprost (Tavatan®) Pacitracin/Polymyxin Ciprofloxacin Solution Erythromycin Ciprofloxacin (Zymar®) Gentamicin Sulfate Ofloxacin Polymyxin/Timethoprim Sulfate Triple Antibolitic Tobramycin/Polymyxin/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Ofloxacin (Floxin OTIC®) Ofloxacin (Floxin OTIC®) Ofloxacin (Floxin OTIC®) Calcitonin-salmon (Miacaicin®) Risedronate (Actonel®)		Matingan	,我们是一个,
Timolol (Bellimol®) Timolol Maleate Inhibitors Binatoprost (Lunigan®) Travoprost (Travatan®) Bacitracin Bacitracin Bacitracin Bacitracin Ciproffaxedin Solution Erythromycin Galifoxacin (Zymar®) Gentamicin Sulfate Ofloxacin Polymyxin/Trimethoprim Sulfacetamide Triple Antibotito Tobramycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC Neomycin/Polymyxin/HC Ciproffoxacin (Floxin OTIC®) Ofloxacin (Floxin OTIC®) Aldendronate (Fosamax Plus D®) Risedronate (Actonel®) Risedronate (Actonel®)		Pilocardine	, 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
Timolol Maleate	A THE PARTY AND ADDRESS OF THE PARTY AND ADDRE	Timolol (Belimol®)	作,我们是一个人,我们
Inhibitors Elimatoprost (Lumigan®) Travoprost (Travalan®)	AND THE RESIDENCE AND THE CONTRACT OF THE CONT	Timolo Malate	TO THE OWNER THE PROPERTY OF T
Inhibitors Bimatoprost (Lumigan®) Travoprost (Travatan®) Travoprost (Travatan®) Travoprost (Travatan®) Bacitracin Bacitracin Bacitracin Bacitracin Ciprofloxacin Solution Erythromycin Garitancin Sulfate Offoxacin Polymyxin/Trimethoprim Sulfacetamide Triple Antibolitic Tobramycin Sulfate Triple Antibolitic Tobramycin Sulfate Neomycin/Polymyxin/H.C (Pediotic®) Neomycin/Polymyxin/H.C (Pediotic®) Neomycin/Polymyxin/H.C (Pediotic®) Neomycin/Polymyxin/H.C (Pediotic®) Offoxacin (Floxin OTIC®) Offoxacin (Floxin OTIC®) Offoxacin (Floxin OTIC®) Calcitonin-salmon (Miacalcin®) Risedronate (Actone®) Ris	AREA CONTRACTOR OF THE CONTRAC		《日本》《《《《《《》》《《《》》《《》》《《》》《《》》《《》》《《》《》《》《》《
Travoprost (Travatan®) Bacitracin/Polymyxin Bacitracin/Polymyxin Ciprofloxacin Solution Erythromycin Gatifloxacin (Zymar®) Gatifloxacin (Zymar®) Garlamicin Sulfate Offeramicin Sulfate Offeramicin Sulfate Offeramicin Sulfate Offeramicin Sulfate Triple Antibolite Offeramycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Aldendronate (Foxamax®) Aldendronate (Foxamax®) Aldendronate (Foxamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actone(®))	Prostaglandin Inhibitors	Bimatoprost (Lumigan®)	Latanoprost (Xalatan®)
Bacitracin Bacitracin Bacitracin Bacitracin Bacitracin Bacitracin Bacitracin Bacitracin Bacitracin Ciprofloxacin Solution Erythromycin Catifloxacin (Zymar®) Gantamicin Sulfate Oloxacin Polymysin/Trimethoprim Sulfacelamide Triple Antibolitic Tobramycin/Polymysin/HC (Padiotic®) Neomycin/Polymysin/HC (Padiotic®) Neomycin/Polymysin/HC (Padiotic®) Neomycin/Polymysin/HC (Padiotic®) Alendronate (Floxin OTIC®) Offoxacin (Floxin OTIC®) Calcitonin-salmon (Miacaicin®) Risedronate (Actone®) Risedronate (Actone®	i defende den esta esta esta esta esta esta esta esta	Travoprost (Travatan®)	
Bacitracin Bacitracin Bacitracin Bacitracin Bacitracin Bacitracin Ciprofloxacin Solution Ciprofloxacin Solution Erythromycin Califloxacin (Zymar®) Gentamicin Sulfate Oloxacin Polymyxin/Trimethoprim Sulfacetamide Triple Antibotito Triple Antibotito Triple Antibotito Tobramycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC Ciprofloxacin/Dexamethasone (Ciprodex OTIC®) Offoxacin (Floxin OTIC®) Offoxacin (Floxin OTIC®) Aldendronate (Fosamax®) Aldendronate (Fosamax®) Risedronate (Actonet®) R			
Bacitracin/Polymyxin Ciprofloxacin Solution Erythromycin Galifloxacin (Zymar®) Gentamicin Sulfate Ofloxacin Polymyxin/Trimethoprim Sulfacetamide Triple Antibolitic Tobramycin Sulfate Neomycin/Polymyxin/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Alendronate (Fosamax®) Alendronate (Fosamax®) Aldendronate (Fosamax Plus D®) Calcitonin-salmon (Mlacalcin®) Risedronate (Actonel®) Risedronate (Actonel®)	Antibiotics, Ophthalmic	Bacitracin	Ciprofloxacin Ointment (Ciloxan®)
Ciprofloxacin Solution Erythromycin Galifloxacin (Zymar®) Gentamicin Sulfate Ofloxacin Polymyxin/Trimethoprim Sulfacetamide Triple Antibolitic Triple Antibolitic Tobramycin Sulfate Neomycin/Polymyxin/H.C (Pediotic®) Neomycin/Polymyxin/H.C (Pediotic®) Neomycin/Polymyxin/H.C (Pediotic®) Neomycin/Polymyxin/H.C (Pediotic®) Neomycin/Polymyxin/H.C (Pediotic®) Alendronate (Fosamax®) Alendronate (Fosamax®) Alendronate (Fosamax Plus D®) Calcitonin-salmon (Mlacalcin®) Risedronate (Actonel®) Risedronate (Actonel®)		Bacitracin/Polymyxin	Levofloxacin (Quixin®)
Erythromycin Galfloxacin (Zymar®) Gentamicin Sulfate Ofloxacin Polymyxin/Trimethoprim Sulfacetamide Triple Antibolitic Triple Antibolitic Triple Antibolitic Tobramycin Sulfate Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Alendronate (Fosamax®) Alendronate (Fosamax®) Ciprofloxacin (Floxin OTIC®) Calcitonin-salmon (Mlacalcin®) Risedronate (Actone®) Risedronate (Actone®)		Ciprofloxacin Solution	Moxifloxacin (Vigamox®)
Galifloxacin (Zymar®) Gentamicin Sulfate Officacin Polymyxin/Trimethoprim Sulfacetamide Triple Antibolite Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Alendronate (Floxin OTIC®) Calcitonin-salmon (Miacalcin®) Risedronate (Actone(®)) Risedronate (Actone(®))		Erythromycin	
Gentamicin Sulfate		Gatifloxacin (Zymar®)	
Polymyxid/Trimethoprim Polymyxid/Trimethoprim Sulfaceterine Triple Antibolite Triple Antibolite Triple Antibolite Triple Antibolite Tobramycin/Collstin/Thonzonlum/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC Neomycin/Polymyxin/HC Neomycin/Polymyxin/HC Neomycin/Doxamethasone (Ciprodex OTIC®) Ciprofloxacin (Floxin OTIC®) Aldendronate (Fosamax®) Aldendronate (Fosamax®) Risedronate (Actonel®) Risedronate (Actonel®)	то у мануну и поделений у деле в се од на косуменация делака, в выборива на манун и поделений поделений менена	Gentamicin Sulfate	
Polymyxin/Trimethoprim Sulfacelamide Triple Antibolitic Tobramycin Sulfate Tobramycin Sulfate Neomycin/Polymyxin/HC (Pediotic®) Alendronate (Fosamax®) Alendronate (Fosamax®) Alendronate (Fosamax®) Subpression Aldendronate (Fosamax®) Risedronate (Actonet®) Risedronate (Actonet®)	The state of the s	Offoxacin	THE CONTRACT OF THE CONTRACT O
Sulfacelamide Triple Antibolitic Tobramycin Sulfate Neomycin/Collstin/Thonzonlum/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Offloxacin/Dexamethasone (Clprodex OTIC®) Offloxacin (Floxin OTIC®) Aldendronate (Fosamax®) Aldendronate (Fosamax®) Calcitonin-salmon (Mlacalcin®) Risedronate (Actone®)	терифення (1 в 10 серен пеней севи на пред пенення положения положения положения положения положения положения	Polymyxin/Trimethoprim	
Triple Antibolitic Tobramydin Sulfate Tobramydin Sulfate Neomycin/Collstin/Thonzonlum/HC (Coly-Mydin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Ciprofloxacin/Dexamethasone (Ciprodex OTIC®) Ofloxacin (Floxin OTIC®) Alendronate (Fosamax®) Aldendronate (Fosamax®) Addendronate/Ntamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actone®)	од д дей у на д од отности потом на под долина нада е во нада в дей насте редисте ду с поста потом на темена ј	Sulfacetamide	AND THE PROPERTY OF THE PROPER
Tobramycin Sulfate Neomycin/Collstin/Thorzonlum/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Suppression (Ciprofloxacin/Dexamethasone (Ciprodex OTIC®) Ofloxacin (Floxin OTIC®) Alendronate (Fosamax®) Aldendronate (Fosamax®) Addendronate (Actonei®) Risedronate (Actonei®)		Triple Antibolitic	
Neomycin/Collstin/Thonzonlum/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC Second (Siprofloxacin/Dexamethasone (Ciprodex OTIC®) Ciprofloxacin (Floxin OTIC®) Alendronate (Fosamax®) Aldendronate (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actonel®)	тере калай бей перей дей (с деней паке реше й да деней теред да деней (с деней перед на перед на перед на пере	Tobramycin Sulfate	
Neomycin/Collstin/Thorzonlum/HC (Coly-Mycin S®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC S Ciprofloxacin/Dexamethasone (Ciprodex OTIC®) Ofloxacin (Floxin OTIC®) Alendronate (Fosamax®) Aldendronate (Fosamax®) Aldendronate/Nitamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actonel®)	OTIC AGENTS	терия деления д	
Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Neomycin/Polymyxin/HC (Pediotic®) Ciprofloxacin/Dexamethasone (Ciprodex OTIC®) Offoxacin (Floxin OTIC®) Alendronate (Fosamax®) Aldendronate (Fosamax®) Aldendronate/Nitamin D3 (Fosamax Plus D®) Calcitonin-salmon (Macalcin®) Risedronate (Actone®)	Antiblotics, Others	Neomycin/Collstin/Thonzonium/HC (Coly-Mycin S®)	Neomycln/Collstin/Thonzonium/HC (Cortisporin -
Suppression Alendronate (Fosamax®) Aldendronate (Fosamax®) Aldendronate (Actone®) Calcitonin-salmon (Macalcin®) Risedronate (Actone®)	energy to a tradition of the contract of the c	Naomining (Dadiotica)	
Suppression Ciprofloxacin/Dexamethasone (Ciprodex OTIC®) Ofloxacin (Floxin OTIC®) Alendronate (Fosamax®) Aldendronate/Niamin D3 (Fosamax Plus D®) Calcitonin-salmon (Macalcin®) Risedronate (Actone®)		Neomycin/Polymyxin/HC	
Suppression (Ciprofloxacin/Dexamethasone (Ciprodex OTIC®) Ofloxacin (Floxin OTIC®) Alendronate (Fosamax®) Aldendronate/Nitamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actone®)			THE PROPERTY OF THE PROPERTY O
Offoxacin (Floxin OTIC@) Suppression Alendronate (Fosamax®) Aldendronate/Nitamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actone®)	Fluoroquinolones	Ciprofloxacin/Dexamethasone (Ciprodex OTIC®)	Ciprofloxacin/Hydrocortisone (Cipro HC OTIC®)
Suppression Alendronale (Fosamax®) Aldendronale/Vitamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronale (Actonel®)	,我们就是我们的人,我们就是我们的人,我们就是我们的人,我们就是我们的人,我们就是我们的人,我们就是我们的人,我们就是我们的人,我们就是我们的人,我们就是我们的	Office and the control of the contro	
Suppression Alendronate (Fosamax®) Aldendronate/Ntamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actone®)	The second secon		
Alendronate (Fosamax®) Aldendronate/Ntamin D3 (Fosamax Plus D®) Calcitonin-salmon (Miacalcin®) Risedronate (Actonel®)	OSTEOPOROSIS		The second secon
Aldendronate/Vitamin D3 (Fosamax Plus D@) Calcitonin-salmon (Mlacalcin®) Risedronate (Actonel®)	Bone Resorption Suppression	Alendronate (Fosamax®)	Calcitonin - Salmon (rDNA origin) nasal spray (Fortical®)
Calcitonin-salmon (Mlacalcin®) Risedronate (Actonel®)	Agents	Aldendronate/Vitamin D3 (Fosamax Plus D®)	Elidronate (Didrone(®)
	M. FORTER PROFESSIONAL AND STRAIN STR	Calcitonin-salmo (Miacalcino)	bandronate Sodium (Boniva®)
	of Aventheavernment before the best and the second control of the	Risedronale (Actone®)	Raloxifone (Fvista®)
Teriparatide (Forteo)			Riserdronate w/ Calcium (Actonel w/ Calcium®)
			Teriparatide (Forteo)
	OF PRINCIPAL BERTON AL LABORITHM DANIES OF FRIENDS AND PRINCIPAL DANIES OF PRINCIPAL ACCUMENTATION OF THE PRINCIPAL ACCUMENT	THE PROPERTY OF THE PROPERTY O	AN AND THE PROPERTY OF THE PRO
	TERM AN PROPERTY OF THE WAR SERVING SERVING SERVING PROPERTY OF THE WAR AND TH		

.	Descriptive Therap	Drugs on PDL	Boue white! Regular PA	Effective Date:
				11,2006
77	PAIN MANAGEMEN	овенняя провом (предоставлення положент в положе	WERT THE PROPERTY AND ADDRESS	
-	Narcotics	Acetaminophen w/Codeine	Acetaminophen/Caffeine/Dihydrocodeine Bitartrate	
Total September		Acetaminophen w/Codelne (Capital w/Codelne®)	(Panlor DC®, Panlor SS®)	
		Aspirin w/Codeine	Fentanyl Citrate (Actiq®)	
***************************************		Belladonna & Opium	Fentanyl Transdermal (Generic)	
-	policy are more the many constant premium became the complete and the presentation of	Butalbital Compound w/Codeine	Morphine Sulfate ER (Avinza®)	
-	THE PROPERTY OF THE PROPERTY O	Butalbital/Caff/APAP/Codeine	Oplum Tincture	
************		Butalbital/Caff/ASA/Codeine	Oxycodone ER	
***************************************	THE PROPERTY OF THE PROPERTY O	Butorphanol Tartrate	Oxycodone (Oxycontin®)	
***************************************		Carisoprodol Compound/Codeine	Oxycodone/Ibuprofen (Combunox®)	To respond to the contract of
of the second for		Codeine Phosphate	Охутогрнопе (Numorphan®)	
OF STREET, ST.	денно да напримерующиму денно на дана на дана на напримента в на надажения на назажения и дужения да данамента	Codeine Sulfate	Propoxyphene Napsylate (Darvon-N®)	
-		Fentanyi Transdermal (Duragesic®) - Brand Only		
		Hydrocodone/Acetaminophen	一个 在 1985年	A NAME AND ADDRESS OF THE PARTY AND ADDRESS AND ADDRESS OF THE PARTY AND ADDRESS OF THE PARTY
		Hydrocodone/Acetaminophen (Maxidone@; Zydone@)	如果我们的,我们就是我们的我们,我们就是我们的我们,我们就是我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我们的我	Consessor on Principle Andreas and Aspenies by Consessor of the Consessor
		Hydrocodone Bitartrate/ibuprofen (Vicoprofen®)		And the state of t
		Hydromorphone HCL	THE PROPERTY AND ADMINISTRATION OF THE PROPERTY AND	Comment of the second of the s
-	STATES AND PROPERTY OF STATES AND	Meperidine HCL		-
-	ON THE STREET WAS STREET OF STREET O	Meperdine w/Promethazine	如果,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们就是一个,我们	
***************************************	WHOTH ANNIAND FOR SHEET WHEN THE SHEET WAS AND	Methadone HCL	TO THE PROPERTY OF THE PROPERT	The state of the s
-	FORMAL SERVICE PROPERTY OF THE STATE OF A STATE STATE OF THE STATE	Methadose	· · · · · · · · · · · · · · · · · · ·	
***************************************	· · · · · · · · · · · · · · · · · · ·	Morphine Sulfate (Oral)	THE PROPERTY OF THE PROPERTY O	The state of the s
***************************************	**************************************	Mornline Sulfate (Rectal)	如果,我们是一个时间,我们是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我	
***************************************	AND THE PROPERTY OF THE PROPER	Mornhine Sulfate ED (Kedlang)	A STATE OF THE THE WAS THE THE STATE OF THE	TO SHE THE POST THE PROPERTY HAS BEEN ASSESSED FOR THE POST OF THE
**********	Security to the security of th	Morbine Collete ID		An inches description of the part photos of the part o
		Authilite Sullate In	SECTION OF STREET,	A THE WAR A STATE OF THE BEAUTIME AND A STATE OF THE STAT
		Oxycadane HCL	THE PROPERTY OF THE PROPERTY O	THE ANGEST CONTINUES OF THE PARTY OF THE PAR
***************************************	The second personal second sec	Oxycodone/Acetaminophen	THE PROPERTY OF THE PROPERTY O	The state of the s
***************************************		Oxycogone/Acetaminopnen (Percocet 10/325mg,		A STATE OF THE STA
-	***********************************	4.3/2/Digit.3/3/20mg@/		
-		Oxycodone w/Acetaminophen (Koxicet®)		And and address of the fact that the fact th
-	V Primaria de Arianne de Marianne de Arianne	UXYCOGONE W/ASpirin	如何,如何如何,这个时间,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我	Section Advance & Supples Confession Confess
***************************************	interest (Netter interest and property of the factor of the superior of the su		THE PROPERTY OF THE PROPERTY O	Application of the second seco
***************************************		Pentazocine/Acetaminophen	THE PROPERTY OF THE PROPERTY O	
-		Propoxyphene HCL	очили в в в в в в в в в в в в в в в в в в	
***********	THE CONTRACTOR OF THE PROPERTY	Propoxyphene HCL Compound		
- Control Control	ы, окууна аламарынын мененин караман к	Propoxyphene HCL w/APAP		THE RESIDENCE AND ADDRESS OF THE PROPERTY OF T
1		Propoxyphene Napsylate w/APAP		Account of the majors have a designed to have been a second of the secon
-	7 да од Странција на при	Tramadol (Ultram®)		A CONTRACTOR DE
-		Tramadol/Acetaminophen (Ultracet®)		the Way of Factor . Who concentrates the symmetry was the factor of the factor
-				
	о деней на при в при			
-	а такуу шаанан алына уулуу алына такуу	от приду де судивателно терев пред пред пред пред пред пред пред пред		
-				
-	AND THE PROPERTY OF THE PROPER	THE PROPERTY OF THE PROPERTY O		
	US MARKAMININAMI	ARTER AND THE PARTY AND THE PA	THE PARTY PROPERTY AND ADDRESS OF THE PARTY AN	
-	10) 1000 одна од учениција од настана на предостава од предоста	nder of the state	THE APPROXIMENT OF THE REPORT TO THE PROPERTY OF THE PROPERTY	The section of the se
1	THE PROPERTY OF THE PROPERTY O	AND THE PARTY OF T		Account minut beam per an appeal a second and a second an
	en de la companya del la companya de la companya del la companya de la companya del la companya de la companya de la companya del la comp	МОНИКА МОНИКА БИТИКА БИТИКА ТИТИКА Т	TO THE MAIN PROPERTY OF THE PR	A OF PERSONS AND PERSONS AND ADDRESS OF THE PERSONS AND ADDRESS AND A
		A THE PROPERTY OF THE PROPERTY	ARREST AR	Anna remineration of a stream decision and principles
-		memera in a superior mentral del mentral d	STRANSPORTED AND AND AND AND AND AND AND AND AND AN	
-	THE RESIDENCE OF THE PROPERTY	With contract contract and are supplied to the contract c	manya adapat danaman kanaman (olon kanaman danaman	
-	TO A CHARLES AND	INTERNATION OF CONTROL		area total and designatery principles extendibute Area
	THE PROPERTY OF THE PROPERTY O	AND THE PROPERTY AND TH	, 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	
***************************************	ANABADA MANABAN MANABAN MANABAN ANABAN MANABAN MAN	TO THE PARTY OF TH	AREA CONTRACTOR OF THE PROPERTY OF THE PROPERT	Paradonium pagament pagament and an analysis (pagas) (pagas)
-	AND THE PROPERTY OF THE PROPER	FERENCE PROCESSARY OF PRESENTANT AND PROCESSARY OF PROCESS	· 10.0000-000-000-000-000-00-00-00-00-00-00	AND STATEMENT OF S
-			如果,我们是我们的我们,我们是我们的,我们是我们的,我们是我们的,我们是我们的,我们是我们的,我们是我们的,我们是我们的,我们是我们的,我们是我们的,我们是我们的	the sea Address that he perfectly generally gold contribution productions and the season of the seas
-	**************************************	interior printed in the first in the three commentations are the contest of the c	The contract of the contract o	giff i which all the Manager representation of a supplication and an experience of the supplication of the

Prior Authorization PDL Implementation Schedule

22	Nbr	bride on PDL	Drugs which Require PA April 1, 2006	, 2006
_	PAIN MANAGEMENT Cont'			
	Nonsteroldal Anti - Inflammatorles	Diclofenac	Celecoxia (Celebrax®)	AND MARKET OF CHICAGO STATES OF CONTRACTOR O
	(NSAIDs)	Etodolac	Diclofenac/Misoprostol (Arthrotec®)	ANY CONTRACTOR OF COMMANDESS AND STATES
Г	a Bootesman or painter of Amendo positional Polishees Polishees Polishees Polishees of Amendos Amendos Polishees Pol	Fenoprofen	Lansoprazole/Naproxen (Prevacid NapraPAC)	and and a contract of the section of
	Amazinatés da arriva a aprésacio atérica de la companya del la companya de la com	Flurbiprofen	Mefenamic Acid (Ponstel®)	AND STATEMENT OF THE STREET OF
		Ibuprofen (Rx Only)	Meloxicam (Mobic®)	
7	дения деней на при выполнения выполне	Indomethacin		
1		Ketoprofen		
十		Ketorolac		cally and flament polices (and and section)
+	We consider the second of the	Meclofenamate Sodium		
\forall	en e	Nabumetone		
+	(A) Department of the analysis of the control of th	Naproxen (Kx Only)		a de anterior de marcola de la composição
\dagger	денимення об воли повероння оборний объекторий повероння объекторий на применя повероння повероння повероння по	Naproxen Sodium	是 经收益的 计多数	
+	North destricts the state of the problem of the problem of the state o	Oxaprozin		in the state of th
+	МАНИЛЬНИКИЙ XVI ВИНИ ГЕОЛИЦИАН РОМИЦЕ ГОЛИМАРАНИЙ ГЕОГИКИЙ КОМИКИЙ ВИНИКИЙ КИТИКИЙ КИТИКИЙ КИТИКИЙ ТИКИЙ ТИКИЙ МАНИЛЬНИКИЙ XVI ВИНИ ГЕОЛИЦИАН ГОЛИМИКИЙ ТИКИЙ	PIOXICAM D		
++-		Juliude Tolmetin Sodium		
	Immunomodulators and Related Agents	Adalimumab (Humira®)	Alefacen (Amerive®)	
+=	for Arthritis	Anakinra (Kineret®)	Infliximab (Remicade®)	
+	inches de destinament mest année de la secondrame mandre de la secondrame	Efalizumab (Raptiva®)	The property of the property o	
-		Etanercept (Enbrel®)		
-				
1-	rent properties and the second	Almotriptan (Axert®)	Eletrolan (Rebax®)	
1	AND	Rizatriptan (Maxalt®, Maxalt MLT®)	Frovatiptan (Frova®)	
_	and debates into the first anticology and construction for the construction of the con	Sumatriptan (Imitrex® Nasal)	Naratriptan (Amerge®)	
		Sumatriptan (Imitrex® Oral)	Zolmitriptan (Zomig, Zomig ZMT®)	
		Sumatriptan (Imitrex® Subcutaneous)	Zolmitriptan (Zomig@ nasal)	
23	PARKINSON'S			
	Antiparkinson Agents -	Benztropine Mesylate	Levodopa/Carbidopa (Parcopa®)	
_	Anticholinergic and Other	Entacapone (Comtan®)	Procyclidine (Kemadrin®)	
-	and parameter in more than the second and arterior that projects are and projects and the second	Levodopa/Carbidopa	Tolcapone (Tasmar®)	
-		(Levodopa/Carbidopa/Entacapone (Stalevo®)		
		Pergolide		
		Pramipexole (Mirapex®)		
		Ropinirole (Requip®)		
<u>-</u> į	A Military Designation and apply and a season of the contract	Selegiline	mer (adaption) of (All property is a supplementary for the supplem	and a second
		Trihexyphenidyl		
1				
		aman maraysia and apond beautiful philosophis in the minimum and an analysis and pharmace and an analysis of an analysis of an appearance of an analysis of	THE PROPERTY OF THE PROPERTY O	
471	SEDATIVE/HYPNOTICS			THE PERSON NAMED IN COLUMN TO SERVICE ASSESSMENT ASSESSMENT OF THE PERSON OF THE PERSO
97	Sedative/Hypnotics	Chloral Hydrate	Quazepam (Dorai@)	***************************************
	Ved an saled administration of a sector of Verticals of the sector of th	Estazolam	Zalepion (Sonata®)	-
-	алынан жайын керепинден кайын керепинден керепинден керепинден керепинден керепинден керепинден керепинден кер	(ESZODICIONE (LUNESTA®)	Zolpidem CK (Ambien CK®)	
-	Naminako katalista ya Naminako kulonin katalista katalista katalista katalista katalista katalista katalista k	Flurazepam	market americki med deben de	
	Adamm) manayir aspanaji poti jima i Anganga apamin dadangi iya bitaniin t dama dadami iyo banin qoʻnamin dadamin ila oʻnin at oʻn	Kameileon (Rozereme)		
-		Temazenam 7 & 22 5 mm (Restoril 7 5mm 22 5mm®)		
1		Triazolam	aran en	
+		Zoloidem (Ambien®)		
-	AN THE PROPERTY OF THE PROPERT	erner en decreament en en des en en des en en des en en des en		
- 1			ана на на принца	
_			тери сустем на принципалний при	

2/20/2008

Prior Authorization PDL Implementation Schedule

	Drugs on PDL 7	Drugs which Require PA	Effective Date:
		第二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十	April 1, 2000
INCONTINENCE	THE PROPERTY OF THE PROPERTY O	THE PROPERTY OF THE PROPERTY O	ey terapesta established estab
Antincontinence Agents	Darfenacin (Enablex®)	Toltandina (Defroig)	ns Westerland for the contract the contract that the contract the contract to the contract to the contract to
a seriorate production and in federal transmission for deviate measurements and interest and in dear 11 inches of deviation and	Oxybutynin	Tolterodine extended-release (Detrol I A®)	
а бабатын каламын каламын балып каламын бабатын байкан байкан байкан байкан байкан байкан байкан байкан байкан Байкан байкан байка	Oxybutynin ER (Ditropan XL®)	The street manufacture of track the street manufacture of tracks to the street of the	er efter fra fra er er efter er e
	Oxybutynin transdermal (Oxytrol®)		Tribitati Primanti Frince Prima Prima Prima Prima Bassinia Bassinia Bassinia Bassinia Bassinia Bassinia Bassinia
-	Solifenacin (VESIcare®)		
	Trospium (Sanctura®)		W
PROSTATE			**************************************
Drug for Treatment of Benign	Alfuzosin (Uroxatral®)	Finasteride (Proscar®)	
Prostatic Hyperplasia (BPH)	Doxazosin		and the second s
, par professionale for a sector and a sector a sector and a sector an	Dutasteride (Avodart®)		
antriorentriorente professionente de la constitución de la constitución de la constitución de la constitución	Tamsulosin (Flomax®)		***************************************
	Terasosin	The second secon	***************************************
		THE PROPERTY OF THE PROPERTY O	
		The survey of th	and the second second decreases of the second secon
		TO THE THE PROPERTY AND	
		The state of the s	e a compression de la constitució de la compressión de la confirmación de la faciones Anthroposon Anth
		TO THE PROPERTY OF THE PROPERT	
And Annual contract of Property Contract of Contract o		THE THE PARTY OF T	THE RESIDENCE IN SECTION OF THE STATE SAME PROPERTY OF THE SAME SAME SAME SAME SAME SAME SAME SAM
		of the control of the	
	refraction of the contraction of	endicente manimismon Advisor (Advisor) Bended inschaids under 1 prosession in the constitution of the cons	
		Andreas of the state of the sta	
		prioritional control to the many and the many priorities of the public of the public of the control to the cont	
			April 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 - 1970 -
		TOTAL PROPERTY AND THE PROPERTY OF THE PROPERT	
	_		de la companya de la
лейн неустана политиран принцинали принцинали од политина пределения политина политина политина политина политина п			
erentuquestispunyerenyiquesisteristesistesisteypesistesistesistesistesistesistesistesis			
	. 1960-ж ^а 1964 да да на принципантичний принципантичний пределений принципантичний принципантичний принципанти		
	eren eren eren eren eren eren eren eren	termen en e	
and in minimum of the feet of		a dan di memenentan manent pemenengan penenthan at di kalemban mapan pangan aparangan apar penintan ing dapa pa	
***************************************	. And the second income the second	Variable (seminated seminated to the september of the september of the seminated semin	
оду урганд і і діпайтнення турорії і фінення праверання праведатура і дірену праведанда праведанда праведана п	танды танатын жарында жарын жайын жайы	V CHARLES THE RESERVE THE PROPERTY OF THE PROP	A Annual Contraction of the Cont
***************************************	ALE THE PARTY OF T	TO DESIGNATION OF THE PROPERTY	
	Ната предендативности папенда принести полиция принести в полиция полиция полиция полиция полиция полиция полици	ARTHUR STATE	
		THE THE PROPERTY OF THE PROPER	y mandining plantamountamo prami papayay apalamanana
THE THE PARTY OF T	. Personale Australia meters constitution in constitution de la constitution de la constitution de la constitu	11920 - 1910 - WILLIAM - 1910 - 1910 - 1910 - 1910 - 1910 - 1910 - 1910 - 1910 - 1910 - 1910 - 1910 - 1910 - 19	THE PROPERTY OF THE PROPERTY O
	ALTERNATURAN PROPERTY AND	THEREIN HERRICHAN THE WAS THE	

and the special control of the second contro	en en entre des entre en en entre des entre en entre entre de l'entre entre de manueur en entre		
THE THE PROPERTY OF THE PROPER	THE ACT OF THE PROPERTY OF THE		des Williams (or greeters (AV), are this report to the first of any approximation of the first o
enter de la company de la comp	erfette etterrer elektroner elektroner i er filmför i fremför fram en kaltarian den men som för etter men frem för en faren av fram för en för		***************************************
	orania periodente de la competitación de la co	AND ALCOHOLOGICA CONTRACTOR OF THE PROPERTY OF	**************************************
, and tendentes described the second of the	aranta seera esta esta esta esta esta esta esta est	ANSWAY WEREALTHE STATE OF THE S	V
. THE PROPERTY OF THE PROPERTY	obs scheen of presentations assessed to the contract of the co	A the state of the	Perfect treesforce white the contract the character sees the character of the contract to the
in the control of the			services that the transfer of the first service for the service of
· · · · · · · · · · · · · · · · · · ·	THE PROPERTY OF THE PROPERTY O	A CONTRACT OF THE PROPERTY OF	
	IN BERNITATION OF THE PROPERTY	AND THE PROPERTY OF THE PROPER	THE THE PARTY OF THE PARTY AND THE PARTY AND THE PARTY OF
			er findere de s'herren ez en

Tanan manayaran da may kaban kab			
	Antilincontinence Agents Antilincontinence Agents Drug for Treatment of Benign Prostatic Hyperplasia (BPH)	Darifenacin (Errablex®) Davibutyrin Oxybutyrin ER (Ditropan XL®) Oxybutyrin transdemat (Oxytrol®) Solifenacin (VEStcare®) Trospium (Sanctura®) Affuzosin (Uroxatral®) Dutasteride (Avodan®) Temsulosin (Flomax®) Temsulosin (Flomax®)	Darlienacin (Enables®) Tollerodine (Dericol®) Tollerodine attended release (Deltol LA®) Oxybulynia (Brother®) Trallerodine attended release (Deltol LA®) Oxybulynia (Brother®) Trallerodine attended (Arcael®) Trallerodine attended (Brosear®) Trallerodine attended (Brosear®) Trallerodine (Brosear®) Transledied (Arcael®) Transledied (Arcael®) Transledied (Arcael®) Transledied (Arcael®) Transledied (Arcael®) Transledied (Brosear®) Transle